WO2023054395A1 - 下垂体ホルモン産生細胞を含む細胞凝集体及びその製造方法 - Google Patents
下垂体ホルモン産生細胞を含む細胞凝集体及びその製造方法 Download PDFInfo
- Publication number
- WO2023054395A1 WO2023054395A1 PCT/JP2022/036018 JP2022036018W WO2023054395A1 WO 2023054395 A1 WO2023054395 A1 WO 2023054395A1 JP 2022036018 W JP2022036018 W JP 2022036018W WO 2023054395 A1 WO2023054395 A1 WO 2023054395A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- pituitary
- signaling pathway
- cell aggregate
- Prior art date
Links
- 239000000960 hypophysis hormone Substances 0.000 title claims abstract description 188
- 238000004519 manufacturing process Methods 0.000 title claims description 76
- 210000004027 cell Anatomy 0.000 claims abstract description 1325
- 210000001778 pluripotent stem cell Anatomy 0.000 claims abstract description 126
- 230000001817 pituitary effect Effects 0.000 claims description 189
- 239000003112 inhibitor Substances 0.000 claims description 181
- 230000019491 signal transduction Effects 0.000 claims description 150
- 230000004069 differentiation Effects 0.000 claims description 133
- 229960000258 corticotropin Drugs 0.000 claims description 131
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 128
- 101800000414 Corticotropin Proteins 0.000 claims description 127
- 210000000130 stem cell Anatomy 0.000 claims description 118
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 99
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 99
- 230000002267 hypothalamic effect Effects 0.000 claims description 85
- 238000004114 suspension culture Methods 0.000 claims description 70
- 239000000556 agonist Substances 0.000 claims description 69
- 238000012258 culturing Methods 0.000 claims description 61
- 230000028327 secretion Effects 0.000 claims description 47
- 230000008410 smoothened signaling pathway Effects 0.000 claims description 39
- 238000012423 maintenance Methods 0.000 claims description 33
- 102000000905 Cadherin Human genes 0.000 claims description 31
- 108050007957 Cadherin Proteins 0.000 claims description 31
- 230000004156 Wnt signaling pathway Effects 0.000 claims description 29
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims description 23
- 239000000725 suspension Substances 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 102000043168 TGF-beta family Human genes 0.000 claims description 15
- 108091085018 TGF-beta family Proteins 0.000 claims description 15
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 12
- 210000002569 neuron Anatomy 0.000 claims description 12
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 208000014993 Pituitary disease Diseases 0.000 claims description 8
- 238000007667 floating Methods 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 abstract description 101
- 239000002609 medium Substances 0.000 description 172
- 210000001519 tissue Anatomy 0.000 description 141
- 102400000739 Corticotropin Human genes 0.000 description 123
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 122
- 239000000126 substance Substances 0.000 description 116
- 230000006698 induction Effects 0.000 description 77
- 108010051696 Growth Hormone Proteins 0.000 description 57
- 102100038803 Somatotropin Human genes 0.000 description 57
- 239000000122 growth hormone Substances 0.000 description 57
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 55
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 55
- 108090000623 proteins and genes Proteins 0.000 description 55
- 229940112869 bone morphogenetic protein Drugs 0.000 description 53
- 230000014509 gene expression Effects 0.000 description 45
- 230000000977 initiatory effect Effects 0.000 description 45
- 230000000694 effects Effects 0.000 description 40
- 239000012679 serum free medium Substances 0.000 description 37
- 238000011282 treatment Methods 0.000 description 36
- 229960003957 dexamethasone Drugs 0.000 description 35
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 35
- 229940088597 hormone Drugs 0.000 description 33
- 239000005556 hormone Substances 0.000 description 33
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 31
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 31
- 239000003795 chemical substances by application Substances 0.000 description 29
- 206010062767 Hypophysitis Diseases 0.000 description 28
- -1 Poly(2-hydroxyethyl methacrylate) Polymers 0.000 description 27
- 230000037361 pathway Effects 0.000 description 27
- 210000003635 pituitary gland Anatomy 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 238000000746 purification Methods 0.000 description 26
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 25
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 25
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 22
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 22
- 230000001780 adrenocortical effect Effects 0.000 description 22
- 229940088598 enzyme Drugs 0.000 description 22
- 102000003946 Prolactin Human genes 0.000 description 21
- 108010057464 Prolactin Proteins 0.000 description 21
- 229940097325 prolactin Drugs 0.000 description 21
- 230000003248 secreting effect Effects 0.000 description 21
- 108010029223 MAP kinase kinase kinase 7 Proteins 0.000 description 20
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 20
- 229940126864 fibroblast growth factor Drugs 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 101150111110 NKX2-1 gene Proteins 0.000 description 19
- 102000011923 Thyrotropin Human genes 0.000 description 19
- 108010061174 Thyrotropin Proteins 0.000 description 19
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 19
- 230000007774 longterm Effects 0.000 description 19
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 102000013814 Wnt Human genes 0.000 description 17
- 108050003627 Wnt Proteins 0.000 description 17
- 239000013543 active substance Substances 0.000 description 17
- 239000002771 cell marker Substances 0.000 description 17
- 230000000638 stimulation Effects 0.000 description 17
- VFSUUTYAEQOIMW-YHBQERECSA-N 3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide Chemical compound C1C[C@@H](NC)CC[C@@H]1N(C(=O)C1=C(C2=CC=CC=C2S1)Cl)CC1=CC=CC(C=2C=CN=CC=2)=C1 VFSUUTYAEQOIMW-YHBQERECSA-N 0.000 description 16
- 239000006185 dispersion Substances 0.000 description 16
- FHYUGAJXYORMHI-UHFFFAOYSA-N SB 431542 Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCOC3=CC=2)=C(C=2N=CC=CC=2)N1 FHYUGAJXYORMHI-UHFFFAOYSA-N 0.000 description 15
- 238000007792 addition Methods 0.000 description 15
- 210000002469 basement membrane Anatomy 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 238000002054 transplantation Methods 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000010586 diagram Methods 0.000 description 13
- 210000002919 epithelial cell Anatomy 0.000 description 13
- 238000012744 immunostaining Methods 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 12
- 108010085895 Laminin Proteins 0.000 description 12
- 239000000853 adhesive Substances 0.000 description 12
- 230000001070 adhesive effect Effects 0.000 description 12
- 210000000981 epithelium Anatomy 0.000 description 12
- 210000004368 gonadotroph Anatomy 0.000 description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 11
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 11
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 11
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 108010070047 Notch Receptors Proteins 0.000 description 11
- 102000005650 Notch Receptors Human genes 0.000 description 11
- 239000012228 culture supernatant Substances 0.000 description 11
- 229940028334 follicle stimulating hormone Drugs 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 10
- 102000009151 Luteinizing Hormone Human genes 0.000 description 10
- 108010073521 Luteinizing Hormone Proteins 0.000 description 10
- 108010088225 Nestin Proteins 0.000 description 10
- 102000008730 Nestin Human genes 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000001671 embryonic stem cell Anatomy 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 229940040129 luteinizing hormone Drugs 0.000 description 10
- 210000005055 nestin Anatomy 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 102000029816 Collagenase Human genes 0.000 description 9
- 108060005980 Collagenase Proteins 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 108700042694 Lhx3 Proteins 0.000 description 9
- 230000005913 Notch signaling pathway Effects 0.000 description 9
- 230000021164 cell adhesion Effects 0.000 description 9
- 229960002424 collagenase Drugs 0.000 description 9
- 230000001120 cytoprotective effect Effects 0.000 description 9
- 108010038862 laminin 10 Proteins 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000031877 prophase Effects 0.000 description 9
- 230000035882 stress Effects 0.000 description 9
- 241001481760 Erethizon dorsatum Species 0.000 description 8
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 8
- 238000004115 adherent culture Methods 0.000 description 8
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 230000031864 metaphase Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 239000003223 protective agent Substances 0.000 description 8
- 229930002330 retinoic acid Natural products 0.000 description 8
- 238000010361 transduction Methods 0.000 description 8
- 230000026683 transduction Effects 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- CJLMANFTWLNAKC-UHFFFAOYSA-N 3-[6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenol Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=NC=C(C=2)C=2C=C(O)C=CC=2)N)=C1 CJLMANFTWLNAKC-UHFFFAOYSA-N 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 7
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 7
- 230000004956 cell adhesive effect Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000011109 contamination Methods 0.000 description 7
- 210000003016 hypothalamus Anatomy 0.000 description 7
- 230000035800 maturation Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 101150103310 pitx1 gene Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- NEQZWEXWOFPKOT-BYRRXHGESA-N 5Z-7-oxozeaenol Chemical compound O([C@@H](C)C\C=C/C(=O)[C@@H](O)[C@@H](O)C/C=C/1)C(=O)C=2C\1=CC(OC)=CC=2O NEQZWEXWOFPKOT-BYRRXHGESA-N 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 239000012825 JNK inhibitor Substances 0.000 description 6
- IVRXNBXKWIJUQB-UHFFFAOYSA-N LY-2157299 Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 IVRXNBXKWIJUQB-UHFFFAOYSA-N 0.000 description 6
- CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000003862 glucocorticoid Substances 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229960000890 hydrocortisone Drugs 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 229940037128 systemic glucocorticoids Drugs 0.000 description 6
- 229960001727 tretinoin Drugs 0.000 description 6
- KHZOJCQBHJUJFY-UHFFFAOYSA-N 2-[4-(2-methylpyridin-4-yl)phenyl]-n-(4-pyridin-3-ylphenyl)acetamide Chemical compound C1=NC(C)=CC(C=2C=CC(CC(=O)NC=3C=CC(=CC=3)C=3C=NC=CC=3)=CC=2)=C1 KHZOJCQBHJUJFY-UHFFFAOYSA-N 0.000 description 5
- FJCDSQATIJKQKA-UHFFFAOYSA-N 2-fluoro-n-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C2=C(N=C(CNC=3C(=CC=CC=3)F)N2)C2=CN3N=CN=C3C=C2)=N1 FJCDSQATIJKQKA-UHFFFAOYSA-N 0.000 description 5
- OQVLOWLEEHYBJH-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethynyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C#CC1=CC=C(C(O)=O)C=C1 OQVLOWLEEHYBJH-UHFFFAOYSA-N 0.000 description 5
- FVRYPYDPKSZGNS-UHFFFAOYSA-N 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline Chemical compound C1=CC(OC)=CC=C1C1=CN2N=CC(C=3C4=CC=CN=C4C=CC=3)=C2N=C1 FVRYPYDPKSZGNS-UHFFFAOYSA-N 0.000 description 5
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 5
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 5
- 101000825086 Homo sapiens Transcription factor SOX-11 Proteins 0.000 description 5
- 206010021067 Hypopituitarism Diseases 0.000 description 5
- 108091005461 Nucleic proteins Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000012826 P38 inhibitor Substances 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 108091005735 TGF-beta receptors Proteins 0.000 description 5
- 102100022415 Transcription factor SOX-11 Human genes 0.000 description 5
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- NEQZWEXWOFPKOT-UHFFFAOYSA-N f152A1 Natural products C1=CCC(O)C(O)C(=O)C=CCC(C)OC(=O)C=2C1=CC(OC)=CC=2O NEQZWEXWOFPKOT-UHFFFAOYSA-N 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 238000012827 research and development Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- HIJMSZGHKQPPJS-UHFFFAOYSA-N 3-(6-methylpyridin-2-yl)-n-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide Chemical compound CC1=CC=CC(C=2C(=CN(N=2)C(=S)NC=2C=CC=CC=2)C=2C3=CC=CC=C3N=CC=2)=N1 HIJMSZGHKQPPJS-UHFFFAOYSA-N 0.000 description 4
- DXLXRNZCYAYUED-UHFFFAOYSA-N 4-[2-[4-(3-quinolin-4-ylpyrazolo[1,5-a]pyrimidin-6-yl)phenoxy]ethyl]morpholine Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=CC=1OCCN1CCOCC1 DXLXRNZCYAYUED-UHFFFAOYSA-N 0.000 description 4
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 4
- BBDGBGOVJPEFBT-UHFFFAOYSA-N 5-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CN=C3C=CC=2)C=C1 BBDGBGOVJPEFBT-UHFFFAOYSA-N 0.000 description 4
- 108010059616 Activins Proteins 0.000 description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 4
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 4
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 4
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 4
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 4
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 4
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 4
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 description 4
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 4
- 101001020452 Homo sapiens LIM/homeobox protein Lhx3 Proteins 0.000 description 4
- 102100026818 Inhibin beta E chain Human genes 0.000 description 4
- 102100029408 Interferon-inducible double-stranded RNA-dependent protein kinase activator A Human genes 0.000 description 4
- 150000000996 L-ascorbic acids Chemical class 0.000 description 4
- 102100036106 LIM/homeobox protein Lhx3 Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108010067372 Pancreatic elastase Proteins 0.000 description 4
- 102000016387 Pancreatic elastase Human genes 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 108010008125 Tenascin Proteins 0.000 description 4
- 102100038126 Tenascin Human genes 0.000 description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- 239000000488 activin Substances 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000003855 cell nucleus Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000011977 dual antiplatelet therapy Methods 0.000 description 4
- 229950000456 galunisertib Drugs 0.000 description 4
- 238000010363 gene targeting Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- ZAVGJDAFCZAWSZ-UHFFFAOYSA-N hydroxyfasudil Chemical compound C1=CC=C2C(O)=NC=CC2=C1S(=O)(=O)N1CCCNCC1 ZAVGJDAFCZAWSZ-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000007758 minimum essential medium Substances 0.000 description 4
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 4
- 210000002894 multi-fate stem cell Anatomy 0.000 description 4
- LXFKEVQQSKQXPR-UHFFFAOYSA-N n-(6-chloro-1,3-benzothiazol-2-yl)-3-(3,4-dimethoxyphenyl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1CCC(=O)NC1=NC2=CC=C(Cl)C=C2S1 LXFKEVQQSKQXPR-UHFFFAOYSA-N 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- ROFMCPHQNWGXGE-SFHVURJKSA-N (3s)-n-[2-[2-(dimethylamino)ethoxy]-4-(1h-pyrazol-4-yl)phenyl]-6-methoxy-3,4-dihydro-2h-chromene-3-carboxamide Chemical compound O=C([C@@H]1COC2=CC=C(C=C2C1)OC)NC(C(=C1)OCCN(C)C)=CC=C1C=1C=NNC=1 ROFMCPHQNWGXGE-SFHVURJKSA-N 0.000 description 3
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 description 3
- JUHTXZGCTPDXRU-UHFFFAOYSA-N 1-[4-(1,3-benzodioxol-5-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxamide Chemical compound CC1=CC=CC(C2=C(N=C(N2)C23CCC(CC2)(CC3)C(N)=O)C=2C=C3OCOC3=CC=2)=N1 JUHTXZGCTPDXRU-UHFFFAOYSA-N 0.000 description 3
- BHUXVRVMMYAXKN-UHFFFAOYSA-N 1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=NC=C(C=2)C=2C=CC(=CC=2)N2CCNCC2)C)=C1 BHUXVRVMMYAXKN-UHFFFAOYSA-N 0.000 description 3
- QTRXIFVSTWXRJJ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-n-(6-phenylpyridazin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC(=O)NC(N=N1)=CC=C1C1=CC=CC=C1 QTRXIFVSTWXRJJ-UHFFFAOYSA-N 0.000 description 3
- BERLXWPRSBJFHO-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-n-pyridin-4-ylpteridin-4-amine Chemical compound FC1=CC=C(Cl)C=C1C1=NC(NC=2C=CN=CC=2)=C(N=CC=N2)C2=N1 BERLXWPRSBJFHO-UHFFFAOYSA-N 0.000 description 3
- RBFDSBJDWZOTGR-UHFFFAOYSA-N 2-[(3,6-dimethyl-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C(C)C=C2SC(NC(=O)CSC3=NC=4CC(SC=4C(=O)N3C)C)=NC2=C1 RBFDSBJDWZOTGR-UHFFFAOYSA-N 0.000 description 3
- QESQGTFWEQMCMH-UHFFFAOYSA-N 2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-n-(5-phenylpyridin-2-yl)acetamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=NC=1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 QESQGTFWEQMCMH-UHFFFAOYSA-N 0.000 description 3
- GKHIVNAUVKXIIY-UHFFFAOYSA-N 2-[3-[4-(1h-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-ylacetamide Chemical compound CC(C)NC(=O)COC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=C4C=NNC4=CC=3)N=2)=C1 GKHIVNAUVKXIIY-UHFFFAOYSA-N 0.000 description 3
- JQGOCCALXFSRHZ-UHFFFAOYSA-N 2-[4-[2-fluoro-5-[5-(6-methylpyridin-2-yl)-1h-pyrazol-4-yl]phenyl]pyrazol-1-yl]ethanol Chemical compound CC1=CC=CC(C=2C(=CNN=2)C=2C=C(C(F)=CC=2)C2=CN(CCO)N=C2)=N1 JQGOCCALXFSRHZ-UHFFFAOYSA-N 0.000 description 3
- HZTYDQRUAWIZRE-UHFFFAOYSA-N 2-[[2-[[1-[2-(dimethylamino)-1-oxoethyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide Chemical compound CNC(=O)C1=C(F)C=CC=C1NC1=C2C=CN=C2NC(NC=2C(=CC=3CCN(C=3C=2)C(=O)CN(C)C)OC)=N1 HZTYDQRUAWIZRE-UHFFFAOYSA-N 0.000 description 3
- RHUJMHOIQBDFQR-UHFFFAOYSA-N 2-[[3-(2-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound COC1=CC=CC=C1N1C(=O)C(SCC2)=C2N=C1SCC(=O)NC1=NC2=CC=C(C)C=C2S1 RHUJMHOIQBDFQR-UHFFFAOYSA-N 0.000 description 3
- XVMHQSDMKWQNBK-UHFFFAOYSA-N 2-[[3-(4-fluorophenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=C(F)C=C1 XVMHQSDMKWQNBK-UHFFFAOYSA-N 0.000 description 3
- XDJCLCLBSGGNKS-UHFFFAOYSA-N 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole Chemical compound C=1C=CC(C=2C3=CC(=CC=C3NN=2)C=2NN=CN=2)=CC=1OCCN1CCCCC1 XDJCLCLBSGGNKS-UHFFFAOYSA-N 0.000 description 3
- GJFCSAPFHAXMSF-UXBLZVDNSA-N 3-[[(e)-4-(dimethylamino)but-2-enoyl]amino]-n-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide Chemical compound CN(C)C\C=C\C(=O)NC1=CC=CC(C(=O)NC=2C=C(C)C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)=CC=2)=C1 GJFCSAPFHAXMSF-UXBLZVDNSA-N 0.000 description 3
- RYKSGWSKILPDDY-UHFFFAOYSA-N 3-[[5-(6-methylpyridin-2-yl)-4-quinoxalin-6-yl-1h-imidazol-2-yl]methyl]benzamide Chemical compound CC1=CC=CC(C2=C(N=C(CC=3C=C(C=CC=3)C(N)=O)N2)C=2C=C3N=CC=NC3=CC=2)=N1 RYKSGWSKILPDDY-UHFFFAOYSA-N 0.000 description 3
- UEOZXMAOIHDDQE-UHFFFAOYSA-N 4-[[4-(2,6-dimethylpyridin-3-yl)oxypyridin-2-yl]amino]benzenesulfonamide Chemical compound CC1=NC(C)=CC=C1OC1=CC=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=C1 UEOZXMAOIHDDQE-UHFFFAOYSA-N 0.000 description 3
- QQWUGDVOUVUTOY-UHFFFAOYSA-N 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)C(C)C QQWUGDVOUVUTOY-UHFFFAOYSA-N 0.000 description 3
- DKPQHFZUICCZHF-UHFFFAOYSA-N 6-[2-tert-butyl-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline Chemical compound CC1=CC=CC(C2=C(N=C(N2)C(C)(C)C)C=2C=C3N=CC=NC3=CC=2)=N1 DKPQHFZUICCZHF-UHFFFAOYSA-N 0.000 description 3
- GCYIGMXOIWJGBU-UHFFFAOYSA-N AZD3463 Chemical compound C=1C=C(NC=2N=C(C(Cl)=CN=2)C=2C3=CC=CC=C3NC=2)C(OC)=CC=1N1CCC(N)CC1 GCYIGMXOIWJGBU-UHFFFAOYSA-N 0.000 description 3
- RYVZYACBVYKUHD-UHFFFAOYSA-N Alk5 Natural products CC#CC#CCCCCC=CC(=O)NCC(C)C RYVZYACBVYKUHD-UHFFFAOYSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 229920001342 Bakelite® Polymers 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- JMIFGARJSWXZSH-UHFFFAOYSA-N DMH1 Chemical compound C1=CC(OC(C)C)=CC=C1C1=CN2N=CC(C=3C4=CC=CC=C4N=CC=3)=C2N=C1 JMIFGARJSWXZSH-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 description 3
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 description 3
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 3
- 101000632178 Homo sapiens Homeobox protein Nkx-2.1 Proteins 0.000 description 3
- 101000845269 Homo sapiens Transcription termination factor 1 Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000025282 Hypothalamo-pituitary disease Diseases 0.000 description 3
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- XXYGTCZJJLTAGH-UHFFFAOYSA-N LGK974 Chemical compound C1=NC(C)=CC(C=2C(=CC(CC(=O)NC=3N=CC(=CC=3)C=3N=CC=NC=3)=CN=2)C)=C1 XXYGTCZJJLTAGH-UHFFFAOYSA-N 0.000 description 3
- IBCXZJCWDGCXQT-UHFFFAOYSA-N LY 364947 Chemical compound C=1C=NC2=CC=CC=C2C=1C1=CNN=C1C1=CC=CC=N1 IBCXZJCWDGCXQT-UHFFFAOYSA-N 0.000 description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 3
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 3
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 3
- 101150081664 PAX6 gene Proteins 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 3
- WGZOTBUYUFBEPZ-UHFFFAOYSA-N SB 505124 Chemical compound CC1=CC=CC(C2=C(N=C(N2)C(C)(C)C)C=2C=C3OCOC3=CC=2)=N1 WGZOTBUYUFBEPZ-UHFFFAOYSA-N 0.000 description 3
- QHKYPYXTTXKZST-UHFFFAOYSA-N SB-202190 Chemical compound C1=CC(O)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 QHKYPYXTTXKZST-UHFFFAOYSA-N 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 description 3
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 3
- 238000011276 addition treatment Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003470 adrenal cortex hormone Substances 0.000 description 3
- 230000031016 anaphase Effects 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 3
- IBGLGMOPHJQDJB-IHRRRGAJSA-N chembl1950289 Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=NC=C(N=C(NC=2C(=CC(F)=CC=2F)F)N2[C@@H]3COCC3)C2=N1 IBGLGMOPHJQDJB-IHRRRGAJSA-N 0.000 description 3
- LLFCXRYULHMNCG-UHFFFAOYSA-N chembl2207988 Chemical compound CC1=CSC(C2=C(NC=N2)C=2C=C3SC=NC3=CC=2)=N1 LLFCXRYULHMNCG-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 3
- ULFUJLFTRWWLPO-UHFFFAOYSA-N ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate Chemical compound CCOC(=O)C1=C(C)NC(CC(C)(C)CC2=O)=C2C1C(C=C1)=CC=C1C1=CC=CC=C1 ULFUJLFTRWWLPO-UHFFFAOYSA-N 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 210000000842 folliculostellate cell Anatomy 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007728 intracellular signaling mechanism Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- SAGZIBJAQGBRQA-UHFFFAOYSA-N n-(oxan-4-yl)-4-[4-(5-pyridin-2-yl-1h-pyrazol-4-yl)pyridin-2-yl]benzamide Chemical compound C=1C=C(C=2N=CC=C(C=2)C2=C(NN=C2)C=2N=CC=CC=2)C=CC=1C(=O)NC1CCOCC1 SAGZIBJAQGBRQA-UHFFFAOYSA-N 0.000 description 3
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 3
- AXXNRMISICMFNS-UHFFFAOYSA-N n-[5-(4-acetylpiperazin-1-yl)pyridin-2-yl]-2-[6-(2-fluoropyridin-4-yl)-5-methylpyridin-3-yl]acetamide Chemical compound C1CN(C(=O)C)CCN1C(C=N1)=CC=C1NC(=O)CC1=CN=C(C=2C=C(F)N=CC=2)C(C)=C1 AXXNRMISICMFNS-UHFFFAOYSA-N 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000006584 pituitary dysfunction Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- FYBHCRQFSFYWPY-UHFFFAOYSA-N purmorphamine Chemical compound C1CCCCC1N1C2=NC(OC=3C4=CC=CC=C4C=CC=3)=NC(NC=3C=CC(=CC=3)N3CCOCC3)=C2N=C1 FYBHCRQFSFYWPY-UHFFFAOYSA-N 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000008672 reprogramming Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001578 tight junction Anatomy 0.000 description 3
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 2
- MWUFVYLAWAXDHQ-HMNLTAHHSA-N (2e,5s,6s,8z,10r,11s)-17-(ethylamino)-5,6,15-trihydroxy-10,11-dimethyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,8,14,16-pentaene-7,13-dione Chemical compound O([C@@H](C)[C@H](C)\C=C/C(=O)[C@@H](O)[C@@H](O)C/C=C/1)C(=O)C=2C\1=CC(NCC)=CC=2O MWUFVYLAWAXDHQ-HMNLTAHHSA-N 0.000 description 2
- QSHGISMANBKLQL-OWJWWREXSA-N (2s)-2-[[2-(3,5-difluorophenyl)acetyl]amino]-n-[(7s)-5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl]propanamide Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C2=CC=CC=C21)=O)C(=O)CC1=CC(F)=CC(F)=C1 QSHGISMANBKLQL-OWJWWREXSA-N 0.000 description 2
- NRHASZRDWOUMFD-SFHVURJKSA-N (2s)-3-phenyl-1-n-(2-pyridin-4-yl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)propane-1,2-diamine Chemical compound C([C@@H](N)CC=1C=CC=CC=1)NC(C=1C=2CCCCC=2SC=1N=1)=NC=1C1=CC=NC=C1 NRHASZRDWOUMFD-SFHVURJKSA-N 0.000 description 2
- AWDORCFLUJZUQS-ZDUSSCGKSA-N (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(C)=C12 AWDORCFLUJZUQS-ZDUSSCGKSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- JLOXTZFYJNCPIS-FYWRMAATSA-N (z)-3-amino-3-(4-aminophenyl)sulfanyl-2-[2-(trifluoromethyl)phenyl]prop-2-enenitrile Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(\C#N)=C(/N)SC1=CC=C(N)C=C1 JLOXTZFYJNCPIS-FYWRMAATSA-N 0.000 description 2
- INGCLXPSKXSYND-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-(1-methylpiperidin-4-yl)-1h-indol-5-ol Chemical compound OC(=O)\C=C/C(O)=O.C1CN(C)CCC1C1=CNC2=CC=C(O)C=C12 INGCLXPSKXSYND-BTJKTKAUSA-N 0.000 description 2
- DVIJFJSZZNOTLP-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-2-[2-(trifluoromethyl)phenyl]guanidine Chemical compound CC1=CC(C)=CC(NC(=N)NC=2C(=CC=CC=2)C(F)(F)F)=C1 DVIJFJSZZNOTLP-UHFFFAOYSA-N 0.000 description 2
- GDVRVPIXWXOKQO-UHFFFAOYSA-N 1-[(3-hydroxyphenyl)methyl]-3-(4-pyridin-4-yl-1,3-thiazol-2-yl)urea Chemical compound OC1=CC=CC(CNC(=O)NC=2SC=C(N=2)C=2C=CN=CC=2)=C1 GDVRVPIXWXOKQO-UHFFFAOYSA-N 0.000 description 2
- IPFOCHMOYUMURK-UHFFFAOYSA-N 1-[3-[4-[2-[4-chloro-2-hydroxy-5-(1-methylcyclopropyl)anilino]acetyl]piperazin-1-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C=1C(NCC(=O)N2CCN(CC2)C2CN(C2)C(=O)C=C)=C(O)C=C(Cl)C=1C1(C)CC1 IPFOCHMOYUMURK-UHFFFAOYSA-N 0.000 description 2
- LNMRSSIMGCDUTP-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[[5-fluoro-2-[1-(2-hydroxyethyl)indazol-5-yl]oxyphenyl]methyl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NCC=2C(=CC=C(F)C=2)OC=2C=C3C=NN(CCO)C3=CC=2)=CC(C(C)(C)C)=N1 LNMRSSIMGCDUTP-UHFFFAOYSA-N 0.000 description 2
- ZQFBVJBAWLZLOM-UHFFFAOYSA-N 1-cyano-2-[2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]guanidine Chemical compound CC1=CC(F)=CC=C1C1=NC(NCCNC(=N)NC#N)=NC2=C1C=CC(=O)N2C1=C(F)C=CC=C1F ZQFBVJBAWLZLOM-UHFFFAOYSA-N 0.000 description 2
- RCYPVQCPYKNSTG-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-2-[2-[2-(3-pyridinyl)ethylamino]-4-pyrimidinyl]acetonitrile Chemical compound N=1C2=CC=CC=C2SC=1C(C#N)C(N=1)=CC=NC=1NCCC1=CC=CN=C1 RCYPVQCPYKNSTG-UHFFFAOYSA-N 0.000 description 2
- XCPPIJCBCWUBNT-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-2-[2-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]pyrimidin-4-yl]acetonitrile Chemical compound N=1C2=CC=CC=C2SC=1C(C#N)C(N=1)=CC=NC=1OCC(C=C1)=CC=C1CN1CCOCC1 XCPPIJCBCWUBNT-UHFFFAOYSA-N 0.000 description 2
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 2
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 2
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 2
- ZSZRUEAFVQITHH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=C)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-N 0.000 description 2
- XKZDWYDHEBCGCG-UHFFFAOYSA-N 2-(4-bromo-2-chlorophenoxy)-n-[[4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl]carbamothioyl]acetamide Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(NC(=S)NC(=O)COC=3C(=CC(Br)=CC=3)Cl)=CC=2)=N1 XKZDWYDHEBCGCG-UHFFFAOYSA-N 0.000 description 2
- YSZJLXPXVFGTNK-UHFFFAOYSA-N 2-(4-ethylphenoxy)-n-(4-fluoro-3-nitrophenyl)acetamide Chemical compound C1=CC(CC)=CC=C1OCC(=O)NC1=CC=C(F)C([N+]([O-])=O)=C1 YSZJLXPXVFGTNK-UHFFFAOYSA-N 0.000 description 2
- VDYRZXYYQMMFJW-UHFFFAOYSA-N 2-(dimethylamino)-n-(1-oxo-2h-isoquinolin-6-yl)-2-thiophen-3-ylacetamide Chemical compound C=1C=C2C(O)=NC=CC2=CC=1NC(=O)C(N(C)C)C=1C=CSC=1 VDYRZXYYQMMFJW-UHFFFAOYSA-N 0.000 description 2
- LSECOAJFCKFQJG-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)-5-[5-[7-(trifluoromethyl)quinolin-4-yl]sulfanylpentoxy]pyran-4-one;dihydrochloride Chemical compound Cl.Cl.C=1C=NC2=CC(C(F)(F)F)=CC=C2C=1SCCCCCOC(C(C=1)=O)=COC=1CN1CCOCC1 LSECOAJFCKFQJG-UHFFFAOYSA-N 0.000 description 2
- QHPKKGUGRGRSGA-UHFFFAOYSA-N 2-({2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl}amino)benzamide Chemical compound NC(=O)C1=CC=CC=C1NC1=CC=NC(NC=2C=C(O)C=CC=2)=N1 QHPKKGUGRGRSGA-UHFFFAOYSA-N 0.000 description 2
- PNPFMWIDAKQFPY-UHFFFAOYSA-N 2-[4-[[4-[1-cyclopropyl-3-(oxan-4-yl)pyrazol-4-yl]oxypyridin-2-yl]amino]pyridin-2-yl]propan-2-ol Chemical compound C1(CC1)N1N=C(C(=C1)OC1=CC(=NC=C1)NC1=CC(=NC=C1)C(C)(C)O)C1CCOCC1 PNPFMWIDAKQFPY-UHFFFAOYSA-N 0.000 description 2
- MCKLJFJEQRYRQT-APGJSSKUSA-N 20-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@](C)(O)CCCC(C)C)[C@@]1(C)CC2 MCKLJFJEQRYRQT-APGJSSKUSA-N 0.000 description 2
- AKUKHICVNCCQHN-UHFFFAOYSA-N 3,4,6-trichloro-2-(2,3,5-trichloro-6-hydroxyphenyl)sulfonylphenol Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1S(=O)(=O)C1=C(O)C(Cl)=CC(Cl)=C1Cl AKUKHICVNCCQHN-UHFFFAOYSA-N 0.000 description 2
- HXMGCTFLLWPVFM-GOSISDBHSA-N 3-(2,4-difluoroanilino)-9-[(2r)-2,3-dihydroxypropoxy]-5,6-dihydrodibenzo[3,1-[7]annulen-11-one Chemical compound C=1C=C2C(=O)C3=CC(OC[C@H](O)CO)=CC=C3CCC2=CC=1NC1=CC=C(F)C=C1F HXMGCTFLLWPVFM-GOSISDBHSA-N 0.000 description 2
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 2
- PMRFEKRJNZQOSY-UHFFFAOYSA-N 3-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethynyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C#CC1=CC=CC(C(O)=O)=C1 PMRFEKRJNZQOSY-UHFFFAOYSA-N 0.000 description 2
- OCUQMWSIGPQEMX-UHFFFAOYSA-N 3-[3-[N-[4-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indol-6-yl]-N-ethylprop-2-ynamide Chemical compound CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4 OCUQMWSIGPQEMX-UHFFFAOYSA-N 0.000 description 2
- MTFAYLZZDJGFGV-UHFFFAOYSA-N 3-[4-[(3-methylphenyl)carbamoylamino]pyrazol-1-yl]-n-(3,4,5-trimethoxyphenyl)benzamide Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)C=2C=C(C=CC=2)N2N=CC(NC(=O)NC=3C=C(C)C=CC=3)=C2)=C1 MTFAYLZZDJGFGV-UHFFFAOYSA-N 0.000 description 2
- ZGXOBLVQIVXKEB-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-N,N-dimethyl-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N(C)C)O ZGXOBLVQIVXKEB-UHFFFAOYSA-N 0.000 description 2
- UNTPTSFVGRSTDC-UHFFFAOYSA-N 3-amino-5-[4-(morpholin-4-ylmethyl)phenyl]thiophene-2-carboxamide Chemical compound NC1=C(C(=O)N)SC(C=2C=CC(CN3CCOCC3)=CC=2)=C1 UNTPTSFVGRSTDC-UHFFFAOYSA-N 0.000 description 2
- UOZVVPXKJGOFIG-UHFFFAOYSA-N 3-n-(1-propylbenzimidazol-2-yl)benzene-1,3-dicarboxamide Chemical compound N=1C2=CC=CC=C2N(CCC)C=1NC(=O)C1=CC=CC(C(N)=O)=C1 UOZVVPXKJGOFIG-UHFFFAOYSA-N 0.000 description 2
- QFRLDZGQEZCCJZ-UHFFFAOYSA-N 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(5-nitro-2-thiazolyl)thio]-1H-1,2,4-triazol-5-one Chemical compound S1C([N+](=O)[O-])=CN=C1SC1=NNC(=O)N1C1=CC=C(OCCO2)C2=C1 QFRLDZGQEZCCJZ-UHFFFAOYSA-N 0.000 description 2
- HEAIGWIZTYAQTC-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-(1h-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxamide Chemical compound N1C(=O)NC(C)=C(C(=O)NC=2C=C3C=NNC3=CC=2)C1C1=CC=C(F)C=C1 HEAIGWIZTYAQTC-UHFFFAOYSA-N 0.000 description 2
- HXBKPYIEQLLNBK-UHFFFAOYSA-N 4-(4-octylphenyl)benzoic acid Chemical compound C1=CC(CCCCCCCC)=CC=C1C1=CC=C(C(O)=O)C=C1 HXBKPYIEQLLNBK-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- KFBPBWUZXBYJDG-UHFFFAOYSA-N 4-[(1,1,3,3-tetramethyl-2-oxoindene-5-carbonyl)amino]benzoic acid Chemical compound C=1C=C2C(C)(C)C(=O)C(C)(C)C2=CC=1C(=O)NC1=CC=C(C(O)=O)C=C1 KFBPBWUZXBYJDG-UHFFFAOYSA-N 0.000 description 2
- JTVBXQAYBIJXRP-SNVBAGLBSA-N 4-[(1R)-1-aminoethyl]-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C1=CC([C@H](N)C)=CC=C1C(=O)NC1=CC=NC2=C1C=CN2 JTVBXQAYBIJXRP-SNVBAGLBSA-N 0.000 description 2
- QIFJOFNVIVQRNJ-UHFFFAOYSA-N 4-[2-(2-fluorophenyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyridine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)NC(C=2C(=CC=CC=2)F)=N1 QIFJOFNVIVQRNJ-UHFFFAOYSA-N 0.000 description 2
- IHLVSLOZUHKNMQ-UHFFFAOYSA-N 4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine Chemical compound C=1C=C2C(C=3C(=NN4CCCC4=3)C=3N=CC=CC=3)=CC=NC2=CC=1OCCN1CCOCC1 IHLVSLOZUHKNMQ-UHFFFAOYSA-N 0.000 description 2
- QBNZBMVRFYREHK-UHFFFAOYSA-N 4-[3-(4-methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1C1N(C=2C=CC(=CC=2)S(N)(=O)=O)N=C(C=2C=CC=CC=2)C1 QBNZBMVRFYREHK-UHFFFAOYSA-N 0.000 description 2
- HSAOETBFVAWNRP-UHFFFAOYSA-N 4-[4-(2-butoxyethoxy)-5-methyl-1,3-thiazol-2-yl]-2-fluorobenzoic acid Chemical compound S1C(C)=C(OCCOCCCC)N=C1C1=CC=C(C(O)=O)C(F)=C1 HSAOETBFVAWNRP-UHFFFAOYSA-N 0.000 description 2
- BGIYKDUASORTBB-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 BGIYKDUASORTBB-UHFFFAOYSA-N 0.000 description 2
- VXPWQNBKEIVYIS-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-2-methylsulfanyl-1h-imidazol-4-yl]-n-(1-phenylethyl)pyridin-2-amine Chemical compound N1C(SC)=NC(C=2C=C(NC(C)C=3C=CC=CC=3)N=CC=2)=C1C1=CC=C(F)C=C1 VXPWQNBKEIVYIS-UHFFFAOYSA-N 0.000 description 2
- KJTYZDORHCDZPS-UHFFFAOYSA-N 4-[5-(6-methylpyridin-2-yl)-1h-pyrazol-4-yl]quinoline Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2C3=CC=CC=C3N=CC=2)=N1 KJTYZDORHCDZPS-UHFFFAOYSA-N 0.000 description 2
- VCQGNUWOMLYNNG-UHFFFAOYSA-N 4-[7-(1-adamantyl)-6-hydroxynaphthalen-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=C(O)C(=C2)C34CC5CC(CC(C5)C3)C4)C2=C1 VCQGNUWOMLYNNG-UHFFFAOYSA-N 0.000 description 2
- KTSDBMVHAKWDRK-UHFFFAOYSA-N 4-chloro-7,10-dioxa-13,17,18,21-tetrazatetracyclo[12.5.2.12,6.017,20]docosa-1(20),2(22),3,5,14(21),15,18-heptaene Chemical compound Clc1cc2OCCOCCNc3ccn4ncc(-c(c1)c2)c4n3 KTSDBMVHAKWDRK-UHFFFAOYSA-N 0.000 description 2
- AFTZZRFCMOAFCR-UHFFFAOYSA-N 4-n-(9-ethylcarbazol-3-yl)-2-n-(3-morpholin-4-ylpropyl)pyrimidine-2,4-diamine Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(N=1)=CC=NC=1NCCCN1CCOCC1 AFTZZRFCMOAFCR-UHFFFAOYSA-N 0.000 description 2
- URUSABQSUCBGGJ-UHFFFAOYSA-N 5-(5,5,8,8-tetramethyl-6,7-dihydroanthracen-2-yl)thiophene-3-carboxylic acid Chemical compound C=1C=C2C=C3C(C)(C)CCC(C)(C)C3=CC2=CC=1C1=CC(C(O)=O)=CS1 URUSABQSUCBGGJ-UHFFFAOYSA-N 0.000 description 2
- NARMJPIBAXVUIE-UHFFFAOYSA-N 5-[2-tert-butyl-4-(4-fluorophenyl)-1h-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.N1=C2N(CC(C)(C)C)C(N)=NC2=CC=C1C=1N=C(C(C)(C)C)NC=1C1=CC=C(F)C=C1 NARMJPIBAXVUIE-UHFFFAOYSA-N 0.000 description 2
- WHIWGRCYMQLLAO-UHFFFAOYSA-N 6-(4-tert-butylphenoxy)pyridin-3-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(N)C=N1 WHIWGRCYMQLLAO-UHFFFAOYSA-N 0.000 description 2
- FYSRKRZDBHOFAY-UHFFFAOYSA-N 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)-3-pyridinecarboxamide Chemical compound FC=1C=CC=C(F)C=1N(C(=O)N)C(N=1)=CC=C(C(N)=O)C=1C1=CC=C(F)C=C1F FYSRKRZDBHOFAY-UHFFFAOYSA-N 0.000 description 2
- MQUYTXDAVCOCMX-UHFFFAOYSA-N 6-phenyl-2-imidazo[2,1-b][1,3,4]thiadiazolesulfonamide Chemical compound N1=C2SC(S(=O)(=O)N)=NN2C=C1C1=CC=CC=C1 MQUYTXDAVCOCMX-UHFFFAOYSA-N 0.000 description 2
- LJCANTASZGYJLG-UHFFFAOYSA-N 9-ethyl-3-(5-phenyltriazol-1-yl)carbazole Chemical compound C(C)N1C2=CC=CC=C2C=2C=C(C=CC1=2)N1N=NC=C1C1=CC=CC=C1 LJCANTASZGYJLG-UHFFFAOYSA-N 0.000 description 2
- IAUZTOZLTFSMIE-UHFFFAOYSA-N 9-hydroxy-4-phenyl-6h-pyrrolo[3,4-c]carbazole-1,3-dione Chemical compound C=12C(=O)NC(=O)C2=C2C3=CC(O)=CC=C3NC2=CC=1C1=CC=CC=C1 IAUZTOZLTFSMIE-UHFFFAOYSA-N 0.000 description 2
- MGGBYMDAPCCKCT-UHFFFAOYSA-N ASP-3026 Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=NC=1NC1=CC=CC=C1S(=O)(=O)C(C)C MGGBYMDAPCCKCT-UHFFFAOYSA-N 0.000 description 2
- 229940121819 ATPase inhibitor Drugs 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- 101100256985 Arabidopsis thaliana SIS3 gene Proteins 0.000 description 2
- 239000000592 Artificial Cell Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 description 2
- 108010040163 CREB-Binding Protein Proteins 0.000 description 2
- 102100021975 CREB-binding protein Human genes 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- PMTPYUTZAJWGPE-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC(=O)C1CN(CC(C1)(F)F)C(C1=CC(=CC=C1)C=1OC=CC=1)=O Chemical compound ClC1=CC=C(C=C1)NC(=O)C1CN(CC(C1)(F)F)C(C1=CC(=CC=C1)C=1OC=CC=1)=O PMTPYUTZAJWGPE-UHFFFAOYSA-N 0.000 description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
- 101100239628 Danio rerio myca gene Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 2
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 2
- 101710181403 Frizzled Proteins 0.000 description 2
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 description 2
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 2
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 description 2
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 2
- 101000583156 Homo sapiens Pituitary homeobox 1 Proteins 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 241000283953 Lagomorpha Species 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 2
- 101150039798 MYC gene Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 2
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- 101000716728 Mus musculus Kit ligand Proteins 0.000 description 2
- 102000005640 Myosin Type II Human genes 0.000 description 2
- 108010045128 Myosin Type II Proteins 0.000 description 2
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 2
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- WQGDQGAFSDMBLA-UHFFFAOYSA-N N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide Chemical compound C1=CC=C2C(C(NC3=C(C=4CCCCC=4S3)C#N)=O)=CC=CC2=C1 WQGDQGAFSDMBLA-UHFFFAOYSA-N 0.000 description 2
- OLIIUAHHAZEXEX-UHFFFAOYSA-N N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyridine-5-carboxamide Chemical compound C1C(=O)NC(C)=C(C(=O)NC=2C(=CC=3NN=CC=3C=2)F)C1C1=CC=C(C(F)(F)F)C=C1 OLIIUAHHAZEXEX-UHFFFAOYSA-N 0.000 description 2
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 2
- HEKAIDKUDLCBRU-UHFFFAOYSA-N N-[4-[2-ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]benzamide Chemical compound S1C(CC)=NC(C=2C=C(C)C=CC=2)=C1C(C=1)=CC=NC=1NC(=O)C1=CC=CC=C1 HEKAIDKUDLCBRU-UHFFFAOYSA-N 0.000 description 2
- 108050000637 N-cadherin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 2
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 2
- KCAJXIDMCNPGHZ-UHFFFAOYSA-N PH 797804 Chemical compound CNC(=O)C1=CC=C(C)C(N2C(C(Br)=C(OCC=3C(=CC(F)=CC=3)F)C=C2C)=O)=C1 KCAJXIDMCNPGHZ-UHFFFAOYSA-N 0.000 description 2
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000006877 Pituitary Hormones Human genes 0.000 description 2
- 108010047386 Pituitary Hormones Proteins 0.000 description 2
- 102100030345 Pituitary homeobox 1 Human genes 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000183024 Populus tremula Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- KCSAJXDPYPCGAE-UHFFFAOYSA-N S1C=NC2=C1C=C(C=C2)C1=CC(=NN1C1=NC(=CC=C1)C)C(=O)NC1=CC=C(C=C1)O Chemical compound S1C=NC2=C1C=C(C=C2)C1=CC(=NN1C1=NC(=CC=C1)C)C(=O)NC1=CC=C(C=C1)O KCSAJXDPYPCGAE-UHFFFAOYSA-N 0.000 description 2
- CATQHDWESBRRQA-UHFFFAOYSA-N SD-06 Chemical compound C1CN(C(=O)CO)CCC1C1=NNC(C=2C=CC(Cl)=CC=2)=C1C1=CC=NC=N1 CATQHDWESBRRQA-UHFFFAOYSA-N 0.000 description 2
- CDKIEBFIMCSCBB-CALJPSDSSA-N SIS3 Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)\C=C\C(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-CALJPSDSSA-N 0.000 description 2
- 101150086694 SLC22A3 gene Proteins 0.000 description 2
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 2
- 102100034201 Sclerostin Human genes 0.000 description 2
- 101710116197 Serine/threonine kinase NLK Proteins 0.000 description 2
- 102100034447 Serine/threonine-protein kinase NLK Human genes 0.000 description 2
- 101710175706 Serine/threonine-protein kinase NLK Proteins 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000004535 Tankyrases Human genes 0.000 description 2
- 108010017601 Tankyrases Proteins 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 108010063130 Type II Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
- 102000010571 Type II Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 description 2
- VEPKQEUBKLEPRA-UHFFFAOYSA-N VX-745 Chemical compound FC1=CC(F)=CC=C1SC1=NN2C=NC(=O)C(C=3C(=CC=CC=3Cl)Cl)=C2C=C1 VEPKQEUBKLEPRA-UHFFFAOYSA-N 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 102000006757 Wnt Receptors Human genes 0.000 description 2
- 108010047118 Wnt Receptors Proteins 0.000 description 2
- 102100038258 Wnt inhibitory factor 1 Human genes 0.000 description 2
- 101710194167 Wnt inhibitory factor 1 Proteins 0.000 description 2
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 2
- NGBKFLTYGSREKK-PMACEKPBSA-N Z-Val-Phe-H Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C(=O)OCC1=CC=CC=C1 NGBKFLTYGSREKK-PMACEKPBSA-N 0.000 description 2
- WBSWWONMTZEOGS-PTGBLXJZSA-N [(e)-indeno[1,2-b]quinoxalin-11-ylideneamino] furan-2-carboxylate Chemical compound C\12=CC=CC=C2C2=NC3=CC=CC=C3N=C2C/1=N/OC(=O)C1=CC=CO1 WBSWWONMTZEOGS-PTGBLXJZSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- WTZMCUOBQPTERK-UHFFFAOYSA-N [2-methoxy-3-(4,5,10-triazatetracyclo[7.7.0.02,6.012,16]hexadeca-1(9),2(6),3,7,10,12(16)-hexaen-11-yl)phenyl]boronic acid Chemical compound COc1c(cccc1-c1nc2ccc3[nH]ncc3c2c2CCCc12)B(O)O WTZMCUOBQPTERK-UHFFFAOYSA-N 0.000 description 2
- PWPNYABQEOGNNC-UHFFFAOYSA-N [3-[[4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carbonyl]amino]phenyl] n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=CC=CC(NC(=O)C2(CN)CCN(CC2)C=2C=3C(C)=CNC=3N=CN=2)=C1 PWPNYABQEOGNNC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- ACPOUJIDANTYHO-UHFFFAOYSA-N anthra[1,9-cd]pyrazol-6(2H)-one Chemical compound C1=CC(C(=O)C=2C3=CC=CC=2)=C2C3=NNC2=C1 ACPOUJIDANTYHO-UHFFFAOYSA-N 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-VQEHIDDOSA-N benzoic acid Chemical compound OC(=O)C1=CC=C[13CH]=C1 WPYMKLBDIGXBTP-VQEHIDDOSA-N 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 2
- LZAXPYOBKSJSEX-UHFFFAOYSA-N blebbistatin Chemical compound C1CC2(O)C(=O)C3=CC(C)=CC=C3N=C2N1C1=CC=CC=C1 LZAXPYOBKSJSEX-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 2
- 108010015046 cell aggregation factors Proteins 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229960001602 ceritinib Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229960003290 cortisone acetate Drugs 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- SWWVFYHSSOWZMF-UHFFFAOYSA-N cyclohexyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,6,8-tetrahydroquinoline-3-carboxylate Chemical compound C1C(C)(C)CC(=O)C2=C1NC(C)=C(C(=O)OC1CCCCC1)C2C1=CC=C([N+]([O-])=O)C=C1 SWWVFYHSSOWZMF-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000002451 diencephalon Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 2
- 229960003336 fluorocortisol acetate Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- SCMLRESZJCKCTC-KMYQRJGFSA-N gtpl8173 Chemical compound C12=CC=C(CSCC)C=C2C2=C(CNC3=O)C3=C3C4=CC(CSCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@](O)(C(=O)OC)C[C@H]4O1 SCMLRESZJCKCTC-KMYQRJGFSA-N 0.000 description 2
- NQQBNZBOOHHVQP-UHFFFAOYSA-N halicin Chemical compound S1C(N)=NN=C1SC1=NC=C([N+]([O-])=O)S1 NQQBNZBOOHHVQP-UHFFFAOYSA-N 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HBQGFROGWOHBAG-UHFFFAOYSA-K manganese(3+);2-[2-[(2-oxidophenyl)methylideneamino]ethyliminomethyl]phenolate;chloride Chemical compound [Cl-].[Mn+3].[O-]C1=CC=CC=C1C=NCCN=CC1=CC=CC=C1[O-] HBQGFROGWOHBAG-UHFFFAOYSA-K 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- DQNMDJGZWFZNHS-UHFFFAOYSA-N n-(4,5-dihydrobenzo[e][1,3]benzothiazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)NC(S1)=NC2=C1CCC1=CC=CC=C21 DQNMDJGZWFZNHS-UHFFFAOYSA-N 0.000 description 2
- KQMPRSZTUSSXND-UHFFFAOYSA-N n-(4-amino-5-cyano-6-ethoxypyridin-2-yl)-2-(2,5-dimethoxyphenyl)acetamide Chemical compound NC1=C(C#N)C(OCC)=NC(NC(=O)CC=2C(=CC=C(OC)C=2)OC)=C1 KQMPRSZTUSSXND-UHFFFAOYSA-N 0.000 description 2
- JIUFLMSAFMXEEC-UHFFFAOYSA-N n-(6-methoxy-1,3-benzothiazol-2-yl)-2-[(4-propyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide Chemical compound CCCN1C(SCC(=O)NC=2SC3=CC(OC)=CC=C3N=2)=NN=C1C1=CC=NC=C1 JIUFLMSAFMXEEC-UHFFFAOYSA-N 0.000 description 2
- JRVSFZKYQCETAH-OAHLLOKOSA-N n-[(1r)-1-(3-methoxyphenyl)ethyl]-4-pyridin-4-ylbenzamide Chemical compound COC1=CC=CC([C@@H](C)NC(=O)C=2C=CC(=CC=2)C=2C=CN=CC=2)=C1 JRVSFZKYQCETAH-OAHLLOKOSA-N 0.000 description 2
- DPZSYTMLVCLGRU-UHFFFAOYSA-N n-[1-[(4-methylsulfanylphenyl)methyl]piperidin-3-yl]-1h-indazol-5-amine Chemical compound C1=CC(SC)=CC=C1CN1CC(NC=2C=C3C=NNC3=CC=2)CCC1 DPZSYTMLVCLGRU-UHFFFAOYSA-N 0.000 description 2
- YOVNFNXUCOWYSG-UHFFFAOYSA-N n-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide Chemical compound C1=C2N(CC)C(C=3C(=NON=3)N)=NC2=CN=C1OC(C=1)=CC=CC=1NC(=O)C(C=C1)=CC=C1OCCN1CCOCC1 YOVNFNXUCOWYSG-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000002220 organoid Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- JYYLVUFNAHSSFE-UHFFFAOYSA-N pamapimod Chemical compound O=C1N(C)C2=NC(NC(CCO)CCO)=NC=C2C=C1OC1=CC=C(F)C=C1F JYYLVUFNAHSSFE-UHFFFAOYSA-N 0.000 description 2
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 2
- 229940069510 parthenolide Drugs 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- MDLUYYGRCGDKGL-UHFFFAOYSA-N propyl 4-[(1-hexyl-4-hydroxy-2-oxoquinoline-3-carbonyl)amino]benzoate Chemical compound O=C1N(CCCCCC)C2=CC=CC=C2C(O)=C1C(=O)NC1=CC=C(C(=O)OCCC)C=C1 MDLUYYGRCGDKGL-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- QSKQVZWVLOIIEV-NSHDSACASA-N ripasudil Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(F)=C12 QSKQVZWVLOIIEV-NSHDSACASA-N 0.000 description 2
- WUILNKCFCLNXOK-CFBAGHHKSA-N salirasib Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O WUILNKCFCLNXOK-CFBAGHHKSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 2
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- ZMELOYOKMZBMRB-DLBZAZTESA-N talmapimod Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)C=2C(=CC=3N(C)C=C(C=3C=2)C(=O)C(=O)N(C)C)Cl)N1CC1=CC=C(F)C=C1 ZMELOYOKMZBMRB-DLBZAZTESA-N 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000002444 unipotent stem cell Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- IIRWNGPLJQXWFJ-KRWDZBQOSA-N (1s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)phenyl]ethanol Chemical compound C1([C@](O)(CN)C=2C=CC(=CC=2)C2=CNN=C2)=CC=C(Cl)C=C1 IIRWNGPLJQXWFJ-KRWDZBQOSA-N 0.000 description 1
- RRJOMESUBQAYOA-BZSNNMDCSA-N (2S)-2-[[(2S)-2-[[2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-6-aminohexanamide Chemical compound NCCCC[C@H](NC(=O)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CN=CN1 RRJOMESUBQAYOA-BZSNNMDCSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BZNPYIWZPTYCQH-KFTPUPIBSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3-(2,3-dihydroxypropoxy)-4-octoxy-2h-furan-5-one Chemical compound CCCCCCCCOC1=C(OCC(O)CO)[C@@H]([C@@H](O)CO)OC1=O BZNPYIWZPTYCQH-KFTPUPIBSA-N 0.000 description 1
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MJQMRGWYPNIERM-HNNXBMFYSA-N (4s)-4-(2,4-difluoro-5-pyrimidin-5-ylphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine Chemical compound C=1C(C=2C=NC=NC=2)=C(F)C=C(F)C=1[C@]1(C)CCSC(N)=N1 MJQMRGWYPNIERM-HNNXBMFYSA-N 0.000 description 1
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- GGXCUZHEJUJACD-UHFFFAOYSA-N 1-(1,2,3-benzothiadiazol-6-yl)-3-[2-(cyclohexen-1-yl)ethyl]urea Chemical compound C=1C=C2N=NSC2=CC=1NC(=O)NCCC1=CCCCC1 GGXCUZHEJUJACD-UHFFFAOYSA-N 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- TXDIRJCYNAWBOS-UHFFFAOYSA-N 1-[4-[4-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-chloropyrimidin-4-yl]amino]-3-methoxyphenyl]piperazin-1-yl]ethanone Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(Cl)C=1NC(C(=C1)OC)=CC=C1N1CCN(C(C)=O)CC1 TXDIRJCYNAWBOS-UHFFFAOYSA-N 0.000 description 1
- YSYIWCNPSZNNKW-UHFFFAOYSA-N 11-nitroso-10h-indeno[1,2-b]quinoxaline Chemical compound C1=CC=C[C]2N[C]3C(N=O)=C(C=CC=C4)C4=C3N=C21 YSYIWCNPSZNNKW-UHFFFAOYSA-N 0.000 description 1
- JDVOIBFEFVKUPL-UHFFFAOYSA-N 2-[(4-bromophenyl)methylsulfanyl]-1,3-benzoxazole Chemical compound C1=CC(Br)=CC=C1CSC1=NC2=CC=CC=C2O1 JDVOIBFEFVKUPL-UHFFFAOYSA-N 0.000 description 1
- UHBFMJAKLZGVDS-UHFFFAOYSA-N 2-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1,3-benzothiazole Chemical compound S1C([N+](=O)[O-])=CN=C1SC1=NC2=CC=CC=C2S1 UHBFMJAKLZGVDS-UHFFFAOYSA-N 0.000 description 1
- QMLOYDPILBUVBV-UHFFFAOYSA-N 2-[5-methyl-4-[2-(trifluoromethyl)pyridin-4-yl]imidazol-1-yl]-N-(5-pyrazin-2-ylpyridin-2-yl)acetamide Chemical compound CC1=C(N=CN1CC(=O)NC1=NC=C(C=C1)C1=NC=CN=C1)C1=CC(=NC=C1)C(F)(F)F QMLOYDPILBUVBV-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- 125000002981 3-(trifluoromethyl)benzoyl group Chemical group FC(C=1C=C(C(=O)*)C=CC1)(F)F 0.000 description 1
- WGPXKFOFEXJMBD-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N)O WGPXKFOFEXJMBD-UHFFFAOYSA-N 0.000 description 1
- RXZDWPYJFCAZCW-UHFFFAOYSA-N 3-chloro-4,7-difluoro-n-[4-(methylamino)cyclohexyl]-n-[(3-pyridin-4-ylphenyl)methyl]-1-benzothiophene-2-carboxamide Chemical compound C1CC(NC)CCC1N(C(=O)C1=C(C2=C(F)C=CC(F)=C2S1)Cl)CC1=CC=CC(C=2C=CN=CC=2)=C1 RXZDWPYJFCAZCW-UHFFFAOYSA-N 0.000 description 1
- ACCBNXMBIMNJHD-UHFFFAOYSA-N 3-chloro-n-[4-(methylamino)cyclohexyl]-n-[(3-pyridin-2-ylphenyl)methyl]-1-benzothiophene-2-carboxamide Chemical compound C1CC(NC)CCC1N(C(=O)C1=C(C2=CC=CC=C2S1)Cl)CC1=CC=CC(C=2N=CC=CC=2)=C1 ACCBNXMBIMNJHD-UHFFFAOYSA-N 0.000 description 1
- AANFHDFOMFRLLR-UHFFFAOYSA-N 3-fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(O)C(=O)NC1=CC=C(C(O)=O)C=C1F AANFHDFOMFRLLR-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BSZQSLWNMVTKJT-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-8-(2-methylphenyl)-7-oxido-1,7-naphthyridin-7-ium Chemical compound CC1=CC=CC=C1C1=[N+]([O-])C=CC2=C(C=3C(=CC(F)=CC=3)F)C=CN=C12 BSZQSLWNMVTKJT-UHFFFAOYSA-N 0.000 description 1
- IYOZTVGMEWJPKR-VOMCLLRMSA-N 4-[(1R)-1-aminoethyl]-N-pyridin-4-yl-1-cyclohexanecarboxamide Chemical compound C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-VOMCLLRMSA-N 0.000 description 1
- FOUVTBKPJRMLPE-FMIVXFBMSA-N 4-[(e)-3-(3,5-ditert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(C(=O)\C=C\C=2C=CC(=CC=2)C(O)=O)=C1 FOUVTBKPJRMLPE-FMIVXFBMSA-N 0.000 description 1
- MFBCDACCJCDGBA-UHFFFAOYSA-N 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid Chemical compound CC(C)(C)C1=CC(C=2C(=CC=C(C=2)C=2C=CC(=CC=2)C(O)=O)OCCO)=CC=C1N1CCCC1 MFBCDACCJCDGBA-UHFFFAOYSA-N 0.000 description 1
- ZQUSFAUAYSEREK-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1-imidazolyl]-1-cyclohexanol Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCC(O)CC2)=N1 ZQUSFAUAYSEREK-UHFFFAOYSA-N 0.000 description 1
- GDTQLZHHDRRBEB-UHFFFAOYSA-N 4-[5-(cyclopropylcarbamoyl)-2-methylanilino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide Chemical compound C12=C(C)C(C(=O)NCCC)=CN2N=CN=C1NC(C(=CC=1)C)=CC=1C(=O)NC1CC1 GDTQLZHHDRRBEB-UHFFFAOYSA-N 0.000 description 1
- CMQXLLAILGGLRV-UHFFFAOYSA-N 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride Chemical compound Cl.Cl.C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12 CMQXLLAILGGLRV-UHFFFAOYSA-N 0.000 description 1
- IBGLGMOPHJQDJB-MOKVOYLWSA-N 4-[[9-[(3s)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol Chemical compound C1CC(O)CCC1NC1=NC=C(N=C(NC=2C(=CC(F)=CC=2F)F)N2[C@@H]3COCC3)C2=N1 IBGLGMOPHJQDJB-MOKVOYLWSA-N 0.000 description 1
- BPVZKUXLOLRECL-UHFFFAOYSA-N 4-chloro-1-piperidin-4-yl-n-(5-pyridin-2-yl-1h-pyrazol-4-yl)pyrazole-3-carboxamide Chemical compound ClC1=CN(C2CCNCC2)N=C1C(=O)NC=1C=NNC=1C1=CC=CC=N1 BPVZKUXLOLRECL-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- IYWFOPPYQUEKHN-VOTSOKGWSA-N 5-[(e)-2-phenylethenyl]benzene-1,2,3-triol Chemical compound OC1=C(O)C(O)=CC(\C=C\C=2C=CC=CC=2)=C1 IYWFOPPYQUEKHN-VOTSOKGWSA-N 0.000 description 1
- GXZDVPICTGFDMP-UHFFFAOYSA-N 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-1H-quinolin-2-one Chemical compound C1=CC(OC)=CC=C1C1=CN2N=CC(C=3C=4C=CC(=O)NC=4C=CC=3)=C2N=C1 GXZDVPICTGFDMP-UHFFFAOYSA-N 0.000 description 1
- IPEXHQGMTHOKQV-UHFFFAOYSA-N 6-piperidin-4-yloxy-2h-isoquinolin-1-one Chemical compound C=1C=C2C(=O)NC=CC2=CC=1OC1CCNCC1 IPEXHQGMTHOKQV-UHFFFAOYSA-N 0.000 description 1
- KMNVOGVCCZNVNU-UHFFFAOYSA-N 6-piperidin-4-yloxy-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.C=1C=C2C(=O)NC=CC2=CC=1OC1CCNCC1 KMNVOGVCCZNVNU-UHFFFAOYSA-N 0.000 description 1
- CJFSBECQAATXRD-UHFFFAOYSA-N 7-(4-propan-2-yloxyphenyl)-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyridine Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC2=NC=C(C3=CNN=C3)N2C=C1 CJFSBECQAATXRD-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 102100034111 Activin receptor type-1 Human genes 0.000 description 1
- 102100034134 Activin receptor type-1B Human genes 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101100455868 Arabidopsis thaliana MKK2 gene Proteins 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 229940123644 Bcl9 inhibitor Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 1
- 101710120271 Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100022291 C-Jun-amino-terminal kinase-interacting protein 1 Human genes 0.000 description 1
- 101710105206 C-Jun-amino-terminal kinase-interacting protein 1 Proteins 0.000 description 1
- XDIGZFOEYRTDPK-UHFFFAOYSA-N C1CSC2=C1N=CN(C2=O)C3=CC=CC=C3 Chemical compound C1CSC2=C1N=CN(C2=O)C3=CC=CC=C3 XDIGZFOEYRTDPK-UHFFFAOYSA-N 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 101100181137 Caenorhabditis elegans pkc-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- 101710116137 Calcium/calmodulin-dependent protein kinase II Proteins 0.000 description 1
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229940076606 Casein kinase 1 inhibitor Drugs 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 description 1
- 241000202252 Cerberus Species 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108091065053 DAN family Proteins 0.000 description 1
- 102000038900 DAN family Human genes 0.000 description 1
- 101100477839 Drosophila melanogaster Smurf gene Proteins 0.000 description 1
- 101100269980 Drosophila melanogaster aPKC gene Proteins 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150099612 Esrrb gene Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000027355 Ferocactus setispinus Species 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 229940125633 GPCR agonist Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 102100038367 Gremlin-1 Human genes 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 description 1
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 1
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 description 1
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 description 1
- 101100287682 Homo sapiens CAMK2G gene Proteins 0.000 description 1
- 101100126883 Homo sapiens CAMK4 gene Proteins 0.000 description 1
- 101100281008 Homo sapiens FGF2 gene Proteins 0.000 description 1
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 description 1
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 1
- 101000958332 Homo sapiens Lymphocyte antigen 6 complex locus protein G6d Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101001069727 Homo sapiens Paired mesoderm homeobox protein 1 Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101000684679 Homo sapiens Protein APCDD1-like Proteins 0.000 description 1
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000687911 Homo sapiens Transcription factor SOX-3 Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229940118135 JNK inhibitor Drugs 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 241000288903 Lemuridae Species 0.000 description 1
- 229940122140 Lim kinase inhibitor Drugs 0.000 description 1
- 241000288986 Lorisidae Species 0.000 description 1
- 102100038210 Lymphocyte antigen 6 complex locus protein G6d Human genes 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 1
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- GYYDQHBKIHQHEB-UHFFFAOYSA-N N-(5-phenylpyridin-2-yl)-2-(5-phenyl-4-pyridin-4-yltriazol-1-yl)acetamide Chemical compound O=C(Cn1nnc(c1-c1ccccc1)-c1ccncc1)Nc1ccc(cn1)-c1ccccc1 GYYDQHBKIHQHEB-UHFFFAOYSA-N 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- QOIOJVPRHIAONM-UHFFFAOYSA-N N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)benzamide trihydrochloride Chemical compound Cl.Cl.Cl.CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(Oc4ccnc5[nH]ccc45)c3)cc2C(F)(F)F)CC1 QOIOJVPRHIAONM-UHFFFAOYSA-N 0.000 description 1
- JGQSLTZPBLZNBX-UHFFFAOYSA-N N-ethyl-2-hydroxy-N-methyl-3-[C-phenyl-N-[4-(piperidin-1-ylmethyl)phenyl]carbonimidoyl]-1H-indole-6-carboxamide Chemical compound CCN(C)C(=O)C1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN4CCCCC4)C5=CC=CC=C5 JGQSLTZPBLZNBX-UHFFFAOYSA-N 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- DEFBCZWQLILOJF-UHFFFAOYSA-N NSC 23766 Chemical compound CCN(CC)CCCC(C)NC1=NC(C)=CC(NC=2C=C3C(N)=CC(C)=NC3=CC=2)=N1 DEFBCZWQLILOJF-UHFFFAOYSA-N 0.000 description 1
- CPUHORIUXPQCHW-UHFFFAOYSA-N NSC 23766 trihydrochloride Chemical compound Cl.Cl.Cl.CCN(CC)CCCC(C)NC1=NC(C)=CC(NC=2C=C3C(N)=CC(C)=NC3=CC=2)=N1 CPUHORIUXPQCHW-UHFFFAOYSA-N 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 101150025249 Notum gene Proteins 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 102000017954 Nuclear factor of activated T cells (NFAT) Human genes 0.000 description 1
- 108050007058 Nuclear factor of activated T cells (NFAT) Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229940121878 P300 inhibitor Drugs 0.000 description 1
- 108700043304 PKC-3 Proteins 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 102100033786 Paired mesoderm homeobox protein 1 Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 108700017836 Prophet of Pit-1 Proteins 0.000 description 1
- 102100023736 Protein APCDD1-like Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 102000011425 S100 Calcium Binding Protein beta Subunit Human genes 0.000 description 1
- 108010023918 S100 Calcium Binding Protein beta Subunit Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101150106167 SOX9 gene Proteins 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 102100030053 Secreted frizzled-related protein 3 Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 1
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000168914 Strepsirrhini Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940125920 TGFβR inhibitor Drugs 0.000 description 1
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 102100024276 Transcription factor SOX-3 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- PHWHNHYZZNJPLB-MRVPVSSYSA-N [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-7-yl]-[(3r)-3-aminopyrrolidin-1-yl]methanone Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=CN=CC=1C(=O)N1CC[C@@H](N)C1 PHWHNHYZZNJPLB-MRVPVSSYSA-N 0.000 description 1
- HSROPTGRSYJPJY-JZGIKJSDSA-N [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-7-yl]-[(3s)-3-aminopyrrolidin-1-yl]methanone;dihydrochloride Chemical compound Cl.Cl.C=12N(CC)C(C=3C(=NON=3)N)=NC2=CN=CC=1C(=O)N1CC[C@H](N)C1 HSROPTGRSYJPJY-JZGIKJSDSA-N 0.000 description 1
- QFYLTUDRXBNZFQ-UHFFFAOYSA-N [4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-[4-(5-methylpyrazol-1-yl)phenyl]methanone Chemical compound CC1=CC=NN1C1=CC=C(C(=O)N2CCN(CC2)S(=O)(=O)C=2C=C(C(Cl)=CC=2)C(F)(F)F)C=C1 QFYLTUDRXBNZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 229910052767 actinium Inorganic materials 0.000 description 1
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003329 adenohypophysis hormone Substances 0.000 description 1
- 210000002867 adherens junction Anatomy 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229930188866 apocynin Natural products 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000019276 ascorbyl stearate Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- HYGWNUKOUCZBND-UHFFFAOYSA-N azanide Chemical compound [NH2-] HYGWNUKOUCZBND-UHFFFAOYSA-N 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 229940074162 belumosudil Drugs 0.000 description 1
- 229950006785 bentamapimod Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 229950003054 binimetinib Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- OVPPMIXGVMXSNS-CLIBVNCNSA-N c-jun peptide Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1[C@H](C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 OVPPMIXGVMXSNS-CLIBVNCNSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N caffeic acid Chemical compound OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 108010007877 calpain inhibitor III Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 101150113535 chek1 gene Proteins 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 102000006533 chordin Human genes 0.000 description 1
- 108010008846 chordin Proteins 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 229950005521 doramapimod Drugs 0.000 description 1
- 108091066386 draxin family Proteins 0.000 description 1
- 102000039185 draxin family Human genes 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 108060002566 ephrin Proteins 0.000 description 1
- 102000012803 ephrin Human genes 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000001955 intestinal smooth muscle cell Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 101150002688 kremen1 gene Proteins 0.000 description 1
- 101150108076 lin28a gene Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- OAWZTKNCHQQRKF-UHFFFAOYSA-L manganese(3+);4-[10,15,20-tris(4-carboxyphenyl)porphyrin-22,24-diid-5-yl]benzoic acid Chemical compound [Mn+3].C1=CC(C(=O)O)=CC=C1C(C1=CC=C([N-]1)C(C=1C=CC(=CC=1)C(O)=O)=C1C=CC(=N1)C(C=1C=CC(=CC=1)C(O)=O)=C1C=CC([N-]1)=C1C=2C=CC(=CC=2)C(O)=O)=C2N=C1C=C2 OAWZTKNCHQQRKF-UHFFFAOYSA-L 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 238000012083 mass cytometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229940071539 mirdametinib Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- PKMBRIPHIVDBSP-UHFFFAOYSA-N mn(iii)tbap Chemical compound C1=CC(C(=O)O)=CC=C1C1=C2N3C(N45)(N67)N8C1CCC8=C(C=1C=CC(=CC=1)C(O)=O)C7=CC=C6C(C=1C=CC(=CC=1)C(O)=O)=C5CCC4C(C=1C=CC(=CC=1)C(O)=O)=C3C=C2 PKMBRIPHIVDBSP-UHFFFAOYSA-N 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- QRJTZIJWDLJKQO-UHFFFAOYSA-N n-(cyclopropylmethyl)-4-[[4-(6-hydroxy-3,4-dihydro-2h-quinolin-1-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1CCC2=CC(O)=CC=C2N1C(N=1)=CC=NC=1NC(C=C1)=CC=C1S(=O)(=O)NCC1CC1 QRJTZIJWDLJKQO-UHFFFAOYSA-N 0.000 description 1
- ANQWETXPBPZVOF-UHFFFAOYSA-N n-cyclopropyl-4-[4-(4-fluorophenyl)-2-piperidin-4-yl-1,3-thiazol-5-yl]pyrimidin-2-amine;dihydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C1=C(C=2N=C(NC3CC3)N=CC=2)SC(C2CCNCC2)=N1 ANQWETXPBPZVOF-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229940069817 neflamapimod Drugs 0.000 description 1
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 229950001749 pamapimod Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000009958 panhypopituitarism Diseases 0.000 description 1
- 229950006299 pelitinib Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229950002913 pexmetinib Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229950002592 pimasertib Drugs 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 208000003068 pituitary dwarfism Diseases 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- AANFHDFOMFRLLR-LJQANCHMSA-N r-3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid Chemical compound O=C([C@H](O)C=1C=C2C(C)(C)CCC(C2=CC=1)(C)C)NC1=CC=C(C(O)=O)C=C1F AANFHDFOMFRLLR-LJQANCHMSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229950008933 refametinib Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229950007455 ripasudil Drugs 0.000 description 1
- 229950008669 salirasib Drugs 0.000 description 1
- 229950009919 saracatinib Drugs 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- HVAKSLUOHARFLM-UHFFFAOYSA-N selenium;sodium Chemical compound [Se][Na] HVAKSLUOHARFLM-UHFFFAOYSA-N 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 description 1
- 229950002902 tanzisertib Drugs 0.000 description 1
- MURCDOXDAHPNRQ-UHFFFAOYSA-N tert-butyl n-[6-[[1-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-5-benzyl-3-hydroxy-6-oxo-1-phenylhexan-2-yl]carbamate Chemical compound C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC=1C=CC=CC=1)CC(O)C(NC(=O)OC(C)(C)C)CC1=CC=CC=C1 MURCDOXDAHPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229950008964 trifarotene Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 229950006594 verosudil Drugs 0.000 description 1
- 229940121396 wnt pathway inhibitor Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Definitions
- the present invention relates to a cell aggregate containing pituitary hormone-producing cells differentiated from pluripotent stem cells in vitro, and a method for producing the same.
- the pituitary gland is a small endocrine organ located in contact with the lower part of the diencephalon and plays a major role as a control center for various hormones. For example, it produces a variety of pituitary hormones, including adrenocorticotropic hormone (ACTH), which promotes the production of adrenocortical hormones essential for sustaining life, and growth hormone, which promotes the growth of children. As such, pituitary dysfunction causes severe systemic disease.
- ACTH adrenocorticotropic hormone
- Patent Document 1 non-patent.
- References 1 and 2 a hypothalamic-pituitary composite tissue is formed in one cell mass by three-dimensional culture.
- Patent Document 1 Non-Patent Document 1
- human ES/iPS cells were cultured in suspension in the presence of Wnt signaling pathway inhibitors, and by adding BMP signaling pathway agonists and Sonic-Hedgehog signaling pathway agonists, cell masses containing pituitary tissue were observed. can be produced efficiently (Patent Document 2).
- the neuroepithelial tissue of the ventral diencephalon and hypothalamus exists inside the cell mass, and the non-neuroepithelial tissue of the oral cavity, which exists outside, has a Rathke's pouch-like structure and a pituitary placode. found to be formed.
- cell markers for efficiently separating only pituitary hormone-producing cells from the cell clusters are used. and the timing of its separation was completely unknown.
- the present inventors searched for a suitable timing for separating pituitary hormone-producing cells and pituitary progenitor cells, which are their progenitor cells, from cell masses in the process of culturing that differentiate pluripotent stem cells into pituitary tissue,
- An object of the present invention is to provide aggregates of pituitary hormone-producing cells having excellent pituitary hormone-secreting ability by reaggregating the cells separated at the timing and further culturing them.
- EpCAM epithelial cell adhesion molecule
- the inventors have also found that the aggregates exhibit excellent pituitary hormone secretion ability by further differentiating and culturing the isolated and purified pituitary hormone-producing cells and pituitary progenitor cells and reaggregating them, and the present invention has been developed. I came to complete it.
- a cell aggregate containing pituitary hormone-producing cells (1) the proportion of cells positive for at least one of EpCAM and E-cadherin in the cell aggregate is 80% or more; (2) the percentage of neurons in the cell aggregate is 20% or less; (3) the proportion of ACTH-positive cells in the cell aggregate is 5% or more, (4) the cell density of the cell aggregate is 3,000 to 20,000 cells/mm 2 ; (5) the length of the cell aggregate is 200 to 3,000 ⁇ m, (6) on the surface of the cell aggregate, cells positive for at least one of EpCAM and E-cadherin adhere to each other to form an epithelial structure; (7) the cell aggregates form a sponge-like structure; A cell aggregate characterized by: [2] The cell aggregate according to [1], wherein the proportion of pituitary stem cells present in the cell aggregate is 3% or more.
- a method for producing a cell aggregate containing pituitary hormone-producing cells comprising the following steps: (1) isolating EpCAM-expressing cells from a dispersed cell population comprising pluripotent stem cell-derived hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells; suspension culture of the EpCAM-expressing cells for 14 days or longer under conditions that allow the pituitary progenitor cells to mature into pituitary hormone-producing cells.
- step (1) The production method of [7], wherein the cell population of step (1) is obtained by the following steps (A) and (B): (A) a step of culturing pluripotent stem cells or cell aggregates thereof under conditions capable of inducing differentiation into cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells; (B) A step of dispersing the cell aggregate containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells obtained in (A) into a cell population. [9] The production method according to [8], wherein step (A) includes the following steps.
- step (A) A first step of culturing pluripotent stem cells in the presence of a Wnt signaling pathway inhibitor to form cell aggregates. (2) culturing the cell aggregate obtained in the first step in the presence of a BMP signaling pathway agonist and a Shh signaling pathway agonist to generate hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells; a second step of obtaining cell aggregates containing; [10]
- step (A) includes the following steps.
- step (A) includes the following steps.
- the cell aggregate obtained in the first step is subjected to suspension culture in the presence of a BMP signaling pathway agonist and Shh signaling pathway agonist, and hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells
- a second step of obtaining a cell aggregate containing [12]
- the suspension culture in the first step is further in the presence of the Shh signaling pathway agonist, and the culture period in the presence of the Shh signaling pathway agonist in the first and second steps is 30 days.
- the culture period in step (A) is a period during which cell aggregates containing pituitary hormone-producing cells that secrete ACTH and not containing pituitary hormone-producing cells that secrete GH or TSH are obtained.
- the cell aggregate containing pituitary hormone-producing cells has the following characteristics: (1) the proportion of cells positive for at least one of EpCAM and E-cadherin in the cell aggregate is 80% or more; (2) the percentage of neurons in the cell aggregate is 20% or less; (3) the proportion of ACTH-positive cells in the cell aggregate is 5% or more, (4) the cell density of the cell aggregate is 3,000 to 20,000 cells/mm 2 ; (5) the length of the cell aggregate is 200 to 3,000 ⁇ m, (6) on the surface of the cell aggregate, cells positive for at least one of EpCAM and E-cadherin adhere to each other to form an epithelial structure; (7) The cell aggregate forms a sponge-like structure.
- functional pituitary hormone-producing cells are obtained by isolating an EpCAM-positive cell population at a specific timing from a cell mass during culture that differentiates pluripotent stem cells into pituitary tissue using EpCAM. and pituitary progenitor cells can be efficiently separated and purified.
- aggregates of pituitary hormone-producing cells obtained by further differentiating and culturing the isolated and purified pituitary hormone-producing cells and pituitary progenitor cells after reaggregation are stimulated by physiological pituitary hormone secretion. Since these cells exhibit excellent pituitary hormone secretion ability, they can be used to treat diseases related to the pituitary gland.
- FIG. 1 shows an overall process chart for producing cell aggregates containing pituitary hormone-producing cells from human ES/iPS cells.
- the manufacturing process includes (1) a step of differentiating human ES/iPS cells into cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells (step 1 differentiation), (2) hypothalamic cells, A step of isolating an EpCAM-positive cell population from a cell aggregate containing pituitary progenitor cells and pituitary hormone-producing cells (step 2 intermediate purification); The three steps are the step of producing cell aggregates containing cells (step 3 maturation culture).
- FIG. 2 shows a protocol for differentiating human ES cells into cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells.
- FIG. 3 is a diagram confirming the expression of various cell markers in cell aggregates 29, 61, and 103 days after initiation of differentiation induction.
- FIG. 4 shows a protocol for reaggregating purified EpCAM-positive cells and culturing them in long-term suspension.
- FIG. 5 is a diagram confirming the expression of various cell markers in cell aggregates (day62 sort + day41) purified using cell aggregates 62 days after the start of differentiation induction and cultured for a long period of 41 days after reaggregation. be.
- FIG. 6 is a diagram confirming the expression of various cell markers in cell aggregates (day 100 sort + day 31) purified using cell aggregates 100 days after the start of differentiation induction and cultured for a long period of 31 days after reaggregation.
- FIG. 7 shows quantification of the ACTH-positive cell ratio, cell density, and major diameter in cell aggregates on day 62 sort + day 41 and day 100 sort + day 31, and bright-field images.
- FIG. 8 shows a protocol for reaggregating purified EpCAM-positive cells and performing long-term suspension culture under Dexamethasone (DX)-added conditions.
- DX Dexamethasone
- FIG. 9 is a diagram confirming the expression of epithelial cell marker EpCAM and pituitary hormone-producing cell marker growth hormone (GH) in cell aggregates on day62 sort + day41 and cell aggregates on day100 sort + day31.
- 10A and 10B show the amounts of ACTH and GH in culture supernatants of EpCAM-positive and EpCAM-negative cell aggregates purified and reaggregated using cell aggregates 62 days after initiation of differentiation induction over time.
- FIG. 10 is a diagram showing the results of objective measurement;
- FIG. 10C is a diagram showing the results of an ACTH stimulation test with CRH using cell aggregates purified and reaggregated from cell aggregates 62 days after the initiation of differentiation induction and subjected to suspension culture for 41 days.
- FIG. 11A and 11B show the amounts of ACTH and GH in the culture supernatants of EpCAM-positive and EpCAM-negative cell aggregates purified and reaggregated using cell aggregates 100 days after initiation of differentiation induction over time.
- FIG. 10 is a diagram showing the results of objective measurement;
- FIG. 12 shows the results of measuring the expression levels of various cell markers in cell aggregates 3, 6, 19, 30, 60, 100, and 201 days after initiation of induction of differentiation.
- FIG. 13 shows various cell markers in cell aggregates purified using cell aggregates 30 days, 60 days, and 100 days after the start of differentiation induction, and cultured after reaggregation until 131 days after the start of differentiation induction. It is a figure confirming the expression of.
- FIG. 10 is a diagram showing the results of objective measurement
- FIG. 12 shows the results of measuring the expression levels of various cell markers in cell aggregates 3, 6, 19, 30, 60, 100, and 201 days after initiation of induction of differentiation.
- FIG. 13 shows various cell markers in cell
- FIG. 14 is a diagram confirming the expression of various cell markers in cell aggregates purified using cell aggregates 60 days after initiation of induction of differentiation, reaggregated, and cultured until 103 days after initiation of induction of differentiation.
- a to C are reaggregates of EpCAM-positive cells
- D to J are reaggregates of EpCAM-negative cells.
- Scale bars in D, E, I indicate 200 ⁇ m
- scale bars in AC, FH, J indicate 50 ⁇ m.
- FIG. 15 is a diagram of electron microscope observation of cell aggregates purified using cell aggregates 60 days after initiation of induction of differentiation, reaggregated, and cultured until 201 days after initiation of induction of differentiation.
- FIG. 16 shows an ACTH stimulation test with CRH or dexamethasone using cell aggregates that were purified using cell aggregates 60 days after the start of differentiation induction, reaggregated, and cultured until 103 days after the start of differentiation induction.
- FIG. 10 is a diagram showing the result of the experiment. **: p ⁇ 0.01, paired t-test.
- FIG. 17 shows the results of transplanting reaggregates of EpCAM-positive cells into the renal capsule of pituitary dysfunction mice, and confirming the expression of various cell markers in the kidney 24 weeks after transplantation.
- FIG. 16 shows an ACTH stimulation test with CRH or dexamethasone using cell aggregates that were purified using cell aggregates 60 days after the start of differentiation induction, reaggregated, and cultured until 103 days after the start of differentiation induction.
- FIG. 10 is a diagram showing the result of the experiment. **: p ⁇ 0.01, paired t-test.
- FIG. 17 shows the results of transplanting reaggregat
- FIG. 18 is a diagram showing the effects of CRH, dexamethasone, or LPS stimulation on ACTH secretion after transplanting reaggregates of EpCAM-positive cells into the renal capsule of hypopituitary dysfunction mice.
- Figure 18A *: p ⁇ 0.05, **: p ⁇ 0.01, ***: p ⁇ 0.001, Mann-Whitney test (shamversusgrafted), paired t-test (grafted preversuspost).
- Figure 18B and C **: p ⁇ 0.01, ***: p ⁇ 0.001, paired t-test.
- Figure 19 shows a protocol for differentiating human iPS cells into cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells.
- FIG. 1 shows a protocol for differentiating human iPS cells into cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells.
- FIG. 10 is a diagram comparing the ACTH secretion ability when SAG is continuously treated thereafter. *: p ⁇ 0.05, Student's t-test.
- FIG. 20 shows a protocol for reaggregating purified EpCAM-positive cells and culturing them in long-term suspension under DX addition conditions with different addition periods.
- FIG. 21 shows cell aggregates purified using cell aggregates 63 days after the start of differentiation induction, treated with DX for 3, 7 or 14 days from 3 days after reaggregation, and cultured until 103 days after the start of differentiation induction.
- FIG. 4 is a diagram confirming the expression of EpCAM, an epithelial cell marker, and growth hormone (GH), a pituitary hormone-producing cell marker, in aggregates.
- GH growth hormone
- Figure 22A and B are purified using cell aggregates 63 days after the start of differentiation induction, treated with DX for 3, 7 or 14 days from 3 days after reaggregation, and cultured until 103 days after the start of differentiation induction.
- FIG. 4 shows the results of measuring the amounts of ACTH and GH in the culture supernatant of cell aggregates over time.
- FIG. 22C shows cell aggregates purified using cell aggregates 63 days after the start of differentiation induction, treated with DX for 14 days from 3 days after reaggregation, and cultured until 103 days after the start of differentiation induction. , shows the results of a GH stimulation test with CRF.
- 22D shows cell aggregates purified using cell aggregates 63 days after the start of differentiation induction, treated with DX for 14 days from 3 days after reaggregation, and cultured until 103 days after the start of differentiation induction. , shows the results of a GH suppression test with somatostatin.
- a “stem cell” means an undifferentiated cell having differentiation potential and proliferation potential (especially self-renewal potential).
- Stem cells include pluripotent stem cells, multipotent stem cells, unipotent stem cells, etc., depending on their ability to differentiate.
- pluripotent stem cell refers to a stem cell that can be cultured in vitro and has the ability to differentiate into all cells that constitute the body (pluripotency). All cells are derived from three germ layers: ectoderm, mesoderm and endoderm.
- multipotent stem cell is meant a stem cell that has the ability to differentiate into multiple, but not all, types of tissues and cells.
- a “unipotent stem cell” means a stem cell that has the ability to differentiate into a specific tissue or cell.
- Pluripotent stem cells can be derived from fertilized eggs, cloned embryos, germ stem cells, tissue stem cells, somatic cells, etc.
- pluripotent stem cells include embryonic stem cells (ES cells: Embryonic stem cells), EG cells (Embryonic germ cells), induced pluripotent stem cells (iPS cells: induced pluripotent stem cells), and the like.
- Muse cells Multi-lineage differentiating Stress Enduring cells obtained from mesenchymal stem cells (MSCs), and GS cells produced from germ cells (e.g., testis) are also included in pluripotent stem cells.
- Human embryonic stem cells were established from human embryos within 14 days of fertilization.
- Embryonic stem cells were first established in 1981 and have been applied to the production of knockout mice since 1989. Human embryonic stem cells were established in 1998 and are being used in regenerative medicine. ES cells can be produced by culturing the inner cell population on feeder cells or in a medium containing a leukemia inhibitory factor (LIF). Methods for producing ES cells are described, for example, in WO96/22362, WO02/101057, US Pat. No. 5843780, US Pat. No. 6200806, US Pat. It is Embryonic stem cells can be obtained from designated institutions and can also be purchased commercially. For example, human embryonic stem cells KhES-1, KhES-2 and KhES-3 are available from Institute for Frontier Medical Sciences, Kyoto University.
- LIF leukemia inhibitory factor
- EG cells can be produced by culturing primordial germ cells in a medium containing mouse stem cell factor (mSCF), LIF and basic fibroblast growth factor (bFGF) (Cell, 70:841-847, 1992).
- mSCF mouse stem cell factor
- bFGF basic fibroblast growth factor
- “Induced pluripotent stem cells” are cells in which pluripotency is induced by reprogramming somatic cells by known methods.
- induced pluripotent stem cells specifically, somatic cells differentiated into fibroblasts, peripheral blood mononuclear cells, etc. are transformed into Oct3/4, Sox2, Klf4, Myc (c-Myc, N-Myc, L-Myc). , Glis1, Nanog, Sall4, lin28, Esrrb, etc., reprogrammed by the expression of a plurality of genes selected from the reprogramming gene group to induce pluripotency.
- Yamanaka et al. established mouse induced pluripotent stem cells (Cell, 2006, 126(4) pp.663-676).
- Induced pluripotent stem cells were also established in human fibroblasts in 2007, and have pluripotency and self-renewal ability like embryonic stem cells (Cell, 2007, 131(5) pp.861-872; Science, 2007, 318(5858) pp.1917-1920; Nat. Biotechnol., 2008, 26(1) pp.101-106).
- induced pluripotent stem cells in addition to the method of producing induced pluripotent stem cells by direct reprogramming by gene expression, induced pluripotent stem cells can also be induced from somatic cells by adding compounds (Science, 2013, 341, pp.651- 654).
- Somatic cells used for producing induced pluripotent stem cells are not particularly limited, but tissue-derived fibroblasts, blood cells (e.g., peripheral blood mononuclear cells, T cells, etc.), hepatocytes, pancreas cells, intestinal epithelial cells, smooth muscle cells, and the like.
- Means for expressing genes include, for example, infection methods using viral vectors (e.g., retroviral vectors, lentiviral vectors, Sendai viral vectors, adenoviral vectors, adeno-associated viral vectors), plasmid vectors (e.g., plasmid vectors, episomal vectors). vector) using gene transfer method (e.g. calcium phosphate method, lipofection method, retronectin method, electroporation method), gene transfer method using RNA vector (e.g. calcium phosphate method, lipofection method, electroporation method), protein A direct injection method and the like can be mentioned.
- viral vectors e.g., retroviral vectors, lentiviral vectors, Sendai viral vectors, adenoviral vectors, adeno-associated viral vectors
- plasmid vectors e.g., plasmid vectors, episomal vectors.
- gene transfer method e.g. calcium phosphate method, lipofection
- induced pluripotent stem cell lines for example, 201B7 cells, 201B7-Ff cells, 253G1 cells, 253G4 cells, 1201C1 cells, 1205D1 cells, and 1210B2 cells established at Kyoto University.
- 1231A3 cells are available from Kyoto University and iPS Academia Japan.
- established induced pluripotent stem cell lines for example, Ff-I01 cells, Ff-I14 cells and QHJI01s04 cells established at Kyoto University are available from Kyoto University.
- Pluripotent stem cells may be genetically modified.
- Genetically modified pluripotent stem cells can be produced, for example, by using homologous recombination techniques.
- Genes on the chromosome to be modified include, for example, cell marker genes, histocompatibility antigen genes, and disease-associated genes based on nervous system cell disorders. Manipulating the Mouse Embryo, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1994), Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), Biomanual Series 8. Gene targeting, preparation of mutant mice using ES cells, methods described in Yodosha (1995), etc. can be used.
- the genomic gene of the target gene to be modified (e.g., cell marker gene, histocompatibility antigen gene, disease-related gene, etc.) is isolated, and the target gene is homologously recombined using the isolated genomic gene.
- Create a target vector for By introducing the produced target vector into stem cells and selecting cells in which homologous recombination has occurred between the target gene and the target vector, stem cells in which genes on chromosomes have been modified can be produced.
- Target vectors for homologous recombination of target genes Preparation of target vectors for homologous recombination of target genes and efficient selection of homologous recombinants are described in Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), Biomanual Series 8, Gene Targeting. , Production of Mutant Mouse Using ES Cells, Yodosha (1995) and others. Either a replacement type or an insertion type target vector can be used.
- methods such as positive selection, promoter selection, negative selection, poly A selection, and the like can be used.
- Methods for selecting the desired homologous recombinant from the screened cell lines include Southern hybridization method and PCR method for genomic DNA.
- Genome-edited pluripotent stem cells can also be used as pluripotent stem cells.
- “Genome editing” is a technique for intentionally modifying a target gene or genomic region by the principle of site-specific cleavage of genomic DNA strands using nucleases, chemical conversion of bases, or the like.
- Site-specific nucleases include zinc finger nucleases (ZFNs), TALENs, CRISPR/Cas9, and the like.
- Disease-specific pluripotent stem cells may be used as pluripotent stem cells.
- a “disease-specific pluripotent stem cell” refers to a pluripotent stem cell with a genetic background or mutation of a gene involved in disease development.
- Disease-specific pluripotent stem cells are obtained by establishing induced pluripotent stem cells from patients with the target disease or their relatives by the method described above, or by obtaining the genome of already established pluripotent stem cells. It can be produced by a modification method using genome editing techniques such as zinc finger nuclease (ZFN), TALEN, and CRISPR.
- ZFN zinc finger nuclease
- TALEN TALEN
- “Mammals” include rodents, ungulates, cats, lagomorphs, primates, and the like. Rodents include mice, rats, hamsters, guinea pigs, and the like. Hoofed animals include pigs, cows, goats, horses, sheep, and the like. The Felida includes dogs, cats, and the like. Lagomorpha includes rabbits and the like.
- the term “primate” refers to a mammal belonging to the order Primate, and includes lemurs, lorises, tsubai, and the like of the order Prosimian, and monkeys, anthropoids, and humans, and the like.
- the pluripotent stem cells used in the present invention are mammalian pluripotent stem cells, preferably rodent (e.g., mouse, rat) or primate (e.g., human, monkey) pluripotent stem cells, most preferably. are human pluripotent stem cells.
- suspension culture refers to culturing cells while maintaining the state in which they are floating in the culture solution.
- suspension culture is carried out under conditions that do not allow cells to adhere to the cultureware and feeder cells on the cultureware (hereinafter referred to as “cultureware, etc.”). culture). More specifically, suspension culture refers to culture under conditions that do not form strong cell-substrate bonds between cells and cultureware. A person skilled in the art can easily determine whether the cultured cells are in a state of suspension culture or adherence culture, for example, by swinging culture equipment during microscopic observation.
- Cell aggregates in suspension culture In cell aggregates in suspension culture, cells adhere to each other. In cell aggregates in suspension culture, strong cell-substrate bonds are not formed between cells and cultureware, and cell-substrate bonds are hardly formed, or even if they are formed, they do not contribute. small. There may be intrinsic cell-substrate binding within cell aggregates in suspension culture.
- Plant attachment between cells refers to surface attachment between cells. More specifically, “cells are surface-adhered” means that the ratio of the surface area of a certain cell that is adhered to the surface of another cell is, for example, 1% or more, preferably 3% or more, more preferably means 5% or more.
- the cell surface can be observed by staining with a membrane staining reagent (eg, DiI), immunostaining with cell adhesion factors (eg, E-cadherin, N-cadherin, etc.), and the like.
- the cultureware used for suspension culture is not particularly limited as long as it is capable of suspension culture, and can be appropriately determined by those skilled in the art.
- Examples of such culture equipment include flasks, tissue culture flasks, dishes, petri dishes, tissue culture dishes, multidishes, microplates, microwell plates, micropores, multiplates, multiwell plates, chamber slides, petri dishes. , tubes, trays, culture bags, spinner flasks and roller bottles.
- These cultureware are preferably cell non-adhesive in order to enable suspension culture.
- the non-cell-adherent cultureware the surface of the cultureware is not subjected to the artificial treatment described above for the purpose of improving the adhesion to cells.
- cultureware whose surface has been artificially treated for the purpose of reducing adhesion to cells can also be used.
- the culture surface of the cultureware may have a flat bottom, a U bottom, a V bottom, or may have unevenness.
- Treatments that reduce adhesion to cells include, for example, 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer, Poly(2-hydroxyethyl methacrylate) (Poly-HEMA), polyethylene glycol (PEG), etc. Low adsorption treatment and the like can be mentioned.
- MPC 2-methacryloyloxyethyl phosphorylcholine
- Poly-HEMA Poly(2-hydroxyethyl methacrylate)
- PEG polyethylene glycol
- the medium used for culturing cells can be prepared using the medium normally used for culturing animal cells as a basal medium.
- a medium for culturing pluripotent stem cells based on the above basal medium preferably a known medium for embryonic stem cells or induced pluripotent stem cells, feeder-free pluripotent stem cells
- a medium (feeder-free medium) or the like for culturing can be used.
- feeder-free media many synthetic media have been developed and are commercially available, for example Essential 8 media.
- Essential 8 medium is DMEM/F12 medium with L-ascorbic acid-2-phosphate magnesium (64mg/l), sodium selenium (14 ⁇ g/1), insulin (19.4mg/l), NaHCO 3 (543mg/l) as additives.
- TGF ⁇ 1 (2 ng/mL) or Nodal (100 ng/mL)
- feeder-free media examples include Essential 8 (manufactured by Thermo Fisher Scientific), S-medium (manufactured by DS Pharma Biomedical), StemPro (manufactured by Thermo Fisher Scientific), hESF9, mTeSR1 (manufactured by STEMCELL Technologies), mTeSR2 (manufactured by STEMCELL Technologies), TeSR-E8 (manufactured by STEMCELL Technologies), mTeSR Plus (manufactured by STEMCELL Technologies), StemFit (manufactured by Ajinomoto), ReproMed iPSC Medium (manufactured by Reprocell), NutriStem XF (manufactured by Biological Industries) ), NutriStem V9 (manufactured by Biological Industries), Cellartis DEF-CS Xeno-Free Culture Medium (manufactured by Takara Bio), Stem-Partner SF (manufactured by Kyokuto Pharmaceutical
- the serum-free medium may contain serum replacement.
- serum substitutes include those appropriately containing albumin, transferrin, fatty acids, collagen precursors, trace elements, 2-mercaptoethanol, 3' thiol glycerol, or equivalents thereof.
- serum substitutes can be prepared, for example, by the method described in WO98/30679. A commercially available product may be used as a serum substitute.
- KSR Knockout Serum Replacement
- Chemically-defined Lipid concentrated manufactured by Thermo Fisher Scientific
- Glutamax manufactured by Thermo Fisher Scientific
- B27 Supplement manufactured by Thermo Fisher Scientific
- N2 Supplement manufactured by Thermo Fisher Scientific
- Serum-free media used in suspension culture and adherent culture suitably contain fatty acids or lipids, amino acids (e.g., non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, pyruvic acid, buffers, and inorganic salts. etc. may be included.
- a serum-free medium containing an appropriate amount (for example, about 0.5% to about 30%, preferably about 1% to about 20%) of commercially available KSR (manufactured by Thermo Fisher Scientific) is added.
- KSR commercially available KSR
- a serum medium eg, a 1:1 mixture of F-12 medium and IMDM medium supplemented with 1 ⁇ chemically-defined Lipid concentrated, 5% KSR and 450 ⁇ M 1-monothioglycerol
- the medium disclosed in JP-T-2001-508302 can be mentioned as a KSR equivalent.
- “Serum medium” means a medium containing unadjusted or unpurified serum.
- the medium contains fatty acids or lipids, amino acids (e.g. non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, 1-monothioglycerol, pyruvic acid, buffers, inorganic salts and the like.
- Cultivation in the present invention is preferably performed under xeno-free conditions.
- Xeno-free means conditions under which components derived from a biological species different from the biological species of cells to be cultured are excluded.
- the medium used in the present invention is preferably a chemically defined medium (CDM) containing components.
- exogenous substance X in the absence of substance X means a medium to which exogenous substance X is not added, a medium free of exogenous substance X, or a medium in which exogenous substance X is not present. means state.
- a “derivative” refers to a group of compounds produced by substituting a part of the molecule of a specific compound with another functional group or another atom.
- a “variant” of a protein refers to a protein in which amino acid residues have been mutated, such as deletion, addition, or substitution, to the extent that the properties of the original protein can be maintained.
- the number of amino acids to be mutated is not particularly limited, but may be 1-4, 1-3, 1-2, or 1.
- a “variant" of a protein is at least 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, It may be a protein having an amino acid sequence showing 99% or more, or 99.5% or more identity.
- after A time (A day) includes A time (A day) and refers to after A time (A day).
- Within B hours (B days) includes B hours (B days) and refers to before B hours (B days).
- feeder cells refer to cells other than the stem cells that coexist when the stem cells are cultured.
- Examples of feeder cells used for undifferentiated maintenance culture of pluripotent stem cells include mouse fibroblasts (MEF), human fibroblasts, SNL cells and the like.
- the feeder cells are preferably growth-inhibitory treated.
- the growth inhibitory treatment includes growth inhibitor (eg, mitomycin C) treatment, UV irradiation, and the like.
- Feeder cells used for undifferentiated maintenance culture of pluripotent stem cells secrete humoral factors (preferably undifferentiated maintenance factors) and prepare scaffolds (extracellular matrix) for cell adhesion, thereby preserving pluripotent stem cells. Contributes to maintenance of differentiation.
- feeder-free means culturing in the absence of feeder cells.
- the absence of feeder cells includes, for example, conditions in which feeder cells are not added or conditions in which feeder cells are not substantially contained (for example, the ratio of feeder cells to the total number of cells is 3% or less).
- Cell aggregate is a clump formed by aggregation of cells, and refers to a clump in which cells adhere to each other.
- Cell aggregates, embryoid bodies, spheres, spheroids, and organoids are also included in cell aggregates.
- the cells are preferably surface-adhered to each other.
- some or all of the cell aggregates have cell-to-cell adhesion, eg, formation of adherence junctions.
- two or more cell aggregates can also be artificially adhered or aggregated together.
- Cell aggregates also include clumps and assembleoids in which cell populations are further adhered or aggregated.
- Uniform cell aggregate means that the size of each cell aggregate is constant when culturing multiple cell aggregates, and the size of the cell aggregate is evaluated by the length of the maximum diameter.
- uniform cell aggregates means that the lengths of the largest diameters have a small variance. More specifically, 75% or more of the plurality of cell aggregates have a maximum diameter within ⁇ 100% of the average maximum diameter of the plurality of cell aggregates, preferably within ⁇ 100% of the average maximum diameter It means within 50%, more preferably within ⁇ 20% of the average maximum diameter.
- Cell population refers to a cell group composed of two or more cells.
- a cell population may be composed of one type of cells, or may be composed of multiple types of cells.
- the cells that make up the cell population may be floating in the medium, or may be adhered to cultureware or the like.
- the cells constituting the cell population may be single cells, or at least a part of the cell population may be cell-adhered to each other to form a cell population.
- the term “single cell” refers to, for example, cells in which cell-to-cell adhesion (eg surface adhesion) is almost lost.
- dispersed in single cells includes a state in which cell-to-cell junctions (eg, adherens junctions) are almost absent.
- a cell population may comprise cell aggregates.
- tissue refers to the structure of a cell population that has a structure in which multiple types of cells with different morphologies and properties are three-dimensionally arranged in a certain pattern.
- cell aggregates, cell populations and tissues are mammalian cell aggregates, cell populations and tissues, preferably rodent (e.g. mouse, rat) or primate (e.g. human, monkey) cells. Aggregates, cell populations and tissues, most preferably human cell aggregates, cell populations and tissues.
- the present invention provides a method for producing a cell aggregate containing pituitary hormone-producing cells (method of the present invention), comprising the following steps. (1) isolating EpCAM-expressing cells from a dispersed cell population comprising pluripotent stem cell-derived hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells; suspension culture of the EpCAM-expressing cells for 14 days or longer under conditions that allow the pituitary progenitor cells to mature into pituitary hormone-secreting cells.
- the method of the present invention comprises a step of isolating cells expressing EpCAM from a dispersed cell population containing pluripotent stem cell-derived hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells (step (1)).
- the dispersed cell population containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells derived from the pluripotent stem cells of step (1) of the present invention is bio-derived hypothalamic cells and pituitary progenitor cells. and pituitary hormone-producing cells, even a dispersed cell population derived from pluripotent stem cells, including hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells. but the latter is preferred.
- a dispersed cell population derived from pluripotent stem cells and containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells is obtained, for example, by the following steps (A) and (B).
- B A step of dispersing the cell aggregate containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells obtained in (A) into a cell population.
- pituitary progenitor cells and pituitary hormone-producing cells differentiated in step (A) for example, pituitary tissue containing pituitary progenitor cells and/or pituitary hormone-producing cells can be classified based on the differentiation stage of Since the hypothalamic tissue containing hypothalamic cells and the pituitary tissue influence each other's differentiation, the differentiation stage of the pituitary tissue and the differentiation stage of the hypothalamic tissue are correlated.
- the differentiation stages from pluripotent stem cells to pituitary tissue are herein defined as pituitary progenitor tissue, which contains only pituitary progenitor cells, and pituitary progenitor cells and the pituitary gland. After classifying the pituitary tissue, which contains hormone-producing cells, into two differentiation stages, the former is further classified into prophase and anaphase, and the latter into prophase, metaphase and anaphase. These differentiation stages are described below.
- Pituitary progenitor tissue as used herein means a tissue in which pituitary progenitor cells are present but pituitary hormone-producing cells are not present.
- pituitary tissue as used herein is a tissue containing at least one type of pituitary hormone-producing cells (eg, ACTH-producing cells), and may contain pituitary progenitor tissue.
- the pituitary precursor tissue can be further classified into the early phase (referred to as the early pituitary precursor tissue) and the late phase (referred to as the late pituitary precursor tissue).
- the early pituitary progenitor tissue the expression of the above-mentioned pituitary progenitor cell markers (e.g., Lhx3 or Pitx1) begins to be induced (begins to be detected), and in the late pituitary progenitor tissue, the expression of these A continuous increase is observed.
- the tissue at the stage where the expression of propituitary progenitor tissue or pituitary progenitor cell marker e.g., Lhx3 or Pitx1
- the late pituitary progenitor tissue includes a tissue in which at least one of Lhx3 and Pitx1 positive cells accounts for 3% or more of the total number of cells.
- a person skilled in the art can measure the ratio by known methods. For example, using an antibody against Lhx3 or Pitx1, it can be measured by techniques such as immunostaining and flow cytometry.
- the hypothalamic tissue is induced.
- the hypothalamic tissue in the cell aggregate containing the propituitary progenitor tissue and the hypothalamic tissue is at the stage where the expression of the above-described hypothalamic marker (eg, Rx or Nkx2.1) begins to be induced.
- the expression of the above-described hypothalamic marker eg, Rx or Nkx2.1
- a continuous increase in their expression is observed in hypothalamic tissue in cell aggregates containing late pituitary progenitor tissue and hypothalamic tissue.
- the expression of Nkx2.1 does not reach its peak as a cell aggregate containing prophase pituitary tissue.
- Examples include cell aggregates containing tissues, and cell aggregates containing late pituitary progenitor tissues include cell aggregates containing Nkx2.1 expression of 3% or more, 10% or more, preferably 20% or more. .
- Pituitary tissue can be classified into early, intermediate, and late stages. In the pituitary tissue, the expression of the pituitary progenitor cell marker reaches a peak, and the expression is maintained approximately constant regardless of the prophase, middle phase, or anaphase.
- the prophase pituitary tissue is defined as one or two types of pituitary hormone-producing cells (e.g., adrenocorticotropic hormone (defined as tissue at the stage where only ACTH)-producing cells and/or prolactin (PRL)-producing cells) are present.
- adrenocorticotropic hormone defined as tissue at the stage where only ACTH
- PRL prolactin
- metapituitary tissue includes 3-4 types of pituitary hormone-producing cells (e.g., ACTH-producing cells and PRL-producing cells, as well as luteinizing hormone (LH)-producing cells and follicle-stimulating hormone (FSH)-producing cells). (including 1-2 types of cells selected from the group consisting of production cells) are present.
- pituitary hormone-producing cells e.g., ACTH-producing cells and PRL-producing cells, as well as luteinizing hormone (LH)-producing cells and follicle-stimulating hormone (FSH)-producing cells.
- LH luteinizing hormone
- FSH follicle-stimulating hormone
- late pituitary tissue refers to five or more types of pituitary hormone-producing cells (e.g., ACTH-producing cells, PRL-producing cells, LH-producing cells and FSH-producing cells, and growth hormone (GH)-producing cells or thyroid It is defined as the tissue at the stage where stimulating hormone (TSH)-producing cells, etc.) are present.
- pituitary hormone-producing cells e.g., ACTH-producing cells, PRL-producing cells, LH-producing cells and FSH-producing cells, and growth hormone (GH)-producing cells or thyroid It is defined as the tissue at the stage where stimulating hormone (TSH)-producing cells, etc.
- the ACTH secretion ability in cell aggregates containing pituitary tissue is 0.5 pg/mL or more in early pituitary tissue, 2 pg/mL or more in intermediate pituitary tissue, and 20 pg/mL or more in late pituitary tissue. is. In one embodiment, the ACTH secretion capacity of cell aggregates comprising pituitary tissue is less than 2 pg/mL for prophase pituitary tissue and less than 20 pg/mL for metaphase pituitary tissue.
- the expression of Rx reaches a peak in hypothalamic tissue in cell aggregates containing prophase pituitary tissue and then decreases. Almost no expression of Rx is observed in hypothalamic tissue in cell aggregates containing post-medium pituitary tissue.
- Nkx2.1 expression continues to decrease in hypothalamic tissue in cell aggregates containing pituitary tissue.
- the expression rate is 10% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less.
- the expression rate of Nkx2.1 is 1% or more, 2% or more, 3% or more, 4% or more, 5% or more in hypothalamic tissue in cell aggregates containing late pituitary tissue. good too.
- the cell aggregate containing metaphase pituitary tissue and hypothalamic tissue is a cell aggregate in which 3 to 4 types of pituitary hormone-producing cells are present and Nkx2.1-expressing cells are present in the hypothalamic tissue. It is an aggregate.
- the ratio of Nkx2.1-expressing cells to the total cells in the cell aggregate may be, for example, more than 2%, 5% or more, 10% or more, or 20% or more.
- the ratio of Nkx2.1-expressing cells to the total cells in the cell aggregate may be, for example, 30% or less, 20% or less, or 10% or less.
- the cell aggregate containing metaphase pituitary tissue and hypothalamic tissue has 3 to 4 types of pituitary hormone-producing cells and substantially Nkx2.1-expressing cells in the hypothalamic tissue. Non-existent cell aggregates.
- the cell aggregate containing late pituitary tissue and hypothalamic tissue contains 5 or more types of pituitary hormone-producing cells and is substantially free of Rx-expressing cells and Nkx2.1-expressing cells. aggregates.
- the specific cells are substantially absent means that the ratio of the specific cells to the total cells in the cell aggregate is 2% or less, 1% or less.
- cell aggregates around 12 days to 30 days after the initiation of differentiation contain late pituitary progenitor tissue, and cell aggregates around 30 days to 60 days after the initiation of differentiation contain early pituitary tissue, Cell aggregates around 60-100 days of differentiation contain metaphase pituitary tissue.
- the cell aggregate containing pluripotent stem cell-derived hypothalamic cells pituitary progenitor cells and pituitary hormone-producing cells obtained in step (A), hypothalamic tissue (containing Nkx2.1-expressing cells and cell aggregates containing pituitary tissue containing one to four types of pituitary hormone-producing cells (cell aggregates around day 30 to day 100 of differentiation).
- hypothalamic tissue containing Nkx2.1-expressing cells and cell aggregates containing pituitary tissue containing one to four types of pituitary hormone-producing cells (cell aggregates around day 30 to day 100 of differentiation.
- hypothalamic tissue containing Nkx2.1-expressing cells and cell aggregates containing the pituitary tissue (cell aggregates around day 30 to day 60 of differentiation).
- the cell aggregate containing pluripotent stem cell-derived hypothalamic cells pituitary progenitor cells and pituitary hormone-producing cells obtained in step (A), hypothalamic tissue (containing Nkx2.1-expressing cells and cell aggregates containing metaphase pituitary tissue (cell aggregates around day 60 to day 100 of differentiation).
- Cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells obtained in step (A) are induced to differentiate into cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells. It can be obtained by culturing pluripotent stem cells under possible conditions.
- Methods for differentiating pluripotent stem cells into aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells include, for example, the method described in International Publication No. 2019/103129. Moreover, for example, it can also be carried out according to the following steps.
- One aspect of the method for differentiating pluripotent stem cells into aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells comprises pituitary tissue, including the following steps (1′) to (2): It is a method for producing a cell population (the production method of the present invention). (1′) a first step of culturing pluripotent stem cells in the presence of a Wnt signaling pathway inhibitor to form a cell population; (2) The cell population obtained in the first step is cultured in the presence of a BMP signaling pathway agent and a Sonic hedgehog (Shh) signaling pathway agent to obtain a cell population containing pituitary tissue. Two steps.
- the first step is a step of forming cell aggregates
- the cell population obtained in the first step subjected to the second step may be a cell aggregate.
- the Wnt signaling pathway inhibitor is used in combination with the JNK signaling pathway inhibitor.
- the cell population containing pituitary tissue obtained in step (2) can become a cell aggregate containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells depending on the length of culture time.
- a more preferred embodiment of the production method of the present invention is a method for producing a cell population containing pituitary tissue, including the following steps (a) and steps (1') to (2).
- the cell population obtained in the first step is cultured (preferably suspension culture) in the presence of the BMP signaling pathway agonist and the Shh signaling pathway agonist to obtain a cell population containing pituitary tissue.
- the first step is a step of forming cell aggregates
- the cell population obtained in the first step subjected to the second step may be a cell aggregate.
- the Wnt signaling pathway inhibitor is used in combination with the JNK signaling pathway inhibitor.
- the cell population containing pituitary tissue obtained in step (2) may be a cell aggregate containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells, depending on the length of culture time.
- a more preferred embodiment of the production method of the present invention is a method for producing a cell population containing pituitary tissue, including the following step (a) and steps (1) and (2) below.
- (a) culturing pluripotent stem cells in a medium containing 1) a TGF ⁇ family signaling pathway inhibitor and/or Shh signaling pathway agonist, and 2) an undifferentiated maintenance factor in the absence of feeder cells (1) a first step of culturing (preferably suspension culture) the pluripotent stem cells obtained in step a in the presence of a JNK signaling pathway inhibitor and a Wnt signaling pathway inhibitor to form a cell population; (2)
- the cell population obtained in the first step is cultured (preferably suspension culture) in the presence of the BMP signaling pathway agonist and the Shh signaling pathway agonist to obtain a cell population containing pituitary tissue.
- the first step is a step of forming cell aggregates
- the cell population obtained in the first step subjected to the second step may be a cell aggregate.
- the cell population containing pituitary tissue obtained in step (2) may be a cell aggregate containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells, depending on the length of culture time.
- the manufacturing method described above may further include the following third step.
- step (a) the pluripotent stem cells are treated with a TGF ⁇ family signaling pathway inhibitor and/or Shh signaling pathway active substance, and then cultured (preferably suspension culture) in the first step to obtain multipotent stem cells.
- the state of the potential stem cells is changed, the efficiency of non-neural epithelial tissue formation is improved, the quality of the obtained cell population (aggregate) is improved, differentiation is easy, cell death is less likely to occur, and the production efficiency of pituitary cells is improved. improves.
- Step (a) is performed in the absence of feeder cells.
- the absence of feeder cells means conditions substantially free of feeder cells (for example, the ratio of feeder cells to the total number of cells is 3% or less).
- the pluripotent stem cells are preferably embryonic stem cells or induced pluripotent stem cells.
- Induced pluripotent stem cells can be obtained from predetermined institutions, and can also be purchased as commercial products.
- human induced pluripotent stem cell lines 201B7, 201B7-Ff cells, 253G1 cells, 253G4 cells, 1201C1 cells, 1205D1 cells, 1210B2 cells, and 1231A3 cells are available from Kyoto University and iPS Academia Japan.
- induced pluripotent stem cell lines for example, Ff-I01 cells, Ff-I14 cells and QHJI01s04 cells established at Kyoto University are available from Kyoto University.
- HC-6 #10 strain, 1231A3 strain and 1383D2 strain are available from National Research and Development Agency RIKEN.
- the TGF ⁇ family signaling pathway (that is, the TGF ⁇ superfamily signaling pathway) is a signaling pathway transduced by the Smad family in cells with transforming growth factor ⁇ (TGF ⁇ ), Nodal/Activin, or BMP as ligands. .
- the TGF ⁇ family signaling pathway inhibitor refers to a substance that inhibits the TGF ⁇ family signaling pathway, that is, the signaling pathway transmitted by the Smad family. Specifically, the TGF ⁇ signaling pathway inhibitor, the Nodal/Activin signaling pathway Inhibitors and BMP signaling pathway inhibitors may be mentioned. As the TGF ⁇ family signaling pathway inhibitor, a TGF ⁇ signaling pathway inhibitor is preferred.
- the TGF ⁇ signal transduction pathway inhibitor is not particularly limited as long as it inhibits the signal transduction pathway caused by TGF ⁇ , and may be any of nucleic acids, proteins, and low-molecular-weight organic compounds. Examples of such substances include substances that act directly on TGF ⁇ (eg proteins, antibodies, aptamers, etc.), substances that suppress the expression of genes encoding TGF ⁇ (eg, antisense oligonucleotides, siRNA, etc.), and substances that inhibit the binding of TGF ⁇ receptors to TGF ⁇ . Inhibitory substances and substances that inhibit physiological activities caused by signal transduction by TGF ⁇ receptors (eg, TGF ⁇ receptor inhibitors, Smad inhibitors, etc.) can be mentioned. Proteins known as TGF ⁇ signaling pathway inhibitors include Lefty.
- SB431542 (sometimes abbreviated as "SB431") (4-[4-(3,4-Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide)
- SB505124 2-[4-(1,3-Benzodioxol-5-yl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-6-methylpyridine
- SB525334 (6-[2 -(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline)
- LY2157299 (4-[5,6-Dihydro-2-(6-methyl- 2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecar
- SB431542 is a compound known as an inhibitor of TGF ⁇ receptor (ALK5) and Activin receptor (ALK4/7) (ie TGF ⁇ R inhibitor).
- SIS3 is a TGF ⁇ signaling pathway inhibitor that inhibits the phosphorylation of SMAD3, an intracellular signaling factor under the control of the TGF ⁇ receptor.
- ITD-1 is a TGF- ⁇ type II receptor proteasomal degradation accelerator.
- the TGF ⁇ signaling pathway inhibitor preferably includes an Alk5/TGF ⁇ R1 inhibitor.
- Alk5/TGF ⁇ R1 inhibitors are preferably SB431542, SB505124, SB525334, LY2157299, GW788388, LY364947, SD-208, EW-7197, A83-01, RepSox, SM16, R268712, IN1130, Galunisertib, AZ12799734, ARCA7-01, A7 0008, GSK 1838705, Crizotinib, Ceritinib, ASP 3026, TAE684, AZD3463, TP0427736, more preferably SB431542 or A83-01.
- the concentration of the TGF ⁇ signaling pathway inhibitor in the medium can be appropriately set according to the substance used within the range where the above effects can be achieved.
- SB431542 is used as the TGF ⁇ signaling pathway inhibitor in step (a)
- it is generally about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 100 ⁇ M, more preferably about 10 nM to about 50 ⁇ M, still more preferably about 100 nM to about 50 ⁇ M
- Concentrations of about 1 ⁇ M to about 10 ⁇ M are particularly preferred.
- a TGF ⁇ signaling pathway inhibitor other than SB431542 it is preferably used at a concentration that exhibits TGF ⁇ signaling pathway inhibitory activity equivalent to that of SB431542 at the concentrations described above.
- a Shh transduction pathway agonist is a substance that can enhance signal transduction mediated by Shh.
- Shh signaling pathway agonists include proteins belonging to the Hedgehog family (e.g., Shh, Ihh), Shh receptors, Shh receptor agonists, Smo agonists, Purmorphamine (9-cyclohexyl-N-[4-(morpholinyl)phenyl] -2-(1-naphthalenyloxy)-9H-purin-6-amine), GSA-10(Propyl 4-(1-hexyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboboxamido)benzoate) , Hh-Ag1.5, 20(S)-Hydroxycholesterol, SAG (Smoothened Agonist: N-Methyl-N'-(3-pyridinylbenzyl)-N'-(3-chlorobenzo[b]thiophene-2-carbonyl)-1
- the Shh signaling pathway agent preferably contains at least one selected from the group consisting of SAG, Purmorphamine and GSA-10, more preferably SAG.
- the concentration of the substance acting on the Shh signal transduction pathway in the medium can be appropriately set according to the substance to be used within a range in which the above effects can be achieved.
- SAG is generally about 1 nM to about 2000 nM, preferably about 10 nM to about 1000 nM, more preferably about 10 nM to about 700 nM, even more preferably about 50 nM to about 700 nM, particularly preferably about 100 nM to about 600 nM in step (a). , most preferably at a concentration of about 100 nM to about 500 nM.
- Shh transduction promoting activity can be determined by a method well known to those skilled in the art, for example, a reporter gene assay focusing on Gli1 gene expression (Oncogene (2007) 26, 5163-5168).
- the medium used in step (a) contains an undifferentiated maintenance factor to enable undifferentiated maintenance culture.
- the undifferentiation maintenance factor is not particularly limited as long as it is a substance that has an effect of suppressing differentiation of pluripotent stem cells.
- Undifferentiated maintenance factors commonly used by those skilled in the art include, in the case of primed pluripotent stem cells (e.g., human ES cells, human iPS cells), FGF signaling pathway agonists, TGF ⁇ family signaling pathways Agents, insulin and the like can be mentioned.
- FGF signaling pathway agonists include fibroblast growth factors (eg, bFGF, FGF4 and FGF8).
- TGF ⁇ family signaling pathway agonists include TGF ⁇ signaling pathway agonists and Nodal/Activin signaling pathway agonists.
- TGF ⁇ signaling pathway agonists include, for example, TGF ⁇ 1 and TGF ⁇ 2.
- Nodal/Activin signaling pathway agonists include, for example, Nodal, ActivinA, and ActivinB. These substances may be used alone or in combination.
- the medium in step (a) preferably contains bFGF as an undifferentiated maintenance factor.
- Undifferentiated maintenance factors are usually mammalian undifferentiated maintenance factors. Examples of mammals include those described above. Since the undifferentiation maintenance factor may have cross-reactivity between species of mammals, any mammalian undifferentiation maintenance factor can be used as long as the undifferentiated state of the pluripotent stem cells to be cultured can be maintained. good too.
- the undifferentiation maintenance factor is preferably a mammalian undifferentiation maintenance factor of the same species as the cells to be cultured.
- human undifferentiated maintenance factors eg, bFGF, FGF4, FGF8, EGF, Nodal, ActivinA, ActivinB, TGF ⁇ 1, TGF ⁇ 2, etc.
- the undifferentiated maintenance factor is preferably isolated.
- the undifferentiation maintenance factor can be produced by any host or artificially synthesized as long as it has the ability to maintain undifferentiation of the pluripotent stem cells to be cultured.
- the factor for maintaining undifferentiation used in the present invention is preferably modified in the same manner as that produced in vivo, and is produced in cells of the same type as the pluripotent stem cells to be cultured under conditions that do not contain xenogeneic components. is more preferred.
- One aspect of the production method according to the present invention includes a step of providing an isolated undifferentiated maintenance factor.
- One aspect of the production method according to the present invention includes the step of exogenously (or exogenously) adding an isolated factor for maintaining undifferentiation to the medium used in step (a).
- An undifferentiation maintenance factor may be added in advance to the medium used in step (a).
- the concentration of the undifferentiated maintenance factor in the medium used in step (a) is a concentration that can maintain the undifferentiated state of the cultured pluripotent stem cells, and can be appropriately set by those skilled in the art.
- concentration is usually about 4 ng/mL to about 500 ng/mL, preferably about 10 ng/mL to about 200 ng/mL, more preferably about 30 ng/mL. mL to about 150 ng/mL.
- Step (a) is performed in the absence of feeder cells.
- Cultivation of pluripotent stem cells in step (a) may be performed under either suspension culture or adherent culture, but adherent culture is preferred.
- an appropriate matrix may be used as a scaffold to provide the pluripotent stem cells with a scaffold that replaces feeder cells.
- Pluripotent stem cells are adherently cultured in a cultureware whose surface is coated with a scaffold matrix.
- Matrices that can be used as scaffolds include laminin (Nat Biotechnol. 28, 611-615 (2010)), laminin fragment (Nat Commun 3, 1236 (2012)), basement membrane preparation (Nat Biotechnol 19, 971-974 (2001)). , gelatin, collagen, heparan sulfate proteoglycan, entactin, vitronectin and the like.
- Laminin 511 is preferably used as the matrix (Nat Biotechnol 28, 611-615 (2010)).
- the laminin fragment is not particularly limited as long as it has adhesiveness to pluripotent stem cells and allows maintenance and culture of pluripotent stem cells under feeder-free conditions, but is preferably an E8 fragment.
- Laminin E8 fragment was identified as a fragment with strong cell adhesion activity among the fragments obtained by digesting laminin 511 with elastase (EMBO J., 3:1463-1468, 1984, J. Cell Biol., 105:589-598, 1987).
- the E8 fragment of laminin 511 is preferably used (Nat Commun 3, 1236 (2012), Scientific Reports 4, 3549 (2014)).
- the laminin E8 fragment need not be an elastase digestion product of laminin and may be recombinant.
- laminin 511 It may be one produced by a genetically modified animal (such as a silkworm). From the viewpoint of avoiding contamination with unidentified components, a recombinant laminin fragment is preferably used.
- the E8 fragment of laminin 511 is commercially available and can be purchased from Nippi Co., Ltd., for example.
- the laminin or laminin fragment used in the present invention is preferably isolated.
- the surface is preferably coated with isolated laminin 511 or the E8 fragment of laminin 511, more preferably with the E8 fragment of laminin 511.
- Pluripotent stem cells are adherently cultured in cultureware.
- the medium used in step (a) is not particularly limited as long as it allows undifferentiated maintenance culture of pluripotent stem cells under feeder-free conditions (feeder-free medium).
- the medium used in step (a) may be serum medium or serum-free medium. From the viewpoint of avoiding contamination with chemically undetermined components, the medium used in step (a) is preferably a serum-free medium.
- the medium may contain serum replacement.
- the culture time of pluripotent stem cells in step (a) is not particularly limited as long as the effect of improving the quality of cell populations (aggregates) that can be formed in the subsequent first step can be achieved, but usually 0.5 to 144 hours. , preferably 2 to 96 hours, more preferably 6 to 48 hours, even more preferably 12 to 48 hours, particularly preferably 18 to 28 hours, for example 24 hours. That is, the step (a) is started 0.5 to 144 hours, preferably 18 to 28 hours before the start of the first step, and the first step is continued after the step (a) is completed.
- human pluripotent stem cells are adherently cultured in a serum-free medium containing bFGF in the absence of feeder cells.
- the adherent culture is preferably carried out in a cultureware surface-coated with laminin-511, the E8 fragment of laminin-511, or vitronectin.
- the adherent culture is preferably performed using StemFit as a feeder-free medium.
- StemFit medium contains bFGF as an undifferentiated maintenance component (Scientific Reports (2014) 4, 3594).
- human pluripotent stem cells are suspended in a bFGF-containing serum-free medium in the absence of feeder cells.
- human pluripotent stem cells may form aggregates of human pluripotent stem cells.
- culture conditions such as culture temperature and CO 2 concentration can be appropriately set.
- the culture temperature is, for example, about 30°C to about 40°C, preferably about 37°C.
- the CO 2 concentration is, for example, about 1% to about 10%, preferably about 5%, when using a bicarbonate-buffered medium.
- the Wnt signaling pathway is a signaling pathway that uses Wnt family proteins as ligands and mainly Frizzled as receptors.
- Examples of the signal pathway include the canonical Wnt pathway, the non-canonical Wnt pathway, and the like.
- the canonical Wnt pathway is mediated by ⁇ -Catenin.
- Non-classical Wnt pathways include Planar Cell Polarity (PCP) pathway, Wnt/JNK pathway, Wnt/Calcium pathway, Wnt-RAP1 pathway, Wnt-Ror2 pathway, Wnt-PKA pathway, Wnt-GSK3MT pathway, Wnt-aPKC pathway , Wnt-RYK pathway, Wnt-mTOR pathway and the like.
- PCP Planar Cell Polarity
- Wnt/JNK pathway Wnt/Calcium pathway
- Wnt-RAP1 pathway Wnt-Ror2 pathway
- Wnt-PKA pathway Wnt-GSK3MT pathway
- Wnt signaling pathway inhibitors are not limited as long as they can suppress signal transduction triggered by Wnt family proteins.
- Inhibitors may be nucleic acids, proteins, or small organic compounds. Examples of such substances include substances that inhibit Wnt processing and extracellular secretion, substances that act directly on Wnt (e.g., proteins, antibodies, aptamers, etc.), and substances that suppress the expression of genes encoding Wnt (e.g., antisense oligos). nucleotides, siRNA, etc.), substances that inhibit the binding of Wnt receptors and Wnt, and substances that inhibit physiological activities caused by signal transduction by Wnt receptors.
- Wnt signaling pathway inhibitors include secreted Frizzled Related Protein (sFRP) class proteins (sFRP1-5, Wnt Inhibitory Factor-1 (WIF-1), Cerberus) and Dickkopf (Dkk) class. Examples include proteins belonging to (Dkk1-4, Kremen), PCDD1, APCDD1L, proteins belonging to the Draxin family, IGFBP-4, Notum, proteins belonging to the SOST/Sclerostin family, and the like.
- sFRP Frizzled Related Protein
- WIF-1 Wnt Inhibitory Factor-1
- Dkk Dickkopf
- Wnt signaling pathway inhibitors Compounds well known to those skilled in the art can be used as Wnt signaling pathway inhibitors.
- Inhibitors of canonical Wnt signaling pathway such as Frizzled inhibitor, Disheveled (Dvl) inhibitor, Tankyrase (TANK) inhibitor, casein kinase 1 inhibitor, catenin-responsive transcription inhibitor, p300 inhibitor, CREB-binding protein (CBP) inhibitors, BCL-9 inhibitors, TCF degradation inducers (Am J Cancer Res. 2015;5(8):2344-2360) and the like.
- Non-classical Wnt pathway inhibitors include, for example, porcupine (PORCN) inhibitors, calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitors, (TGF- ⁇ -activated kinase 1 (TAK1) inhibitors, Nemo-Like Kinase (NLK) inhibitor, LIM Kinase inhibitor, mammalian target of rapamycin (mTOR) inhibitor, Rac inhibitor, c-Jun NH 2-terminal kinase (JNK) inhibitor, protein kinase C (PKC) inhibitor, Methionine Aminopeptidase 2 (MetAP2) inhibitors, calcineurin inhibitors, nuclear factor of activated T cells (NFAT) inhibitors, ROCK inhibitors, etc.
- PORCN porcupine
- CaMKII calcium/calmodulin-dependent protein kinase II
- NLK Nemo-Like Kinase
- Wnt signaling pathway inhibitors KY02111 N-(6-Chloro-2-benzothiazolyl)-3,4-dimethoxybenzenepropanamide
- KY03-I 2-(4-(3,4-dimethoxyphenyl)butanamide)-6-Iodobenzothiazole. Substances may be used alone or in combination.
- PORCN inhibitors such as IWP-2(N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin) -2-yl)thio]-acetamide), IWP-3 (2-[[3-(4-fluorophenyl)-3,4,6,7-tetrahydro-4-oxothieno[3,2-d]pyrimidin-2 -yl]thio]-N-(6-methyl-2-benzothiazolyl)-acetamide), IWP-4(N-(6-methyl-2-benzothiazolyl)-2-[[3,4,6,7-tetrahydro -3-(2-methoxyphenyl)-4-oxothieno[3,2-d]pyrimidin-2-yl]thio]-acetamide), IWP-L6(N-(5-phenyl-2-pyridinyl
- the Wnt signaling pathway inhibitor preferably contains at least one selected from the group consisting of a PORCN inhibitor, KY02111 and KY03-I, more preferably a PORCN inhibitor.
- Wnt signaling pathway inhibitors also preferably include substances having inhibitory activity on the non-canonical Wnt pathway of Wnt.
- Wnt signaling pathway inhibitors more preferably include substances having inhibitory activity on the Wnt/Planar Cell Polarity (PCP) pathway.
- PORCN inhibitors used in the present invention are preferably the group consisting of IWP-2, IWP-3, IWP-4, IWP-L6, IWP-12, LGK-974, Wnt-C59, ETC-159 and GNF-6231 It contains at least one selected from the above, more preferably contains IWP-2 or Wnt-C59, and still more preferably contains IWP-2.
- the concentration of the Wnt signaling pathway inhibitor in the medium can be appropriately set according to the substance used within the range where the above effects can be achieved. From the viewpoint of improving the production efficiency of cells that constitute the pituitary gland, for example, when using IWP-2, which is a PORCN inhibitor, as a Wnt signaling pathway inhibitor, the concentration is usually about 10 nM to about 50 ⁇ M. , preferably about 10 nM to about 30 ⁇ M, more preferably about 100 nM to about 10 ⁇ M, most preferably about 0.5 ⁇ M.
- one of the PORCN inhibitors When using Wnt-C59, one of the PORCN inhibitors, its concentration is usually about 10 nM to about 30 ⁇ M, preferably about 20 nM to about 10 ⁇ M, more preferably about 500 nM.
- concentration When KY02111 is used, its concentration is usually about 10 nM to about 50 ⁇ M, preferably 10 nM to about 30 ⁇ M, more preferably about 100 nM to about 10 ⁇ M, even more preferably about 5 ⁇ M.
- step (1) is the first step of culturing pluripotent stem cells in the presence of a JNK signaling pathway inhibitor and a Wnt signaling pathway inhibitor.
- JNK is a kinase belonging to the MAPK family and is involved in the intracellular signaling of stimulation by various environmental stresses, inflammatory cytokines, growth factors, and GPCR agonists.
- the JNK signaling pathway inhibitor is not limited as long as it can suppress signal transduction transmitted by JNK.
- a JNK signaling pathway inhibitor for example, a mechanism that inhibits upstream or downstream factors of the JNK signaling mechanism, or the enzymatic activity of JNK itself, multimerization, binding to other factors or nucleic acids, or promotes degradation
- JNK signaling pathway inhibitors include JNK inhibitors, Rac inhibitors, MKK inhibitors, MEK inhibitors, Src inhibitors, receptor tyrosine kinase (RTK) inhibitors, ASK inhibitors, and the like. Not limited.
- JNK inhibitors examples include JNK-IN-8((E)-3-(4-(dimethylamino)but-2-enamido)-N-(3-methyl-4-( (4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide), SP600125 (Anthra[1-9-cd]pyrazol-6(2H)-one), DB07268 (2-[[2 -[(3-Hydroxyphenyl)amino]-4-pyrimidinyl]amino]benzamide), Tanzisertib (trans-4-[[9-[(3S)-Tetrahydro-3-furanyl]-8-[(2,4,6 -trifluorophenyl)amino]-9H-purin-2-yl]amino]cyclohexanol), Bentamapimod(1,3-Benzothiazol-2-yl
- Rac inhibitors include EHT1864 (5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-(morpholinomethyl)-4H-pyran-4-one dihydrochloride), NSC23766 (N6-[ 2-[[4-(Diethylamino)-1-methylbutyl]amino]-6-methyl-4-pyrimidinyl]-2-methyl-4,6-quinolinediamine trihydrochloride), EHop-016(N4-(9-Ethyl-9H -carbazol-3-yl)-N2-[3-(4-morpholinyl)propyl]-2,4-pyrimidinediamine), 1A-116(N-(3,5-Dimethylphenyl)-N'-[2-(trifluoromethyl )phenyl]guanidine), ZCL278(2-(4-broMo-2-chlorophenoxy)-N-(4-(N-(4,6
- the timing of addition of the JNK signaling pathway inhibitor in the present invention is not limited as long as the effect of improving the efficiency of production of pituitary tissue from human pluripotent stem cells is exhibited. It is preferably already added at the time of adding the agent, and within 72 hours from the start of differentiation induction. A more preferable time to add the JNK signaling pathway inhibitor is at the same time as the initiation of differentiation induction.
- a TGF ⁇ signaling pathway inhibitor is preferably further present in the medium of the first step (step (1) or step (1')).
- the TGF ⁇ signaling pathway inhibitor used in the first step the same substances as exemplified in step (a) can be used.
- the TGF ⁇ signaling pathway inhibitors in step (a) and the first step may be the same or different, but are preferably the same.
- the concentration of the TGF ⁇ signaling pathway inhibitor in the medium can be appropriately set according to the substance used within the range where the above effects can be achieved.
- SB431542 is used as a TGF ⁇ signaling pathway inhibitor, it is usually used at a concentration of about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 100 ⁇ M, more preferably about 100 nM to about 50 ⁇ M, still more preferably about 500 nM to about 10 ⁇ M.
- a TGF ⁇ signaling pathway inhibitor other than SB431542 it is preferably used at a concentration that exhibits TGF ⁇ signaling pathway inhibitory activity equivalent to that of SB431542 at the concentrations described above.
- TAK1 Transforming growth factor- ⁇ -activated kinase 1
- MAKKK Transforming growth factor- ⁇ -activated kinase 1
- BMP bone morphogenetic protein
- IL-1 interleukin-1
- a TAK1 inhibitor is not limited as long as it can suppress signal transduction mediated by TAK1. Any of nucleic acids, proteins, and low-molecular-weight organic compounds may be used. Examples of such substances include substances that inhibit the binding of TAK1 to substrates, substances that inhibit phosphorylation of TAK1, substances that promote dephosphorylation of TAK1, substances that inhibit transcription and translation of TAK1, and substances that promote degradation of TAK1. etc.
- TAK1 inhibitors include (5Z)-7-Oxozeaenol ((3S,5Z,8S,9S,11E)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3- methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione), N-Des(aminocarbonyl)AZ-TAK1 inhibitor (3-Amino-5-[4-(4-morpholinylmethyl)phenyl]-2-thiophenecarboxamide) , Takinib (N1-(1-Propyl-1H-benzimidazol-2-yl)-1,3-benzenedicarboxamide), NG25 (N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl )phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-
- the TAK1 inhibitor is preferably (5Z)-7-Oxozeaenol.
- (5Z)-7-Oxozeaenol is used as the TAK1 inhibitor in the first step, it is usually about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 50 ⁇ M, more preferably about 100 nM to about 25 ⁇ M, still more preferably about 500 nM to A concentration of about 10 ⁇ M is used.
- a TAK1 inhibitor other than (5Z)-7-Oxozeaenol it is preferably used at a concentration that exhibits TAK1 inhibitory activity equivalent to that of (5Z)-7-Oxozeaenol at the above concentrations.
- the TAK1 inhibitor can be added at any stage of the first step and subsequent steps and then removed.
- the TAK1 inhibitor is added at the start of step (b) described below.
- the medium used in the first step is not particularly limited as long as it is as described in the definition section above.
- the medium used in the first step can be serum medium or serum-free medium. From the viewpoint of avoiding contamination with chemically undetermined components, a serum-free medium is preferably used in the present invention. In order to avoid complicated preparation, it is preferable to use a serum-free medium supplemented with an appropriate amount of a serum substitute such as commercially available KSR.
- the amount of KSR added to the serum-free medium for example, in the case of human ES cells, is generally about 1% to about 30%, preferably about 2% to about 20%.
- serum-free media examples include a 1:1 mixture of IMDM and F-12 supplemented with 5% KSR, 450 ⁇ M 1-monothioglycerol and 1x Chemically Defined Lipid Concentrate, or 5% to 20% KSR in GMEM. , NEAA, pyruvate and 2-mercaptoethanol.
- the cells may be in either an adherent state or a floating state.
- pluripotent stem cells are dispersed into single cells and then reaggregated to form cell aggregates in a floating state. For this reason, it is preferable to disperse the pluripotent stem cells, for example the pluripotent stem cells obtained in step (a), into single cells before starting the first step.
- the "dispersed cells” obtained by the dispersing operation are preferably single cells, but may include cell clusters consisting of a small number of cells, for example, 2 or more and 100 or less. It may contain clumps of different cells. "Dispersed cells” may contain, for example, 70% or more single cells and 30% or less cell clumps, preferably 80% or more single cells and 20% or less cell clumps.
- Methods for dispersing pluripotent stem cells include mechanical dispersion treatment, cell dispersion treatment, and cell protective agent addition treatment, and these treatments may be combined.
- a method for dispersing the cells it is preferable to carry out the cell-dispersing solution treatment at the same time as the cell protective agent addition treatment, followed by mechanical dispersion treatment.
- Cell protective agents used in cytoprotective agent addition treatment include FGF signaling pathway agonists, heparin, Rho-associated protein kinase (ROCK) inhibitors, myosin inhibitors, polyamines, integrated stress response: ISR) inhibitors, caspase inhibitors, serum, or serum substitutes.
- Preferred cytoprotective agents include ROCK inhibitors.
- a ROCK inhibitor In order to suppress cell death of pluripotent stem cells (in particular, human pluripotent stem cells) induced by dispersal, it is preferable to add a ROCK inhibitor from the start of culture in the first step.
- ROCK inhibitors include Y-27632 ((R)-(+)-trans-4-(1-Aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide, dihydrochloride), Fasudil (HA1077) (1-(5- Isoquinolinylsulfonyl)homopiperazine, hydrochloride), H-1152 (5-[[(2S)-hexahydro-2-methyl-1H-1,4-diazepin-1-yl]sulfonyl]-4-methyl-isoquinoline, dihydrochloride), HA -1100(Hydroxyfasudil) ([1-(1-Hydroxy-5-isoquinolinesulfonyl)homopiperazine,hydrochloride), Chroman 1((3S)-N-[2-[2-(dimethylamino)ethoxy]-4-(1H-pyrazol) -4-yl)
- a prepared cell protective agent can also be used as the cell protective agent.
- ready-to-use cytoprotective agents include RevitaCell Supplement (manufactured by Thermo Fisher Scientific) and CloneR (manufactured by Stemcell Technologies). These substances may be used alone or in combination.
- the concentration is usually about 10 nM to about 10 mM, preferably about 100 nM to about 1 mM, more preferably about 1 ⁇ M to about 100 ⁇ M. Add to the culture environment as follows.
- the concentration is usually about 10 pM to about 1 mM, preferably about 100 pM to about 100 ⁇ M, more preferably about 1 nM to about 10 ⁇ M. to the culture environment.
- the cell dispersion used for cell dispersion treatment can include a solution containing at least one enzyme such as trypsin, collagenase, hyaluronidase, elastase, pronase, DNase, papain, or a chelating agent such as ethylenediaminetetraacetic acid.
- a chelating agent such as ethylenediaminetetraacetic acid.
- Commercially available cell dispersions such as TripLE Select (manufactured by Thermo Fisher Scientific), TripLE Express (manufactured by Thermo Fisher Scientific) and Accumax (manufactured by Innovative Cell Technologies) can also be used.
- a preferred cell dispersion for treatment of pluripotent stem cells obtained after step (a) is TrypLE Select or phosphate buffered saline (PBS) supplemented with 5 mM EDTA, but not limited thereto.
- PBS phosphate buffered saline
- Mechanical dispersion methods include pipetting or scraping with a scraper.
- the dispersed cells are suspended in the medium.
- Methods for dispersing pluripotent stem cells include, for example, treating colonies of pluripotent stem cells with TrypLE Select, ethylenediaminetetraacetic acid or Accumax in the presence of a ROCK inhibitor, and further dispersing by pipetting.
- a suspension of dispersed pluripotent stem cells is seeded in a non-adhesive cultureware.
- the cultureware is non-adhesive, cells are cultured in suspension, and multiple pluripotent stem cells aggregate to form cell aggregates.
- a plurality of cell aggregates may be simultaneously formed in one culture vessel.
- a certain number of cells are dispersed in each well of a multi-well plate (U bottom, V bottom) such as a cell non-adhesive 96-well microplate.
- Pluripotent stem cells are preferably seeded.
- the cells rapidly aggregate to form one cell aggregate in each well.
- the cultureware can be made non-adherent to cells by processing such as coating the surface of the cultureware with a superhydrophilic polymer.
- Non-adherent multiwell plates include, for example, PrimeSurface 96V bottom plate (MS-9096V, manufactured by Sumitomo Bakelite). Centrifugation may be performed to form cell aggregates more quickly. A uniform population of cell aggregates can be obtained by collecting the cell aggregates formed in each well from a plurality of wells. If the cell aggregates are uniform, in subsequent steps, production efficiency can be more stabilized for each well and for each repeated experiment, and cells that constitute the pituitary gland can be produced with higher reproducibility.
- MS-9096V manufactured by Sumitomo Bakelite
- Another embodiment for forming cell aggregates from dispersed pluripotent stem cells is a mortar, a downward-facing square pyramid, a concave shape, etc., in which cells settle in one place on the bottom surface to promote the formation of aggregates. It is also possible to use a cultureware that has a plurality of processing, grids, ridges, etc., or a cultureware that has been processed so that cells can adhere to only a part of the bottom surface so that it is easy to form aggregates.
- Examples of the cultureware as described above include embryoid formation plate AggreWell (manufactured by StemCell Technologies), PAMCELL (manufactured by ANK), spheroid microplate (manufactured by Corning), NanoCulture Plate/Dish (manufactured by Organogenix), Cell -able (manufactured by Toyo Gosei Co., Ltd.), EZSPHERE (manufactured by AGC Techno Glass Co., Ltd.), SPHERICALPLATE 5D (manufactured by Mito Kogyo Co., Ltd.), TASCL (manufactured by Sims Bio), etc., but not limited thereto.
- a three-dimensional cell culture vessel that can replace the medium of the entire plate at once while cell aggregates remain in each well.
- three-dimensional cell culture vessels include PrimeSurface 96 slit well plate (manufactured by Sumitomo Bakelite Co., Ltd.).
- the plate has narrow openings (slits) that allow the medium to flow in and out at the top of each of the 96 wells. Since the slit is set to a width that makes it difficult for cell aggregates to pass through, it is possible to exchange the medium for the entire plate at once while preventing cell aggregates from adhering to each other. quality can be improved.
- the concentration of pluripotent stem cells in the first step can be appropriately set so as to form cell aggregates more uniformly and efficiently.
- human pluripotent stem cells for example, human iPS cells obtained from step (a)
- a 96-well microwell plate usually about 1 ⁇ 10 3 to about 1 ⁇ 10 5 cells per well , preferably about 3 ⁇ 10 3 to about 5 ⁇ 10 4 cells, more preferably about 4 ⁇ 10 3 to about 2 ⁇ 10 4 cells, still more preferably about 4 ⁇ 10 3 to about 1.6 ⁇ 10 4 cells, particularly preferably
- a solution adjusted to give about 8 ⁇ 10 3 to about 1.2 ⁇ 10 4 cells is added to each well, and the plate is allowed to stand to form cell aggregates.
- Cell numbers can be determined by counting with a hemocytometer.
- the suspension culture time required to form cell aggregates can be appropriately determined depending on the pluripotent stem cells used, but it is desirable to be as short as possible in order to form uniform cell aggregates.
- the process by which dispersed cells form cell aggregates is divided into a process of cell aggregation and a process of aggregated cells forming aggregates. From the time the dispersed cells are seeded (i.e., at the start of suspension culture) until the cells aggregate, for example, in the case of human pluripotent stem cells (human iPS cells, etc.), preferably within about 24 hours, more preferably Within about 12 hours.
- cell aggregates From the time of seeding dispersed cells (i.e., the start of suspension culture) to the formation of cell aggregates, for example, in the case of human pluripotent stem cells (human iPS cells, etc.), preferably within about 72 hours, More preferably within about 48 hours.
- the time required to form cell aggregates can be appropriately adjusted by adjusting the tool for aggregating cells, centrifugation conditions, and the like.
- epithelial-like structures can be reproducibly formed in cells differentiated from the formed aggregates.
- Experimental manipulations to form cell aggregates include, for example, plates with small wells (for example, plates with a well bottom area of about 0.1 to 2.0 cm 2 in terms of a flat bottom), micropores, etc., to place cells in a small space.
- Examples of plates with small wells include 24-well plates (area of about 1.88 cm 2 when converted to flat bottom), 48-well plates (area of about 1.0 cm 2 when converted to flat bottom), 96-well plates (area of about 0.35 cm 2 when converted to flat bottom). , inner diameter of about 6 to 8 mm), and 384-well plates.
- a 96-well plate is preferred.
- the shape of the plate with small wells the shape of the bottom when the wells are viewed from above includes polygonal, rectangular, elliptical, and perfect circle, preferably perfect circle.
- the shape of a plate with small wells the shape of the bottom surface when the wells are viewed from the side is preferably a structure in which the outer periphery is high and the interior is low and recessed.
- V-bottoms U-bottoms or V-bottoms, most preferably V-bottoms, may be mentioned.
- a cell culture dish eg, 60 mm to 150 mm dish, culture flask
- the bottom of the small plate of wells preferably uses a cell non-adhesive bottom, preferably a cell non-adhesive coated bottom.
- a three-dimensional printer or a 3D printer Dispersed single cells or spheroids composed of multiple cells are suspended in biocompatible ink (bioink) and printed on a bio 3D printer (such as Cellink's BIO X), or A cell population with a desired form can be prepared by a technique of pricking a cell population with a needle and stacking it (Spike manufactured by Cyfuse, etc.).
- cell aggregates are determined by the size and number of cells of cell aggregates, macroscopic morphology, microscopic morphology by tissue staining analysis and its uniformity, expression of differentiation and undifferentiated markers and their uniformity, differentiation markers can be determined based on the expression control and its synchrony, reproducibility of differentiation efficiency between aggregates, and the like.
- adherent culture is performed.
- the pluripotent stem cells on the cultureware after step (a) may be used as they are in the first step, or the pluripotent stem cells may be dispersed into single cells and then seeded again on the adhesive cultureware. good.
- Appropriate extracellular matrices or synthetic cell adhesion molecules may be used as scaffolds in performing reseeding after dispersal of pluripotent stem cells into single cells.
- the scaffold allows adherent culture of pluripotent stem cells in a surface-coated cultureware.
- the extracellular matrix is preferably matrigel or laminin.
- Synthetic cell adhesion molecules include poly-D-lysine, synthetic peptides containing a cell adhesion domain such as the RGD sequence, and the like.
- the number of seeded cells is not particularly limited as long as differentiation to the pituitary gland occurs, but from the viewpoint of reproducing the adhesion and interaction between cells, the cell density should be within 72 hours after seeding on the cultureware. It is also preferable that the density is such that it reaches semi-confluence corresponding to 60% or more.
- micropatterned cultureware as the adhesive cultureware.
- the micropattern on the cultureware can be composed of a cell-adhesive region and a cell-non-adhesive region, and cells are preferably adherently cultured in the cell-adhesive region.
- the shapes of the cell adhesive region and the cell non-adhesive region are not limited as long as they can be developed on the cultureware.
- a single cell-adhesive region and a cell-non-adhesive region may be formed on one culture device, or a plurality of regions may be formed.
- the cell adhesive region is preferably artificially treated for the purpose of improving adhesiveness.
- micropatterned cultureware examples include CYTOOchip (manufactured by CYTOO) and ibidi Micropatterning (manufactured by ibidi).
- a cultureware can also be prepared using a PDMS mold, matrix, and the like.
- cultureware coated with an extracellular matrix, a substrate that promotes cell adhesion, or the like is processed with a laser or the like using a cell processing device (Model: CPD-017, manufactured by Kataoka Seisakusho) to obtain a cell adhesive region. and the cell non-adhesive region may be formed in any shape.
- a cell processing device Model: CPD-017, manufactured by Kataoka Seisakusho
- the cultureware preferably has a channel (microchannel) for perfusion of the medium, and cells may be cultured under a perfusion environment in the first step and subsequent steps.
- a culture device is also called a microfluidic chip.
- the culture device e.g., microfluidic chip
- may be connected to another culture device e.g., microfluidic chip for culturing cells or tissues other than the cells cultured in the production method of the present invention via channels. This makes it possible to reproduce the interaction of the pituitary gland with other cells or tissues.
- Other cells or tissues to be co-cultured with the pituitary gland include tissues regulated by hormones secreted from the pituitary gland, tissues promoting the growth, differentiation, maturation, and survival of the pituitary gland, such as brain, blood vessels, bones, and muscles. , fat, thyroid, liver, adrenal gland, testis, ovary, breast cells or tissue, and the like.
- Methods for medium perfusion include, but are not limited to, the use of magnetic stirrers, peristaltic pumps, and the like.
- the cultureware may have a membrane permeable to oxygen or medium.
- the cultureware may be capable of forming concentration gradients of compounds, growth factors, and the like.
- the membrane is for example a porous membrane.
- cells can be cultured by the production method of the present invention on one side separated by the membrane, and other cells or tissues, feeder cells, etc. can be cultured on the other side.
- the cells constituting the pituitary gland, their progenitor cells, and the cell population containing these cells can be cultured without contamination with other cells or tissues.
- a medium exchange operation for example, an operation to add a new medium without discarding the original medium (medium addition operation)
- about half the original medium (30% of the volume of the original medium about 90%, for example, about 40-60%) and about half of the new medium (30-90% of the volume of the original medium, for example, about 40-60%) is added (half-volume medium replacement operation).
- An operation of discarding about the entire amount (90% or more of the volume of the original medium) and adding about the entire amount (90% or more of the volume of the original medium) of new medium can be mentioned.
- Half volume medium exchange operation When adding a specific component at a certain point, for example, after calculating the final concentration, about half of the original medium is discarded, and about half of the new medium containing the specific component at a higher concentration than the final concentration is added ( Half volume medium exchange operation) may be performed.
- the medium exchange operation is performed multiple times a day, preferably multiple times (for example, 2 to 3 times) within 1 hour. good.
- the cells or cell aggregates may be transferred to another culture vessel if the components contained in the original medium are diluted to a lower concentration.
- Tools used for the medium exchange operation are not particularly limited, and examples thereof include pipettors, Pipetman (registered trademark), multichannel pipettes, continuous pipettors, and the like.
- pipettors When using a 96-well plate as culture equipment, a multichannel pipette may be used.
- the culture time in the first step is usually 8 hours to 6 days, preferably 12 hours to 60 hours.
- a compound that promotes differentiation into placode regions in the first step and subsequent steps.
- compounds having the above effects include BRL-54443, Phenanthroline, Parthenolide, etc. described in US Pat. No. 20160326491A1.
- BRL-54443 as a compound that promotes differentiation into placode regions, the concentration is usually about 10 nM to about 100 ⁇ M, when using Phenanthroline, usually about 10 nM to about 100 ⁇ M, and when using Parthenolide, the concentration is usually about 10 nM to about 100 ⁇ M. used in
- culturing may be performed in the presence of an agent acting on the Shh signal transduction pathway.
- an agent acting on the Shh signal transduction pathway As the Shh signal transduction pathway active substance used in the first step, those exemplified in step (a) can be used.
- the Shh signaling pathway agonists in step (a) and the first step may be the same or different, but are preferably the same and are preferably SAG.
- the concentration of the substance acting on the Shh signal transduction pathway in the medium can be appropriately set according to the substance to be used within a range in which the above effects can be achieved.
- SAG When SAG is used as the Shh signaling pathway agonist in the first step, it is generally about 1 nM to about 3 ⁇ M, preferably about 10 nM to about 2 ⁇ M, more preferably about 30 nM to about 1 ⁇ M, still more preferably about 50 nM to about 500 nM. used at a concentration of
- step (2) the cell population obtained in the first step is cultured in the presence of the BMP signaling pathway agonist and the Shh signaling pathway agonist.
- the formed cell aggregates may be continuously cultured in suspension in step (2).
- the cells may be adherently cultured in the step (2).
- adhesion culture may be performed in step (2).
- a BMP signaling pathway agonist is a substance that can enhance the signaling pathway mediated by BMP.
- Substances that can enhance signaling pathways mediated by BMPs include, for example, substances that stabilize and enhance the potency of BMP ligands in the culture environment, the type I BMP receptors ALK-1, ALK-2, ALK- 3.
- BMP signaling pathway agonists examples include BMP proteins such as BMP2, BMP4 or BMP7, GDF proteins such as GDF5, 6 and 7, anti-BMP receptor antibodies and BMP partial peptides. These substances may be used alone or in combination.
- BMP signaling pathway agonist from the viewpoint of biological activity, osteoblasts against cells such as mouse progenitor chondrocyte cell line ATDC5, mouse calvaria-derived cell line MC3T3-E1, mouse striated muscle-derived cell line C2C12, etc. Examples thereof include substances capable of inducing differentiation into cell-like cells and alkaline phosphatase production.
- substances having the above activity examples include BMP2, BMP4, BMP5, BMP6, BMP7, BMP9, BMP10, BMP13/GDF6, BMP14/GDF5, GDF7 and the like.
- BMP2 and BMP4 proteins are available from e.g. R&D Systems, BMP7 proteins e.g. from Biolegend, GDF5 proteins e.g. from Peprotech, GDF6 proteins e.g. from PrimeGene, GDF7 proteins e.g. be.
- the BMP signaling pathway agonist preferably contains at least one protein selected from the group consisting of BMP2, BMP4, BMP7, BMP13 and GDF7, more preferably BMP4.
- the concentration of the BMP signaling pathway agonist in the medium can be appropriately set according to the substance used within the range where the above effects can be achieved. From the viewpoint of improving the production efficiency of cells constituting the pituitary gland, when BMP4 is used as a BMP signaling pathway agonist, it is usually about 1 pM to about 100 nM, preferably about 10 pM to about 50 nM, more preferably about 25 pM to about 25 nM. , more preferably from about 25 pM to about 5 nM, particularly preferably from about 100 pM to about 5 nM, most preferably from about 500 pM to about 2 nM.
- BMP signaling pathway agonist other than BMP4
- the activity described in the product package insert for example, the ED50 value of the ability to induce alkaline phosphatase production in the mouse progenitor chondrocyte cell line ATDC5
- BMP signaling pathway agonists include, for example, Smurf1 inhibitors, Chk1 inhibitors, phosphorylated Smad stabilizers, and the like.
- Examples of compounds having the above activity include A-01 ([4-[[4-Chloro-3-(trifluoromethyl)phenyl]sulfonyl]-1-piperazinyl][4-(5-methyl-1H-pyrazol -1-yl)phenyl]methanone), PD407824 (9-Hydroxy-4-phenyl-pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione), SB4(2-[[(4 -Bromophenyl)methyl]thio]benzoxazole), SJ000291942 (2-(4-Ethylphenoxy)-N-(4-fluoro-3-nitrophenyl)-acetamide) and derivatives thereof.
- the Shh signal transduction pathway active substance used in step (2) As the Shh signal transduction pathway active substance used in step (2), those exemplified in step (a) can be used.
- the Shh signaling pathway agonists in steps (a) and (2) may be the same or different, but are preferably the same and are preferably SAG.
- the concentration of the substance acting on the Shh signal transduction pathway in the medium can be appropriately set according to the substance to be used within a range in which the above effects can be achieved.
- SAG is used as the Shh signaling pathway agonist in step (2), it is generally about 1 nM to about 5 ⁇ M, preferably about 10 nM to about 4.5 ⁇ M, more preferably about 50 nM to about 4 ⁇ M, still more preferably about 100 nM to Used at a concentration of approximately 3 ⁇ M.
- the medium used in step (2) is not particularly limited as long as it contains the Shh signaling pathway active substance and the BMP signaling pathway active substance.
- Examples of the medium used in step (2) include the medium mentioned in the first step.
- the start time of step (2) is preferably 0.5 hours to 6 days, more preferably 0.5 hours to 72 hours, from the start of culture in the first step. It is preferably between 24 hours and 60 hours.
- step (2) is started during the above period in the presence of a Wnt signaling pathway inhibitor, a non-neuroepithelium-like tissue is formed on the surface of the cell aggregates, and the pituitary gland is formed very efficiently. be.
- the start time of step (2) is preferably the surface layer of the cell aggregates formed in the first step. It is the stage when 10% or more, more preferably 30% or more, and still more preferably 50% or more of the cells form tight junctions with each other.
- a person skilled in the art can easily determine whether tight junctions are formed in cell aggregates by, for example, microscopic observation, immunostaining using an anti-ZO-1 antibody, or the like.
- Initiation of culture in the presence of the BMP signaling pathway agent in step (2) is performed by performing the above-described medium replacement operation (e.g., medium addition operation, half volume medium replacement operation, full volume medium replacement operation, etc.) may be performed, or the cells may be transferred to another culture vessel.
- medium replacement operation e.g., medium addition operation, half volume medium replacement operation, full volume medium replacement operation, etc.
- the period of culture in the medium containing the BMP signaling pathway active substance in step (2) can be set as appropriate.
- the culture time in step (2) is usually 8 hours or longer, preferably 10 hours or longer, more preferably 12 hours or longer, still more preferably 14 hours or longer, and most preferably 16 hours or longer.
- the period of culture in the medium containing the Shh signaling pathway agonist in step (2) can be set as appropriate.
- the culture period in the presence of the Shh signaling pathway agent in steps (1) and (2) is 30 days is preferred.
- FGF signaling pathway agent it is also preferable to add an FGF signaling pathway agent to the culture environment from the viewpoint of promoting differentiation into pituitary placodes.
- the FGF signal transduction pathway agonist is not particularly limited as long as it is a substance capable of enhancing the signal transduction pathway mediated by FGF (fibroblast growth factor).
- FGF signaling pathway agents include FGF proteins such as FGF1, FGF2 (sometimes referred to as bFGF), FGF3, FGF8 and FGF10, anti-FGF receptor antibodies, FGF partial peptides and the like. These substances may be used alone or in combination.
- FGF2 protein and FGF8 protein are available, for example, from FUJIFILM Wako Pure Chemical Industries, Ltd.
- FGF signaling pathway agent preferably contains at least one selected from the group consisting of FGF2, FGF3, FGF8 and FGF10, and variants thereof, more preferably FGF2, more preferably recombinant human FGF2 include.
- the concentration of the FGF signaling pathway active substance in the medium can be appropriately set according to the substance used within the range where the above effects can be achieved. From the viewpoint of differentiation into cells constituting the nasal epithelium and promotion of cell survival and proliferation, when FGF2 is used as an active substance of the FGF signaling pathway, it is usually about 1 pg/ml to about 100 ⁇ g/ml, preferably about 10 pg. /ml to about 50 ⁇ g/ml, more preferably about 100 pg/ml to about 10 ⁇ g/ml, more preferably about 500 pg/ml to about 1 ⁇ g/ml, most preferably about 1 ng/ml to about 200 ng/ml. be done.
- an FGF signaling pathway active substance other than FGF2 when using an FGF signaling pathway active substance other than FGF2, it is preferably used at a concentration that exhibits an FGF signaling pathway promoting activity equivalent to that of FGF2 at the above concentrations.
- the FGF signaling pathway promoting activity of the substance to be added can be measured, for example, by a method such as a cell proliferation test using 3T3 cells.
- Heparin is available as the sodium salt from, for example, Fujifilm Wako Pure Chemical Industries.
- the concentration of heparin or heparan sulfate in the medium can be appropriately set within a range in which the above effects can be achieved.
- the concentration of sodium heparin in the medium is usually about 1 ng/ml to about 100 mg/ml, preferably about 10 ng/ml to about 50 mg/ml, more preferably about 100 ng/ml to about 10 mg/ml, still more preferably about 500 ng.
- heparan sulfate When heparan sulfate is used, it is preferably at a concentration that has the same FGF protein-protecting activity as heparin at the concentration described above.
- modified FGF such as Thermostable FGF2 described in US Pat.
- FGF2 sustained-release beads of Thermostable FGF2 is available, for example, from HumanZyme.
- StemBeads FGF2 are available, for example, from StemCulture.
- the timing of addition of the FGF signaling pathway agonist in step (2) and subsequent steps can be set as appropriate.
- the FGF signaling pathway agonist is added 6 hours or later, more preferably 12 hours or later, more preferably 18 hours or later, from the addition of the BMP signaling pathway agonist in step (2).
- step (2) the additives used in step (a) or step 1, such as JNK signaling pathway inhibitors, Wnt signaling pathway inhibitors, TGF ⁇ signaling pathway inhibitors, TAK1 inhibitors, etc., are continuously added. is also preferred.
- the JNK signaling pathway inhibitor, Wnt signaling pathway inhibitor, or TGF ⁇ signaling pathway inhibitor added in step (2) may be different from the substance used in the previous steps, but is preferably the same. be.
- the concentration and type of additive can be adjusted as appropriate.
- the timing of addition of these substances may be simultaneous with the start of step (2), or may be different.
- Step (b) The following step (b) may be further included after step (2).
- step (b) the cell population obtained in step (2) is cultured under conditions in which a BMP signaling pathway inhibitor is added.
- the formed cell aggregates may be continuously cultured in suspension in step (b).
- the cells may be adherently cultured in step (b).
- BMP signaling pathway inhibitors are not limited as long as they can suppress signal transduction triggered by BMP family proteins. Any of nucleic acids, proteins, and low-molecular-weight organic compounds may be used. Examples of such substances include substances that inhibit BMP processing and extracellular secretion, substances that directly act on BMPs (e.g., proteins, antibodies, aptamers, etc.), and substances that suppress the expression of genes encoding BMPs (e.g., antisense oligos). nucleotides, siRNA, etc.), substances that inhibit binding between BMP receptors and BMPs, and substances that inhibit physiological activities caused by signal transduction by BMP receptors. BMP receptors include type I BMP receptors and type II BMP receptors.
- Type I BMP receptors are BMPR1A, BMPR1B, and ACVR
- type II BMP receptors are TGF-beta R-II and ActR-II. , ActR-IIB, BMPR2, and MISR-II.
- BMP signaling pathway inhibitors include, for example, Noggin, Chordin, Follistatin, Gremlin, Inhibin, TwistedGastrulation, Coco, and secretory proteins belonging to the DAN family. Since the BMP signaling pathway agent is added to the culture medium in the above step (2), the BMP signaling pathway in step (b) from the viewpoint of more effectively inhibiting the subsequent BMP signaling pathway
- An inhibitory substance is a substance that inhibits the signal transduction pathway after BMP secretion to the outside of the cell, such as a substance that inhibits the binding of a BMP receptor and a BMP, or that inhibits physiological activity resulting from signal transduction by a BMP receptor. It preferably contains a substance or the like, more preferably an inhibitor of the type I BMP receptor.
- BMP signaling pathway inhibitors include, for example, inhibitors of type I BMP receptors.
- Examples of compounds having the above activity include K02288 (3-[(6-Amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenol,3-[6-Amino-5-( 3,4,5-trimethoxyphenyl)-3-pyridinyl]-phenol), Dorsomorphin (6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)pyrazolo[1,5- a]pyrimidine), LDN-193189 (4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride), LDN-212854 (5-[6 -[4-(1-Pipera
- the BMP signaling pathway inhibitor is preferably a type I BMP receptor inhibitor, more preferably selected from the group consisting of K02288, Dorsomorphin, LDN-193189, LDN-212854, LDN-214117, ML347, DMH1 and DMH2 At least one, more preferably K02288 to LDN-193189.
- the concentration of the BMP signaling pathway inhibitor in the medium can be appropriately set according to the substance used within the range where the above effects can be achieved. From the viewpoint of pituitary tissue formation efficiency, when K02288 is used as the BMP signaling pathway inhibitor in step (b), the It is used at a concentration of 50 ⁇ M, more preferably from about 500 nM to about 25 ⁇ M. When LDN-193189 is used as a BMP signaling pathway inhibitor, it is usually used at a concentration of about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 10 ⁇ M, more preferably about 25 nM to about 1 ⁇ M, still more preferably about 100 nM to about 500 nM. used.
- LDN-212854 When LDN-212854 is used as a BMP signaling pathway inhibitor, it is usually used at a concentration of about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 10 ⁇ M, more preferably about 25 nM to about 5 ⁇ M, still more preferably about 250 nM to about 3 ⁇ M. used.
- ML-347 When ML-347 is used as a BMP signaling pathway inhibitor, it is usually used at a concentration of about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 50 ⁇ M, more preferably about 100 nM to about 50 ⁇ M, still more preferably about 1 ⁇ M to about 25 ⁇ M. used.
- DMH2 When used as a BMP signaling pathway inhibitor, it is usually used at a concentration of about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 10 ⁇ M, more preferably about 25 nM to about 5 ⁇ M, still more preferably about 250 nM to about 3 ⁇ M. be.
- a BMP signaling pathway inhibitor other than K02288 when using a BMP signaling pathway inhibitor other than K02288, it is preferably used at a concentration that exhibits the same BMP signaling pathway inhibitory activity as K02288 at the above concentrations.
- the timing of starting step (b) after step (2) is implemented can be set as appropriate.
- the timing of starting step (b) is usually 8 hours or more and 15 days or less, preferably 10 hours or more and 12 days or less, more preferably 12 hours or more and 9 days or less, and further It is preferably 14 hours or more and 8 days or less, most preferably 16 hours or more and 7 days or less.
- the cell population may be treated with adrenocortical hormones by adding the adrenocortical hormones to the medium.
- Pituitary hormone-producing cells other than ACTH-producing cells i.e., GH-producing cells, PRL-producing cells, TSH-producing cells, LH-producing cells, FSH-producing cells, etc.
- differentiation is promoted.
- adrenocortical hormones include natural glucocorticoids such as hydrocortisone, cortisone acetate and fludrocortisone acetate; artificially synthesized glucocorticoids such as dexamethasone, betamethasone, prednisolone, methylprednisolone and triamcinolone. It can be, but is not limited to.
- the concentration of adrenocortical hormones in the medium is not particularly limited as long as it can promote differentiation from the pituitary placode and/or Rathke's pouch into pituitary hormone-producing cells (excluding ACTH-producing cells).
- it can be appropriately set depending on the type of adrenocortical hormones.
- hydrocortisone it is usually 100 ng/ml or more, preferably 1 ⁇ g/ml or more.
- concentration of hydrocortisone is no particular upper limit to the concentration of hydrocortisone as long as it does not adversely affect differentiation into pituitary hormone-producing cells (excluding ACTH-producing cells). It is below.
- the concentration of hydrocortisone in the medium is usually about 100 ng/ml to about 1000 ⁇ g/ml, preferably about 1 to about 100 ⁇ g/ml.
- concentration in the medium can be about 1/25 that of hydrocortisone.
- the pituitary placode and/or Rathke's pouch differentiate into pituitary hormone-producing cells (excluding ACTH-producing cells).
- ACTH-producing cells excluding ACTH-producing cells.
- adrenocortical hormones are added to the medium. That is, until the appearance of ACTH-producing cells is confirmed in the cell aggregates, the cell aggregates are cultured in a medium without addition of adrenocortical hormones, and after the appearance of ACTH-producing cells is confirmed, the adrenal cortex
- the second step and subsequent steps are continued in a medium containing hormones.
- the appearance of ACTH-producing cells can be confirmed by immunohistological staining using an antibody against ACTH. When human pluripotent stem cells are used, the appearance of ACTH-producing cells can generally be expected after 30 days from the start of the first step. add adrenocortical hormones to
- the period for treating the cell aggregates with adrenocortical hormones is not particularly limited as long as the differentiation from the pituitary placode and/or Rathke's pouch to pituitary hormone-producing cells (excluding ACTH-producing cells) can be promoted.
- the adrenocortical hormone-untreated group in the adrenocortical hormone-treated group, promotion of differentiation into pituitary hormone-producing cells (excluding ACTH-producing cells) is confirmed.
- Aggregates are treated with corticosteroids.
- the treatment period is usually 7 days or more, preferably 12 days or more.
- the upper limit of the treatment period is not particularly limited. Once the promotion is confirmed, corticosteroids may be removed from the culture medium.
- Retinoic acid transduction pathway agents include, for example, substances that bind to retinoic acid receptor (RAR) or retinoid X receptor (RXR) and activate downstream transcription.
- Examples of compounds having the above effects include all-trans retinoic acid, isotretinoin, 9-cis retinoic acid, TTNPB (4-[(E)-2-[(5,5,8,8-Tetramethyl-5 ,6,7,8-tetrahydronaphthalene)-2-yl]-1-propenyl]benzoic acid), Ch55(4-[(E)-3-(3,5-di-tert-butylphenyl)-3-oxo- 1-propenyl]benzoic acid), EC19(3-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethynyl]benzoic acid), EC23(4- [2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethynyl)-benzoicacid), Fenretinide(4-hydroxyphenylretinamide
- the retinoic acid transduction pathway active substance in step (2) and subsequent steps preferably contains all-trans retinoic acid or EC23.
- the concentration of the retinoic acid transduction pathway active substance in the medium is not particularly limited as long as it is within the range where the above effects can be achieved. It is about 30 ⁇ M, preferably about 100 pM to about 20 ⁇ M, more preferably about 10 nM to about 10 ⁇ M, even more preferably about 100 nM to about 5 ⁇ M.
- a retinoic acid transduction pathway active substance other than EC23 it is preferably used at a concentration that exhibits retinoic acid transduction pathway activity equivalent to that of EC23 at the concentration described above.
- the Notch signaling pathway is a signal activated by direct interaction between the Notch protein, which is a receptor expressed on the cell membrane, and the Notch ligand (Delta, Jagged, etc.) expressed on the membrane of adjacent cells. Represents the transfer pathway. In cells transduced with Notch signals, Notch proteins undergo stepwise processing, and the intracellular domains excised on the membrane are transported into the nucleus to regulate the expression of downstream genes.
- the Notch signaling pathway inhibitor is not particularly limited as long as it can suppress signal transduction mediated by Notch. Any of nucleic acids, proteins, and low-molecular-weight organic compounds may be used. Examples of such substances include functional-deficient Notch receptors and ligands, substances that inhibit Notch processing (S1 cleavage), substances that inhibit glycosylation of Notch and Notch ligands, substances that inhibit cell membrane translocation, and Notch. Substances that inhibit intracellular domain (NICD) processing (S2 cleavage, S3 cleavage) ( ⁇ -secretase inhibitors), substances that degrade NICD, substances that inhibit NICD-dependent transcription, and the like can be mentioned.
- NBD intracellular domain
- Notch signaling pathway inhibitors Compounds well known to those skilled in the art can also be used as Notch signaling pathway inhibitors.
- Examples of compounds having activity as Notch signaling pathway inhibitors include DAPT (N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester), DBZ ((2S)- 2-[[2-(3,5-difluorophenyl)acetyl]amino]-N-[(7S)-5-methyl-6-oxo-7H-benzo[d][1]benzazepin-7-yl]propanamide) , MDL28170 (benzyl N-[(2S)-3-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]butan-2-yl]carbamate), FLI-06 (cyclohexyl 2,7,7-tri
- the concentration of the Notch signaling pathway inhibitor in the medium is not particularly limited as long as the above effects can be achieved. to about 50 ⁇ M, preferably about 1 nM to about 30 ⁇ M, more preferably about 100 nM to about 20 ⁇ M, even more preferably about 1 ⁇ M to about 10 ⁇ M.
- a Notch signaling pathway inhibitor other than DAPT it is preferably used at a concentration that exhibits Notch signaling pathway inhibitory activity equivalent to that of DAPT at the above concentrations.
- the third step is the cell population cultured in step (2) or step (b) under conditions where no Shh signaling pathway agonist is added. to culture.
- the cell population obtained in the second step is cultured in the absence of an agent acting on the Shh transduction pathway to obtain a cell population containing pituitary tissue.
- the third step of culturing the population in the absence of the Shh signaling pathway agonist to obtain a cell population containing pituitary tissue is step (3′).
- the formed cell aggregates may be cultured in suspension in the third step.
- the cells may be adherently cultured in the third step.
- adhesion culture may be performed in the third step.
- the medium used in the third step is not particularly limited as long as it does not contain an active substance of the Shh signaling pathway.
- the conditions under which the Shh signaling pathway agonist is not added in this step refer to conditions in which the Shh signaling pathway agonist is not intentionally added to the culture environment of the cell population.
- the case where the active substance of the signaling pathway is contained in the culture environment is also included in the condition of not adding the active substance of the Shh signaling pathway.
- Examples of the medium used in the third step include the medium mentioned in the first step, gfCDM medium containing 10% to 20% KSR, and the like.
- the third step and subsequent steps may include a step of embedding the cell aggregates in a gel and culturing them.
- gels include gels using agarose, methylcellulose, collagen, Matrigel, etc. Matrigel is preferably used.
- the cell aggregates may be embedded as they are, or the cells after dispersion and isolation may be seeded in the gel. good too.
- Specific cell tumors such as basal cells may be sorted using a cell sorter or the like, and then seeded.
- co-culturing with cells other than the pituitary gland such as fibroblasts, mesenchymal cells, and vascular cells, can also be carried out.
- Gel-embedding culture as described above can be performed with reference to, for example, Nature 501, 373-379 (2013), Nature, 499, 481-484 (2013), Nat Protoc 14, 518-540 (2019), Genes 2020, 11, 603, etc. can.
- a culture method in which cells are physically shaken for the purpose of improving nutrition and oxygen supply to cells and improving substance exchange.
- Examples of such culture methods include methods other than stationary culture such as shaking culture, rotary culture, and agitation culture.
- the means for performing shaking culture, rotary culture, stirring culture, etc. is not particularly limited. This can be done by putting down A person skilled in the art can appropriately set parameters such as the speed of shaking culture, rotation culture, and agitation culture within a range that does not cause damage to the cells.
- the speed is, for example, 5 to 60 rpm, preferably 5 to 40 rpm, more preferably 5 to 20 rpm.
- Shaking speed range can be set.
- the shaking speed range is set in the range of, for example, 15-60 rpm, preferably 15-50 rpm, more preferably 15-45 rpm. It is possible.
- the shaking speed range is set in the range of, for example, 5 to 50 rpm, preferably 5 to 40 rpm, more preferably 5 to 30 rpm. It is possible.
- a spinner flask e.g., 3152, manufactured by Corning
- the culture is performed at a rotational speed that does not allow the cell aggregates to settle visually.
- Cultivation can also be performed using a three-dimensional rotary suspension culture device (eg, CellPet CUBE, manufactured by J-Tech; Clinostar, manufactured by Celvivo). From the viewpoint of suppressing physical damage to cells such as friction, it is also preferable to culture the cell aggregates embedded in the gel with shaking, rotation, or agitation.
- a three-dimensional rotary suspension culture device eg, CellPet CUBE, manufactured by J-Tech; Clinostar, manufactured by Celvivo.
- the third step (3) and subsequent steps it is also preferable to culture in a high-oxygen atmosphere from the viewpoint of suppressing cell death and promoting cell growth.
- High-oxygen conditions in the culture process can be realized, for example, by connecting an oxygen bomb to an incubator for culturing cells and artificially supplying oxygen.
- the oxygen concentration for such purposes is usually 25% to 80%, more preferably 30% to 60%.
- culture equipment with high gas exchange efficiency can be used from the viewpoint of increasing the amount of oxygen supplied to the medium in which the cell aggregates are cultured.
- examples of such cultureware include a cell culture dish, a Lumox dish with a gas-permeable film on the bottom of the plate (manufactured by Sarstedt), and a VECELL 96well plate (manufactured by Bethel Co., Ltd.). It is also preferable to use in combination with the above-described culture under high oxygen concentration conditions.
- a cell protective agent can be added to the medium from the viewpoint of maintaining the structure of the epithelial tissue in the cell aggregates.
- Cell protective agents used in step (3) and subsequent steps include the above-mentioned FGF signaling pathway agonists, heparin, ROCK inhibitors, basement membrane preparations, myosin inhibitors, polyamines, ISR inhibitors, caspase inhibitors agents, serum, serum substitutes, and the like.
- myosin inhibitors include Blebbistatin, which is a non-muscle myosin II ATPase inhibitor, ML-7, ML-9, W-7, MLCK inhibitor peptide 18, which are inhibitors of myosin light chain kinase (MLCK), and these and derivatives thereof.
- the added cytoprotective agent may be different from that added in the first step, but is preferably the same.
- Preferred cytoprotective agents include ROCK inhibitors.
- the ROCK inhibitor Y-27632 when added as a cytoprotective agent, it is usually about 10 nM to about 10 mM, preferably about 100 nM to about 1 mM, more preferably about 1 ⁇ M to about 100 ⁇ M.
- the concentration is When the ROCK inhibitor Chroman 1 is added, it is usually added to the culture environment at a concentration of about 10 pM to about 1 mM, preferably about 100 pM to about 100 ⁇ M, more preferably about 1 nM to about 10 ⁇ M.
- the concentration is usually about 10 nM to about 10 mM, preferably about 100 nM to about 1 mM, more preferably about 1 ⁇ M to about 100 ⁇ M.
- Add to the culture environment as follows.
- substances other than cell protective agents that have the effect of maintaining the structure of the epithelial tissue.
- substances that promote cell adhesion include substances that promote cell adhesion, substances that promote synthesis of basement membrane components, substances that inhibit decomposition of basement membrane components, and the like.
- Substances that promote cell adhesion may be those that promote cell-to-cell adhesion, cell-to-basement membrane adhesion, cell-to-cultureware adhesion, or the like, and production of factors involved in cell adhesion.
- Substances that promote cell adhesion include, for example, adhesamine, adhesamine-RGDS derivatives, Pyrintegrin, Biotin tripeptide-1, Acetyl Tetrapeptide-3, RGDS Peptide and derivatives thereof.
- Substances that promote the synthesis of basement membrane components include, for example, ascorbic acid derivatives.
- ascorbic acid derivatives include sodium ascorbyl phosphate, magnesium ascorbyl phosphate, ascorbyl 2-glucoside, 3-O-ethyl ascorbyl acid, ascorbyl tetrahexyldecanoate, ascorbyl palmitate, ascorbyl stearate, ascorbyl-2 Phosphate-6-palmitate, glyceryl octyl ascorbic acid and the like.
- Substances that inhibit degradation of basement membrane components include, for example, inhibitors of matrix metalloproteases and serine proteases.
- the amount is usually 10 ⁇ g/ml or more and 1000 ⁇ g/ml or less, preferably 30 ⁇ g/ml or more and 500 ⁇ g/ml. Subsequently, it is added to the culture environment at a concentration of 50 ⁇ g/ml or more and 300 ⁇ g/ml or less, more preferably. When other ascorbic acid, ascorbic acid derivatives, etc. are added, they may be added so that the above concentration and molar equivalent are approximately the same.
- substances having the above activity include antioxidant substances, substances having free radical scavenger action, NADPH oxidase inhibitors, cyclooxygenase inhibitors, lipoxygenase (LOX) inhibitors, superoxide dismutase (SOD)-like substances, and Nrf2 activators. agents and the like.
- Reagents prepared for cell culture can also be used.
- the substance having the action of reducing oxidative stress used in the present invention preferably contains at least one selected from the group consisting of ascorbic acid, N-acetyl-L-cysteine and derivatives thereof.
- Ascorbic acid for example, as its derivative, ascorbic acid diphosphate, at a concentration of about 1 nM to about 1 M, preferably about 10 nM to about 100 mM, more preferably about 100 nM to about 10 mM, even more preferably about 1 ⁇ M to about 3 mM.
- N-acetyl-L-cysteine is added to the medium at a concentration of, for example, about 1 nM to about 1 M, preferably about 10 nM to about 100 mM, more preferably about 100 nM to about 10 mM, even more preferably about 1 ⁇ M to about 5 mM. be able to.
- a substance that inhibits the stress response signaling pathway (a substance that inhibits the intracellular signaling mechanism against stress).
- the stress-activated protein kinase (SAPK) pathway is one of the major intracellular signaling mechanisms for stress.
- Inhibitors of the stress-responsive MAP kinase pathway include e.g. MAP3K inhibitors, MAP2K inhibitors, ASK inhibitors, MEK inhibitors, Akt inhibitors, Rho family kinase inhibitors, JNK inhibitors, p38 inhibitors, MSK inhibitors, STAT inhibitors, NF- ⁇ B inhibitors, CAMK inhibitors and the like.
- MEK inhibitors include Selumetinib (AZD6244, 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carbboxamide), Mirdametinib (PD0325901, N-[ (2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide), Trametinib (GSK1120212, N-[3-[3-cyclopropyl-5-(2- fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide), U0126(1,4-diamino-2,3- dicyano-1,4-bis(2-aminophenylthio)butadiene), PD184352
- Examples of p38 inhibitors include SB203580 (4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine), Doramapimod (BIRB 796,1-[5-tert -butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea), SB202190 (FHPI,4-[4-( 4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]phenol), Ralimetinib dimesylate(5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5- yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine;methanesulfonic acid), V
- JNK inhibitors include those mentioned in the first step.
- the substance that inhibits the intracellular signaling mechanism against stress used in the present invention is preferably one or more selected from the group consisting of MEK inhibitors, p38 inhibitors and JNK inhibitors.
- SB203580 When SB203580 is used as a p38 inhibitor, it is usually added to the medium at a concentration of about 1 nM to about 1 mM, preferably about 10 nM to about 100 ⁇ M, more preferably about 100 nM to about 10 ⁇ M, still more preferably about 500 nM to about 5 ⁇ M. can do.
- PD0325901 When PD0325901 is used as a MEK inhibitor, it is usually added to the medium at a concentration of about 1 nM to about 1 mM, preferably about 10 nM to about 100 ⁇ M, more preferably about 100 nM to about 10 ⁇ M, still more preferably about 500 nM to about 5 ⁇ M. can do.
- JNK-IN-8 When JNK-IN-8 is used as the JNK inhibitor, it can be added to the medium at the same concentration as described in the first step.
- other MEK inhibitors, p38 inhibitors, and JNK inhibitors When other MEK inhibitors, p38 inhibitors, and JNK inhibitors are used, it is preferable to add them at a concentration having an inhibitory activity equivalent to that of the above inhibitors.
- the pluripotent stem cells cultured under conditions capable of inducing differentiation into cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells are aggregates of pluripotent stem cells. There may be.
- a pluripotent stem cell aggregate is cultured in the presence of a differentiation inducer, it can be cultured, for example, according to the method described in International Publication No. 2016/013669.
- the cell aggregate containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells obtained in step (A) contains pituitary hormone-producing cells secreting ACTH, and , GH or TSH-secreting cell aggregates free of pituitary hormone-producing cells.
- the cell aggregate containing hypothalamic cells, pituitary progenitor cells, and pituitary hormone-producing cells obtained in step (A) contains pituitary hormone-producing cells that secrete ACTH and pituitary secretes GH or TSH.
- pituitary hormone-producing cells may further contain other pituitary hormone-producing cells, although it is not particularly limited, for example, pituitary hormone-producing cells that secrete PRL, pituitary gland that secretes LH It may contain at least one pituitary hormone-producing cell selected from the group consisting of hormone-producing cells and pituitary hormone-producing cells that secrete FSH.
- step (A) may be a period during which the cell aggregates of (i) to (iv) above are obtained.
- the cell aggregate containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells obtained in step (A) contains pituitary hormone-producing cells can be confirmed by known means. , GH-producing cell marker (anti-Pit1 antibody, anti-GH antibody, etc.), PRL-producing cell marker (anti-Pit1 antibody, anti-PRL antibody, etc.), ACTH-producing cell marker (anti-T-Pit antibody, anti-NeuroD1 antibody, anti-ACTH antibody, etc.) ), TSH-producing cell markers (anti-GATA2 antibody, anti-TSH antibody, etc.), FSH-producing cells, and immunohistochemistry using LH-producing cell markers (anti-GATA2 antibody, anti-SF1 antibody, anti-FSH antibody, anti-LH antibody, etc.) and can be detected by techniques such as ELISA for secreted hormones.
- GH-producing cell marker anti-Pit1 antibody, anti-GH antibody, etc.
- PRL-producing cell marker anti-P
- pluripotent stem cells or cell aggregates thereof are cultured under conditions that can induce differentiation into cell aggregates containing hypothalamic cells, pituitary progenitor cells, and pituitary hormone-producing cells, about 30 days after initiation of differentiation induction Pituitary hormone-producing cells that secrete ACTH begin to appear in the eye. In addition, pituitary hormone-producing cells that secrete GH or TSH begin to appear about 100 days after initiation of differentiation induction. Therefore, the culture period in step (A) may be about 30 days or more and about 100 days or less. 60 days or more and about 100 days or less.
- step (A) When the culture period in step (A) is about 60 days or more and about 100 days or less, cell aggregates containing pituitary hormone-producing cells that secrete ACTH are always present, and the ACTH secretion ability is 0.5 pg/mL or more. (prophase pituitary tissue: ⁇ 0.5 pg/mL, metaphase: ⁇ 2 pg/mL).
- step (A) The cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells obtained in step (A) as described above are dispersed into cell populations in step (B) (this step is referred to as " sometimes collectively referred to as “intermediate purification”).
- the obtained cell aggregates may be pretreated with a ROCK inhibitor.
- a ROCK inhibitor is preferably added before starting the pretreatment in order to suppress cell death induced by subsequent dispersion of cell aggregates.
- a ROCK inhibitor is added, for example, at least 24 hours, at least 12 hours, at least 6 hours, at least 3 hours, at least 2 hours, at least 1 hour before the start of the treatment.
- ROCK inhibitors include Y-27632 ((+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride) and the like.
- the concentration of the ROCK inhibitor used in the treatment is a concentration capable of suppressing cell death induced by subsequent dispersal of cell aggregates.
- concentrations are usually about 0.1-200 ⁇ M, preferably about 2-50 ⁇ M.
- concentration of the ROCK inhibitor may be varied during the period of addition, eg, the concentration can be halved later in the period.
- the medium for performing the pretreatment the medium used in the culture step of step (A) can be used.
- the pretreatment step is not necessary.
- the pretreated cell aggregates are dispersed by enzymatic treatment. Specifically, first, the pretreated cell aggregates are transferred to an incubator containing PBS and washed with the same medium.
- Enzymes for dispersal are not particularly limited as long as they can disperse cells. Examples include papain, EDTA; trypsin, collagenase (collagenase types I to VII), metalloprotease, hyaluronidase, elastase, dispase, enzymes such as deoxyribonuclease and mixtures thereof.
- Preferred enzymes include papain.
- the enzyme treatment conditions (temperature, time, etc.) can be appropriately set depending on the enzyme used.
- the cell aggregates are physically shredded (e.g., scalpel, scissors, etc.), or the cell aggregates are physically shredded (e.g., scalpel, scissors, etc.). ) may be cut.
- the floating cells may be collected and the enzyme treatment may be performed again. May be repeated multiple times.
- the enzymatic treatment can also be performed with the above-mentioned enzymes, etc., and preferred enzymes include EDTA; mixtures.
- Preferred enzymes include collagenase, more preferably collagenase type I.
- the enzyme treatment conditions (temperature, time, etc.) can be appropriately set depending on the enzyme used.
- the enzymatic treatment can also be performed with the enzymes described above, and preferred enzymes include EDTA; trypsin, more preferably EDTA; trypsin and deoxyribonuclease. Also, EDTA; a commercial product such as TrypLE (Invitrogen) may be used instead of trypsin.
- the enzyme treatment conditions (temperature, time, etc.) can be appropriately set depending on the enzyme used.
- a single cell suspension can be prepared by the above series of enzymatic treatments. In addition, when preparing the single cell suspension, dead cells may be removed by a method known per se.
- step (1) of the present invention pituitary progenitor cells are obtained from a dispersed cell population containing pluripotent stem cell-derived hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells as described above.
- Cells expressing EpCAM, a cell surface marker specific for cells and pituitary hormone-producing cells are isolated.
- Methods for separating the desired EpCAM-expressing cells from the dispersed cell population include methods using flow cytometry and mass cytometry, magnetic cell separation methods, and the like, and these methods are known per se. method.
- EpCAM-expressing cells can be isolated by a method comprising the step of contacting the cells with a substance (eg, antibody, etc.) that specifically binds to the EpCAM molecule.
- the above substances include those with detectable labels (eg, GFP, PE) attached to themselves and those without labels attached to themselves. If the substance itself is not labeled, the separation can be achieved by further using a substance with a detectable label that directly or indirectly recognizes the substance.
- a substance with a detectable label that directly or indirectly recognizes the substance.
- the substance is an antibody
- a fluorescent dye, a metal isotope or beads e.g., magnetic beads
- the antibodies used at this time may be of one type, or two or more types of antibodies.
- the method of the present invention involves exposing isolated EpCAM-expressing cells (the cells may be collectively referred to as "intermediate purified bodies") for 14 days under conditions that allow the maturation of pituitary progenitor cells into pituitary hormone-producing cells.
- the above step of suspension culture (step (2) of the present invention) is included.
- Conditions under which pituitary progenitor cells can mature into pituitary hormone-producing cells are culture conditions under which pituitary progenitor cells differentiate into pituitary hormone-producing cells and the hormone-producing ability of the differentiated pituitary hormone-producing cells is maintained or improved. Say.
- a medium (about 0.18 to about 20 mL) that can be used for culturing pituitary hormone-producing cells, preferably a free medium containing KSR, is used.
- Serum medium e.g. IMDM, DMEM, EMEM, ⁇ MEM, GMEM, F-12 medium, DMEM/F12, IMDM/F12, epithelial cell medium (e.g. CnT-Prime epithelial culture medium), or mixed medium of these, etc.
- Cultivation in The culture may be adherent culture or suspension culture, but suspension culture is preferred.
- the suspension culture period under conditions that allow pituitary progenitor cells to mature into pituitary hormone-producing cells is usually 14 days or more, preferably 30 days or more.
- One aspect of the method of the present invention includes the following production method. The following steps: (1) A dispersed cell population derived from pluripotent stem cells and containing one to four types of pituitary hormone-producing cells (e.g., containing pituitary hormone-producing cells that secrete ACTH and secreting GH or TSH and (2) separating the isolated EpCAM-expressing cells from a cell population free of pituitary hormone-producing cells, and (2) allowing the isolated EpCAM-expressing cells to mature from pituitary progenitor cells to pituitary hormone-producing cells. Suspension culture for 14 days or more under conditions, A method for producing a cell aggregate containing pituitary hormone-producing cells, comprising:
- Another aspect of the method of the present invention includes the following production method.
- a method for producing a cell aggregate containing pituitary hormone-producing cells comprising:
- Another aspect of the method of the present invention includes the following production method. The following steps: (1) separating cells expressing EpCAM from a cell population obtained by dispersing cell aggregates derived from pluripotent stem cells and containing one to four types of pituitary hormone-producing cells; and (2) a step of suspension culture of the separated EpCAM-expressing cells for 14 days or longer under conditions that allow the pituitary progenitor cells to mature into pituitary hormone-producing cells;
- a method for producing a cell aggregate containing pituitary hormone-producing cells comprising:
- Still another aspect of the method of the present invention includes the following production method. The following steps: (1) from a cell population obtained by dispersing cell aggregates derived from pluripotent stem cells, containing one to four types of pituitary hormone-producing cells and containing Nkx2.1-expressing cells in hypothalamic tissue; (2) suspension culture of the isolated EpCAM-expressing cells for 14 days or longer under conditions that allow the pituitary progenitor cells to mature into pituitary hormone-producing cells; A method for producing a cell aggregate containing pituitary hormone-producing cells, comprising:
- a cell aggregate containing pituitary hormone-producing cells obtained by the method of the present invention has the following characteristics.
- the proportion of EpCAM-positive cells and at least one of E-cadherin-positive cells in the cell aggregate is 80% or more.
- the existence ratio of nerve cells in the cell aggregate is 20% or less.
- the proportion of ACTH-positive cells in the cell aggregate is 5% or more.
- the cell density of the cell aggregate is 3,000-20,000 cells/mm 2 .
- the length of the cell aggregate is 200-3,000 ⁇ m.
- EpCAM-positive cells and at least one E-cadherin-positive cells adhere to each other on the surface of the cell aggregate to form an epithelial structure.
- the cell aggregate forms a sponge-like structure.
- EpCAM-positive cells occupy many cells in the cell aggregate.
- Cell aggregates obtained by the method of the present invention also include E-cadherin-positive cells. Some or all of the EpCAM-positive cells may be EpCAM-positive and E-cadherin-positive cells.
- the ratio of the number of cells positive for at least one of EpCAM and E-cadherin to the total number of cells present in the cell aggregate depends on the separation efficiency of the step of separating EpCAM-expressing cells. or more, preferably 85% or more, 90% or more, or 95% or more.
- EpCAM and E-cadherin are expressed in neurons that constitute the hypothalamus (e.g., hypothalamic progenitor cells, such as neurons and glial cells; these are also called “hypothalamus cells”). do not have. Therefore, these cells are removed by separating the cells expressing EpCAM. That is, the ratio of the number of neurons (hypothalamic cells) to the total number of cells present in the cell aggregate (ratio of neurons) depends on the isolation efficiency of the step of isolating EpCAM-expressing cells. For example, it may be 20% or less, preferably 15% or less, 10% or less, or 5% or less. Markers expressed in neurons that constitute the hypothalamus include Rx, NKx2.1, Nestin and Pax6.
- the ratio of the number of cells expressing Rx, NKx2.1, Nestin and/or Pax6 to the total number of cells present in the cell aggregate may be, for example, 20% or less, preferably 15%. 10% or less, or 5% or less.
- the cell aggregate contains pituitary hormone-producing cells.
- the ratio of the number of ACTH-positive (producing) cells to the total number of cells present in the cell aggregate (proportion of the number of ACTH-positive cells) may be 5% or more, preferably 10% or more.
- ACTH-positive cells co-express NeuroD1 and Tbx19. Therefore, the ratio of the number of NeuroD1-positive and/or Tbx19-positive cells to the total number of cells present in the cell aggregate may be equivalent to the ratio of the number of ACTH-positive cells.
- the ACTH secretion ability of the cell aggregates may be 200 to 1,000,000 pg/mL, and in one embodiment, 1,000 to 500,000 pg/mL, 5,000 to 300,000 pg/mL, and 10,000 to 100,000 pg/mL.
- the ACTH secretion ability is affected by the number of ACTH cells and culture conditions.
- the ACTH secretion ability in the present specification is expressed by the concentration of ACTH secreted into the medium from one cell aggregate under specific culture conditions.
- the specific culture conditions are (1) a medium that can be used for culturing the pituitary hormone-producing cells described above, preferably a serum-free medium containing KSR (e.g., IMDM, DMEM, EMEM, ⁇ MEM, GMEM , F-12 medium, DMEM/F12, IMDM/F12, medium for epithelial cells (e.g.
- CnT-Prime epithelial culture medium or mixed medium of these
- externally affecting ACTH production This means conditions under which no substance (eg, Notch signal inhibitor that increases ACTH production) is added, (3) medium volume is set to 0.18 to 20 mL, and (4) culture is performed for 3 to 4 days. After culturing under these conditions, the medium may be collected and the concentration of ACTH in the medium may be measured. A person skilled in the art can measure the concentration of ACTH using known techniques such as ELISA.
- the cell aggregate may contain pituitary hormone-producing cells other than ACTH-producing cells.
- pituitary hormone-producing cells include PRL-producing cells, FSH-producing cells, LH-producing cells, GH-producing cells, TSH-producing cells and the like.
- it contains two types of ACTH-producing cells and PRL-producing cells, and in another aspect, 1 or 2 selected from the group consisting of ACTH-producing cells, PRL-producing cells, and FSH-producing cells and LH-producing cells. cells (ie, containing 3 or 4 types of pituitary hormone-producing cells).
- Yet another embodiment may comprise 1 or 2 cells selected from the group consisting of ACTH-producing cells, PRL-producing cells, FSH-producing cells and LH-producing cells, and GH-producing cells and TSH-producing cells (i.e., 5 or 6 types of pituitary hormone-producing cells).
- the pituitary hormone-producing cells contained in the cell aggregates depend on the above-mentioned differentiation stage, that is, the timing of separating cells expressing EpCAM and the subsequent culture period.
- the presence of various pituitary hormone-producing cells can be confirmed by confirming the above-described hormone production state using ELISA, immunostaining, or the like. Therefore, those skilled in the art can adjust the separation timing and culture period in order to obtain the necessary cell aggregates containing pituitary hormone-producing cells.
- the cell aggregate may further contain pituitary stem cells.
- pituitary stem cells refer to undifferentiated multipotent stem cells and progenitor cells that exist in the pituitary gland and contribute to the regeneration of pituitary tissue and the supply of pituitary hormone-producing cells.
- the ratio of the number of pituitary stem cells to the total number of cells present in the cell aggregate may be 1% or more, preferably 3% or more, or 5% or more.
- Pituitary stem cells include, for example, Sox2, Sox9, E-Cadherin, Nestin, S100 ⁇ , GFR ⁇ 2, Prop1, CD133, ⁇ -Catenin, Klf4, Oct4, Pax6, coxsackievirus-adenovirus common receptor (CXADR), PRRX1/2, Ephrin -Co-express pituitary stem cell markers such as B2 and ACE. Therefore, the ratio of the number of pituitary stem cells present can be determined by measuring the ratio of the number of pituitary stem cell marker (e.g., CXADR)-positive cells to the total number of cells present in the cell aggregate.
- CXADR coxsackievirus-adenovirus common receptor
- the cell density of the cell aggregates may be 3,000-20,000 cells/mm 2 , preferably 5,000-10,000 cells/mm 2 , more preferably 6,000-9,000 cells/mm 2 .
- the cell density of the cell aggregates in the specification of the present application is expressed by the number of cells per unit area at a position within 200 ⁇ m from the cut surface of the cell aggregates, for example, the center.
- a person skilled in the art can measure the cell density of cell aggregates using known techniques. Specifically, a section obtained by cutting a cell aggregate is prepared, the number of cells is measured by a technique such as immunostaining using DAPI, an anti-E-cadherin antibody, or the like, and the number is divided by the area of the section.
- the long diameter (or circle equivalent diameter) of the cell aggregate may be, for example, 200 to 3,000 ⁇ m, preferably 300 to 2,000 ⁇ m, more preferably 400 to 1,500 ⁇ m.
- the method for measuring the major axis, minor axis, and height of the cell aggregate is not particularly limited, and may be measured, for example, from images captured under a microscope.
- cell aggregates during culture in a 96-well culture plate can be imaged with a 10x Keyence inverted microscope and measured from the captured image.
- the major axis means the longest line segment and its length among line segments connecting two end points of the cell aggregate in the captured image.
- the equivalent circle diameter means the diameter of a perfect circle corresponding to the area of a figure (circle or ellipse) obtained when projected onto a two-dimensional surface.
- the aggregates are spherical aggregates, and their major diameters and equivalent circle diameters are close to each other.
- the aggregate is a spherical aggregate.
- a "sphere-like cell aggregate” as used herein means a cell aggregate having a three-dimensional shape close to a sphere.
- a three-dimensional shape close to a sphere is a shape having a three-dimensional structure, and includes, for example, a spherical shape that exhibits a circular or elliptical shape when projected onto a two-dimensional surface.
- the aggregate is preferably a spherical aggregate close to a true sphere.
- a sphere-like aggregate close to a true sphere means a cell aggregate having a three-dimensional shape close to a true sphere.
- a three-dimensional shape close to a perfect sphere is defined as a plurality of circles obtained when projected onto a two-dimensional surface from multiple directions, all of which have the same length from the center to the outer circumference of the circle, or the longest line segment. and the shortest line segment is 10% or less, 5% or less, 3% or less, 2% or less, or 1% or less.
- EpCAM-positive cells and at least one E-cadherin-positive cells may adhere to each other to form an epithelial structure.
- “Surface adhesion” means that adjacent cells adhere to each other on the surface. More specifically, surface adhesion means that the ratio of the surface area of a cell that is adhered to the surface of another cell is, for example, 1% or more, preferably 3% or more, more preferably 5% or more, and still more preferably means 10% or more.
- the surface of a cell refers to the cell membrane surface. Cell surfaces can be observed by immunostaining for cell adhesion factors (eg, E-cadherin and EpCAM). Point adhesion can be mentioned as a state that is not surface adhesion. Point adhesion refers to point-to-cell adhesion.
- Epithelial structure means a structure characteristic of epithelial tissue, such as the apical surface or basement membrane. It can be confirmed by immunostaining using the apical surface and basement membrane markers described below.
- the epithelial tissue is polarized to form an "apical surface” and a “basement membrane”.
- basement membrane refers to a basement membrane in which there is a layer (basement membrane) on the basal side produced by epithelial cells of 50 to 100 nm containing a large amount of laminin and type IV collagen, which are markers of the basement membrane. say.
- the “apical surface” refers to the surface (superficial surface) formed on the side opposite to the “basement membrane”.
- apical surface is immunostained using antibodies against apical surface markers (e.g., atypical-PKC (hereinafter abbreviated as “aPKC”), E-cadherin, N-cadherin), which is well known to those skilled in the art. can be identified by the law, etc.
- aPKC atypical-PKC
- E-cadherin E-cadherin
- N-cadherin e.g., atypical-PKC (hereinafter abbreviated as “aPKC”), E-cadherin, N-cadherin), which is well known to those skilled in the art. can be identified by the law, etc.
- Epithelial tissue is a tissue formed by cells that cover the surface of the body surface, lumen (such as the digestive tract), and body cavity (such as the pericardial cavity) without gaps. Cells forming epithelial tissue are called epithelial cells. Epithelial cells have an apical-basal cell polarity. Epithelial cells can form a layer of cells by forming strong connections between epithelial cells through adherence junctions and/or tight junctions. Epithelial tissue is a tissue made up of one to ten and several layers of these cell layers.
- the cell aggregate has multiple island-like structures formed by surface adhesion of EpCAM-positive cells and/or E-cadherin-positive cells to each other.
- a sponge-like structure is formed by gathering a plurality of island-like structures.
- Islet-like structure means about 2 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 15, 20) of EpCAM-positive cells and/or E-cadherin-positive cells are surface-adhered to each other.
- the number of cells contained in each island-shaped structure may be different for each island-shaped structure.
- Surface adhesion means that adjacent cells adhere to each other at their surfaces. More specifically, surface adhesion means that the percentage of cells that adhere to each other on the surface is, for example, 1% or more, preferably 3% or more, more preferably 5% or more, and still more preferably 10% or more. Say.
- Cells present in the island-like structure may have a long axis of, for example, 2 to 50 ⁇ m, preferably 4 to 30 ⁇ m, and a short axis of, for example, 0.5 to 20 ⁇ m, preferably 1 to 10 ⁇ m.
- the island-shaped structures may contain pituitary hormone-producing cells.
- Specific examples include ACTH-positive cells, PRL-positive cells, FSH-positive cells, LH-positive cells, GH-positive cells, TSH-positive cells and the like.
- a "sponge-like structure” is a structure in which multiple island-like structures are gathered and voids exist between the island-like structures. It is not necessary for all island structures to have voids. Due to the presence of voids, nutrients and oxygen in the culture medium can reach the inside of the cell aggregates, so the ratio of necrotic cells is small even in the center of the cell aggregates.
- Island-like structure and “sponge-like structure” are not observed in the cell aggregates obtained before sorting by EpCAM, that is, by culturing pluripotent stem cells in suspension.
- Island-like structure and “sponge-like structure” are structures confirmed for the first time by reaggregation after sorting by EpCAM.
- the GH secretion ability of the cell aggregates may be 0.05-100 ng/mL. There may be.
- GH secretion ability is affected by the number of GH cells and culture conditions.
- GH secretion ability in the present specification is expressed by the concentration of GH secreted into the medium from one cell aggregate under specific culture conditions.
- the specific culture conditions are (1) a medium that can be used for culturing the pituitary hormone-producing cells described above, preferably a serum-free medium containing KSR (e.g., DMEM, MEM, GMEM, epithelial cell Using a medium (e.g. CnT-Prime epithelial culture medium), (2) without adding external substances that affect GH production (e.g. adrenocortical hormones that increase GH production (e.g.
- dexamethasone 3) Set the amount of medium to 0.18-20 mL, and (4) Cultivate for 3-4 days.
- the medium after culturing under these conditions may be collected and the concentration of GH in the medium may be measured.
- a person skilled in the art can measure the concentration of GH using known techniques such as ELISA.
- culturing in the presence of specific substances can increase the amount of secretion of specific pituitary hormone production.
- the GH secretion ability is improved by changing the condition (2) to culture in a medium containing adrenocortical hormones.
- adrenocortical hormones include artificially synthesized glucocorticoids such as dexamethasone, betamethasone, prednisolone, methylprednisolone and triamcinolone; and natural glucocorticoids such as hydrocortisone, cortisone acetate and fludrocortisone acetate.
- a person skilled in the art can appropriately set the concentration of adrenocortical hormones. mL.
- the GH secretion ability of cell aggregates containing pituitary hormone-producing cells after culturing in the presence of adrenocortical hormones is 0.1 to 10,000 ng/mL, 0.5 to 5,000 ng/mL, 5 to 1,000 ng/mL. mL, may be 20-500 ng/mL.
- the ACTH secretion ability is 10-500,000 pg/mL, preferably 100-100,000 pg/mL, more preferably 500-30,000 pg/mL, and still more preferably 1,000-10,000 pg/mL.
- cell aggregates containing pituitary hormone-producing cells after culture in the presence of adrenocortical hormones contain more pituitary hormone-producing cells than before initiation of differentiation induction.
- the ratio of the number of ACTH-positive (producing) cells to the total number of cells present in the cell aggregate may decrease.
- the proportion of ACTH-positive cells present is 2% or more, preferably 3% or more, and more preferably 5% or more.
- the present invention also provides a cell population (cell population of the present invention) containing 40% or more of the total number of cell aggregates of the present invention.
- the cell population of the present invention may contain the cell aggregates of the present invention generally at 40% or more, preferably 60% or more, more preferably 80% or more of the total number of cell aggregates.
- the ratio of the cell aggregates of the present invention to the total cell aggregates may vary to some extent depending on the cell line, differentiation induction method, and maturation culture.
- the cell population of the present invention may have the following characteristics. (1) the proportion of EpCAM-positive cells and E-cadherin-positive cells is 80% or more, (2) the abundance of neurons is 20% or less; and (3) the ACTH secretion ability of the cell aggregate is 200 to 1,000,000 pg/mL.
- One aspect of the present invention includes a pharmaceutical composition (a composition for transplantation, a tissue for transplantation, or a Transplant) containing the cell aggregate of the present invention or a portion thereof.
- a pharmaceutical composition preferably contains a pharmaceutically acceptable carrier in addition to the cell aggregate of the present invention or a portion thereof.
- a part of the cell aggregate is a part of the cell aggregate that can be used in the pharmaceutical composition, and can be obtained by excising a pituitary tissue having a size necessary for transplantation from the cell aggregate.
- a physiological aqueous solvent can be used as a pharmaceutically acceptable carrier.
- the pharmaceutical composition may contain preservatives, stabilizers, reducing agents, tonicity agents, etc., which are commonly used in medicines containing tissues or cells to be transplanted in transplantation medicine.
- the present invention can also provide therapeutic agents for diseases based on pituitary disorders (therapeutic agents of the present invention), which contain the cell aggregates of the present invention or a portion thereof, or the cell populations of the present invention.
- Therapeutic agents for diseases based on pituitary disorders include, for example, implants containing suspensions containing the cell populations of the present invention.
- Suspensions include, for example, liquids in which the cell population of the present invention is suspended in artificial tears or physiological saline.
- the suspension may contain pituitary hormone-producing cells isolated from the cell population of the present invention, and may contain factors that promote cell adhesion, such as extracellular matrix and hyaluronic acid.
- the pituitary disorder-based disease may be a pituitary disorder-based animal disease or a pituitary disorder-based non-human animal disease.
- diseases based on pituitary disorders include panhypopituitarism, pituitary dwarfism, hypoadrenocorticism, partial hypopituitarism, and isolated anterior pituitary hormone deficiency.
- pituitary function/hormone secretion deficiency after surgery such as pituitary adenoma, craniopharyngioma, etc.
- Example 1 Example of Forming Cell Aggregates Containing Hypothalamic Cells, Pituitary Progenitor Cells, and Pituitary Hormone-Producing Cells from Human ES Cells
- the entire process chart step 1: differentiation, step 2: intermediate purification, step 3: maturation culture) until the production of aggregates is shown.
- human ES cells were induced to differentiate into cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells, and the composition and structure of the cell aggregates on each day after induction of differentiation was examined.
- Human ES cells KhES-1 strain, obtained from Kyoto University) were cultured under feeder-free conditions according to the method described in Scientific Reports, 4, 3594 (2014).
- StemFit medium (AK03, Ajinomoto Co.) was used as a feeder-free medium, and Laminin511-E8 (Nippi Co.) was used as a feeder-free scaffold.
- Laminin511-E8 Nappi Co.
- As a specific maintenance culture operation first, subconfluent human ES cells (KhES-1 strain) were washed with PBS, and then dispersed into single cells using TrypLE Select (manufactured by Life Technologies). . Thereafter, the human ES cells dispersed into single cells were seeded on a plastic culture dish coated with Laminin511-E8, and feeder-free cultured in StemFit medium in the presence of Y27632 (ROCK inhibitor, 10 ⁇ M).
- Y27632 Y27632
- FIG. 2 shows a protocol for inducing differentiation of human ES cells into cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells.
- human ES cells KhES-1 strain
- SB431542 5 ⁇ M
- SAG 300 nM
- the prepared subconfluent human ES cells were treated with a cell dispersion using TrypLE Select (manufactured by Life Technologies), and dispersed into single cells by pipetting.
- the human ES cells dispersed in the above single cells were placed in a non-adherent 96-well culture plate (PrimeSurface 96V bottom plate, MS-9096V, manufactured by Sumitomo Bakelite Co., Ltd.) at 1.0 ⁇ 10 4 cells per well.
- the cells were suspended in 100 ⁇ L of serum-free medium and cultured in suspension at 37°C and 5% CO 2 .
- the serum-free medium (gfCDM+KSR) was a 1:1 mixture of F-12 medium and IMDM medium supplemented with 5% KSR, 450 ⁇ M 1-monothioglycerol, and 1xChemically defined lipid concentrate. Using.
- Y27632 final concentration 20 ⁇ M
- IWP-2 0.5 ⁇ M
- SB431542 1 ⁇ M
- SAG 100 nM
- 100 ⁇ L of a serum-free medium containing IWP-2, SB431542, BMP4 (0.5 nM) and SAG (700 nM) without Y27632 was added per well.
- half the medium was replaced with a serum-free medium containing IWP-2, SB431542, and SAG but without Y27632 and BMP4. .
- the partial pressure of oxygen during culture was set at 40%.
- 60 cell aggregates per dish were transferred to 10 cm suspension culture dishes, and cultured in a serum-free medium under 40% O 2 and 5% CO 2 conditions.
- Suspension culture was continued at Cells were cultured in a serum-free medium supplemented with 10% KSR from 29 days to 50 days after the initiation of differentiation induction, and using a serum-free medium supplemented with 20% KSR after 50 days after initiation of differentiation induction.
- the cell aggregates on days 29, 61, and 103 after initiation of differentiation induction were each fixed with 4% paraformaldehyde, and frozen sections were prepared.
- the pituitary progenitor markers Pitx1 anti-Pitx1 antibody, home-made (Non-Patent Documents 1 and 2), guinea pig) and Lhx3 (anti-Lhx3 antibody, home-made (Non-Patent Documents 1 and 2), rabbit)
- epithelial cell markers E-cadherin anti-E-cadherin antibody, TAKARA, rat
- EpCAM anti-EpCAM antibody, R&D, goat
- ventral hypothalamic marker Nkx2.1 anti-Nkx2.
- Example 2 Purification of an EpCAM-positive cell population from cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells, followed by long-term culture after purification to produce cell aggregates containing pituitary hormone-producing cells Examples It was found that the cell aggregates prepared by the differentiation induction method of Example 1 contained not only pituitary progenitor tissue and pituitary tissue, but also hypothalamic tissue and neural tissue. In order to prepare highly pure cell aggregates containing only pituitary tissue from these cell aggregates, purification using EpCAM and long-term culture were performed, and the composition and structure of the cell aggregates obtained after purification were investigated. .
- Cell sorting using an anti-EpCAM antibody was performed on the cell aggregates obtained by the same differentiation induction method as in Example 1, 62 days and 100 days after initiation of differentiation induction. Cell sorting was performed in three steps: (1) pretreatment, (2) dispersion of cell aggregates, and (3) isolation of EpCAM-positive cells.
- (1) Pretreatment with Y27632 In order to suppress cell death due to dispersion treatment, Y27632 (20 ⁇ M) was added to the medium the day before the work day to pretreat cell aggregates. For subsequent manipulations up to and including cell sorting, 20 ⁇ M Y27632 was added to all solutions to which cells were exposed.
- the composition of the collagenase solution is the above DMEM/F12 supplemented with 0.2% collagenase type I (manufactured by Wako) and 0.1% BSA (manufactured by Themofisher). After collagenase treatment, wash with PBS, add 10x TrypLE Select solution (manufactured by Themofisher) + 0.2mg/mL DNaseI (manufactured by Roche), perform enzyme treatment at 37°C for 10 minutes, and then pipette. Dispersed into single cells.
- FACS fluorescence-activated cell sorting
- EpCAM-positive cells were separated and collected.
- a cell sorter for FACS a Stream-In-Air type FACS Aria Fusion from BD was used. Purified EpCAM-positive cells were reaggregated in serum-free medium supplemented with 200 ⁇ L of 20% KSR, 20 ⁇ M Y27632 at 10 ⁇ 10 4 cells per well of a cell-nonadherent 96-well culture plate and incubated at 37°C. Suspension culture was performed under conditions of 40% O 2 and 5% CO 2 .
- a serum-free medium supplemented with 20% KSR without Y27632 was used, and half of the medium was changed once every 3 to 4 days for long-term culture (Fig. 4).
- Cell aggregates (day 100 sort + day 31) that were purified and long-term cultured for 31 days after reaggregation were fixed with 4% paraformaldehyde and frozen sections were prepared.
- pituitary progenitor marker Lhx3, epithelial cell markers EpCAM and E-cadherin pituitary hormone-producing cell markers adrenocorticotropic hormone (ACTH), prolactin (PRL) (anti-PRL antibody , Dako, rabbit), follicle stimulating hormone (FSH) (anti-FSH antibody, Dako, mouse), luteinizing hormone (LH) (anti-LH antibody, Dako, mouse), thyroid stimulating hormone (TSH) Immunostaining was performed using (anti-TSH antibody, Dako, mouse). Cell nuclei were stained with DAPI.
- ACTH adrenocorticotropic hormone
- PRL prolactin
- FSH follicle stimulating hormone
- LH luteinizing hormone
- TSH thyroid stimulating hormone
- Immunostaining was performed using (anti-TSH antibody, Dako, mouse). Cell nuclei were stained with DAPI.
- the cell aggregate obtained by long-term culture after EpCAM purification was a cell aggregate that formed an epithelial structure and contained at least one or more types of pituitary hormone-producing cells. Furthermore, the ACTH-positive cell ratio, cell density, and long diameter in the day62 sort + day41 cell aggregate and the day100 sort + day31 cell aggregate were quantified. To quantify the ratio of ACTH-positive cells, the number of ACTH-positive cells per aggregate was determined from the images taken with a confocal laser scanning microscope (manufactured by Olympus) with a 10x lens, where ACTH-positive cells were observed in each aggregate. And the number of DAPI-positive cells was analyzed and the ratio was calculated.
- the images captured above were used to analyze and calculate the number of DAPI-positive cells per aggregate and the surface area of the aggregate.
- an image captured with a 10-fold lens of an inverted microscope (manufactured by Keyence) was used for measurement (FIGS. 7C and 7D).
- the ACTH-positive cell rates were 11% and 18%, respectively (Fig. 7A)
- the densities were 7880 cells/mm2 and 7720 cells/ mm2 , respectively.
- mm 2 (FIG. 7B)
- the major diameter was 633 ⁇ m and 639 ⁇ m (FIG. 7E), respectively.
- Example 3 Production of cell aggregates containing ACTH and GH pituitary hormone-producing cells by adding dexamethasone during long-term culture after EpCAM purification It was found to contain mainly ACTH-producing cells. Therefore, we investigated whether it is possible to increase the number of GH-producing cells in cell aggregates by using dexamethasone as a steroid during culture after purification.
- EpCAM-positive cells were purified under the same conditions as in Example 2 using cell aggregates obtained under the same conditions as in Example 1 at 62 days and 100 days after initiation of differentiation induction, 10 ⁇ 10 4 cells per well of a cell-nonadherent 96-well culture plate were reaggregated in serum-free medium supplemented with 200 ⁇ L of 20% KSR, 20 ⁇ M Y27632, 37° C., 40% O 2 , 5%. Suspension culture was carried out under CO2 conditions. Three days after the start of suspension culture, half the medium was replaced with a serum-free medium containing no Y27632 and supplemented with dexamethasone (DX, manufactured by Aspen Japan, 400 ng/mL) and 20% KSR.
- DX dexamethasone
- Serum-free medium supplemented with DX (400 ng/mL) and 20% KSR was used from day 3 to day 24 after the start of suspension culture, and serum-free medium supplemented with 20% KSR was used from day 24 after the start of suspension culture. and cultured for a long time (Fig. 8).
- Cell aggregates (day 100 sort + day 31) that were purified and long-term cultured for 31 days after reaggregation were fixed with 4% paraformaldehyde and frozen sections were prepared.
- GH-positive pituitary hormone-producing cells were present in the day62 sort + day41 cell aggregates and the day100 sort + day31 cell aggregates even in culture conditions without the addition of DX (Fig. 9B, D). ), it was found that the number of GH-positive cells further increased under the culture conditions in which DX was added (FIGS. 9F and 9H). That is, it was shown that differentiation into GH-producing cells was induced by adding DX after purification and reaggregation.
- Example 4 Example of ACTH and GH secretion test of cell aggregates containing pituitary hormone-producing cells by long-term culture after EpCAM purification pituitary hormone-producing cells. Therefore, we investigated the effect of long-term culture after purification on the secretion of ACTH and GH. Using the cell aggregates obtained under the same conditions as in Example 1, 62 days and 100 days after the start of differentiation induction, purification under the same conditions as in Example 2 or Example 3, Long-term suspension culture carried out. Culture supernatants of EpCAM-positive and EpCAM-negative cell aggregates purified and reaggregated using cell aggregates on days 62 and 100 after initiation of differentiation induction were collected over time, and ACTH and GH were added. The amount of secretion was measured.
- the concentrations of ACTH and GH in the collected culture supernatant were measured by ELISA method used in clinical testing (testing commissioned to SRL Co., Ltd.). Based on the data of ACTH and GH concentrations (pg/mL, ng/mL) obtained, secretion amount per cell aggregate (pg/aggregate, ng/aggregate) was calculated and graphed.
- An ACTH stimulation test with CRH was performed using cell aggregates purified and reaggregated from the cell aggregates on day 62 after initiation of differentiation induction and subjected to suspension culture for 41 days. Twenty cell aggregates were transferred to a 10 cm suspension culture dish containing 10 mL of serum-free medium supplemented with 20% KSR, cultured at 37° C. and 40% O 2 for 24 hours, and the culture supernatant was collected. The cell aggregates were washed with a serum-free medium supplemented with 20% KSR, transferred to a 10 cm suspension culture dish containing 10 mL of a new serum-free medium supplemented with 20% KSR, and added with 5 ⁇ g/mL of CRH.
- Example 5 Formation of cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells from human ES cells
- a cell aggregate containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells was produced using a method not performed).
- Expression changes of pituitary markers (PITX1, LHX3, POMC (ACTH progenitor cells)) and hypothalamic markers (RAX, NKX2.1 (TTF1)) in order to confirm the degree of differentiation at each culture day after initiation of differentiation induction was examined by quantitative PCR. Specifically, it was carried out as follows. RNA was extracted from 6 cell aggregates per sample using the RNeasy Micro Kit (Qiagen).
- Quantitative PCR was performed using the StepOne Plus real-time PCR system (Applied Biosystems) or Biomark HD (Fluidigm).
- the probes for each gene are GAPDH (Hs02758991_g1), PITX1 (Hs00267528-m1), LHX3 (Hs01033412_m1), POMC (Hs01596743_m1), RAX (Hs00429459-m1), TTF1 (Hs00968940-m1) (Taq Fisher Scientific Probes; ) was used.
- the obtained data were normalized using GAPDH as an endogenous control, and quantitative results were obtained using the comparative Ct method ( ⁇ Ct method).
- Example 6 Purification of an EpCAM-positive cell population from cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells, followed by long-term culture after purification to produce cell aggregates containing pituitary hormone-producing cells Using the same differentiation induction method as in Example 1, cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells were produced. Cell aggregates without cell sorting were cultured until 131 days after initiation of differentiation induction. Some cell aggregates were subjected to cell sorting using an anti-EpCAM antibody 30 days, 60 days and 100 days after initiation of differentiation induction. Cell sorting was performed in the same manner as in Example 2.
- EpCAM-positive or EpCAM-negative cells were reaggregated in serum-free medium supplemented with 200 ⁇ L of 20% KSR, 20 ⁇ M Y27632 at 10 ⁇ 10 4 cells per well of a non-adherent 96-well culture plate. , 37° C., 40% O 2 , 5% CO 2 in a suspension culture. After 3 days from the start of suspension culture, serum-free medium without Y27632 and supplemented with 20% KSR was used, and half of the medium was changed once every 3 to 4 days, and cultured until 131 days after the start of differentiation induction. (Fig. 4). After that, gene expressions of POMC, NESTIN and SOX11 in the obtained cell aggregates were quantified using quantitative PCR.
- Example 7 Purification of an EpCAM-positive cell population from cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells, followed by long-term culture after purification to produce cell aggregates containing pituitary hormone-producing cells Using the same differentiation induction method as in Example 1, cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells were produced. Sixty days after initiation of differentiation induction, cell sorting was performed using an anti-EpCAM antibody, and then EpCAM-negative cells and EpCAM-positive cells were reaggregated. Cell sorting and reaggregation were performed as in Example 6.
- Example 2 Thereafter, the cells were cultured until the 103rd day or 107th day from the initiation of differentiation induction, and frozen sections were prepared in the same manner as in Example 2. Immunostaining was performed on these frozen sections using the antibody described in Example 2, and cell nuclei were stained with DAPI. These stained sections were observed using a confocal laser scanning microscope (manufactured by Olympus) to obtain immunostained images. As a result, staining images similar to those in Example 2 were obtained for reaggregates of EpCAM-positive cells.
- EpCAM-positive cell reaggregates contained not only pituitary hormone-producing cells but also CXADR-positive pituitary stem cells, and that CXADR-positive cells existed separately from ACTH-secreting cells.
- hypothalamic cells RAX-positive cells: FIGS. 14E, F, H
- non-target cells NESTIN-positive cells, SOX11 cells: FIGS. 14E, F, G, I, J
- FSCs folliculo-stellate cells
- FIGS. 15B, C dashed lines
- FSCs folliculo-stellate cells
- FIGS. 15B, C dashed lines
- the response of reaggregates of EpCAM-positive cells to hormones was examined.
- Cell sorting was performed using an anti-EpCAM antibody 60 days after initiation of differentiation induction, and then EpCAM-positive cells were reaggregated and cultured until 103 days after initiation of differentiation induction.
- an ACTH stimulation test was performed using CRH (manufactured by Nipro ES Pharma) or Dexamethasone (DX, manufactured by Aspen Japan).
- 20 cell aggregates were transferred to a 10 cm suspension culture dish containing 10 mL of serum-free medium supplemented with 20% KSR, and cultured at 37 °C and 40% O for 24 hours. Clear was collected. After washing the cell aggregates with serum-free medium supplemented with 20% KSR, they were transferred to a 10 cm suspension culture dish containing 10 mL of fresh serum-free medium supplemented with 20% KSR, and CRH 5 ⁇ g/mL or dexamethasone 500 ng/mL was added. added. A non-addition group was set as a control. After culturing for 24 hours under conditions of 37°C and 40% O 2 , the culture supernatant was collected.
- Example 8 Transplantation of reaggregates of EpCAM-positive cells into pituitary dysfunction mice to confirm efficacy Hypothalamus cells, pituitary progenitor cells and pituitary hormones were treated using the same differentiation induction method as in Example 1.
- Cell aggregates containing producer cells were produced. Sixty days after initiation of differentiation induction, cell sorting was performed using an anti-EpCAM antibody, and then EpCAM-positive cells were reaggregated. Cell sorting and reaggregation were performed as in Example 6. After that, the cells were cultured until 107 days after initiation of differentiation induction, and transplanted under the left renal capsule of mice with hypopituitarism (10 to 17 weeks old) from which the hypophysis had been surgically removed (implantation group).
- mice with hypopituitarism in which the pituitary gland was surgically excised were prepared by performing known joint surgery on SCID mice (7-9 weeks old, male). Twenty-four weeks after transplantation, the kidney was removed and various antibodies (human nuclei (mouse, 1:1000; Millipore), ACTH (mouse, 1:200; Fitzgerald), EpCAM (goat; 1:500; R&D Systems), CXADR ( rabbit; 1:100; Atlas antibodies)), immunostaining was carried out by a conventional method.
- mice were administered CRH (2 ⁇ g/kg, intraperitoneal injection) 4 weeks, 12 weeks or 24 weeks after transplantation, and blood was collected before CRH administration and 1 hour after CHR administration.
- Each blood ACTH concentration was measured using an ACTH ELISA kit (MD Bioproducts).
- the blood ACTH concentration in the transplanted group was significantly elevated compared to the sham group (Fig. 18A).
- a further increase in blood ACTH concentration was also observed upon CRH stimulation (Fig. 18A).
- An increase in blood ACTH concentration and a further increase in ACTH concentration due to CRH stimulation were observed until 24 weeks after transplantation (Fig. 18A).
- Dexamethasone stimulation was added to the transplanted group, and the effect on ACTH secretion ability was examined. Specifically, dexamethasone was administered (0.2 mg, intramuscularly) 6 weeks after transplantation, and blood was collected before administration of dexamethasone and 2 hours after administration of dexamethasone. After blood was collected 2 hours after administration of dexamethasone, CRH was further administered (2 ⁇ g/kg, intraperitoneal administration), and blood was collected 1 hour after administration of CRH. Blood ACTH concentration was measured in the same manner as above. As a result, it was found that in the group of mice administered with dexamethasone 6 weeks after transplantation, the blood ACTH level decreased significantly (Fig. 18B).
- mice were administered LPS (2.2 ⁇ g/kg, intraperitoneal injection) 4 weeks after transplantation, and blood was collected before LPS administration and 2 hours after LPS administration. Blood ACTH concentration was measured in the same manner as above.
- LPS 2.2 ⁇ g/kg, intraperitoneal injection
- Blood ACTH concentration was measured in the same manner as above.
- Fig. 18C The effect was increased by increasing the number of transplanted EpCAM-positive cell aggregates, and was dose-dependent (Fig. 18C). Therefore, it was suggested that the transplanted EpCAM-positive cells showed a response to infection stress.
- Example 9 Example of forming cell aggregates containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells from human iPS cells Differentiation induction method similar to Example 1 (cell sorting using anti-EpCAM antibody A cell aggregate containing hypothalamic cells, pituitary progenitor cells and pituitary hormone-producing cells was produced using a method not performed).
- the treatment period of SAG the group to which SAG was added from immediately after the start of differentiation induction to 30 days (see Fig. 2), and the group after 30 days from immediately after the start of differentiation induction (61 days, 103 days ) were also set up in two groups, one to which SAG was added, and the ACTH secretion ability was compared. As a result, it was found that the ACTH secretion ability was improved by stopping the SAG treatment 30 days after the initiation of differentiation induction (Fig. 19).
- Example 10 Production of Cell Aggregates Containing Different Ratios of ACTH and GH Pituitary Hormone-Producing Cells by Changing the Addition Period of Dexamethasone During Long-Term Culture After EpCAM Purification From the Results of Examples 3 and 4 , it was found that differentiation into GH-producing cells can be induced by using DX during the culture of cell aggregates after purification. Therefore, the effect of differentiating the cell aggregates into ACTH-producing cells and GH-producing cells by changing the DX addition period during culture was examined.
- Example 2 Using cell aggregates obtained under the same conditions as in Example 1 and 63 days after initiation of differentiation induction, purification was performed under the same conditions as in Example 2, and the resulting EpCAM-positive cells Reaggregate in serum-free medium supplemented with 200 ⁇ L of 20% KSR, 20 ⁇ M Y27632 at 10 ⁇ 10 4 cells per well of a 96-well culture plate, 37° C., 40% O 2 , 5% CO 2 . It was cultured in suspension under the conditions of Three days after the start of suspension culture, half the medium was replaced with a serum-free medium containing no Y27632 and supplemented with DX (400 ng/mL) and 20% KSR.
- DX 400 ng/mL
- the ACTH concentration in the collected culture supernatant was measured by the ELISA method used in clinical testing (contracted to SRL Co., Ltd.).
- the addition of GRF increased the amount of GH secretion to less than double (Fig. 22C), and the amount of GH secretion decreased by 20% by the addition of somatostatin (Fig. 22D).
- the cell aggregates obtained by DX treatment during long-term culture after purification and reaggregation were cells containing functional pituitary hormone-producing cells that possessed not only GH secretion ability but also responsiveness. It was found to be an aggregate.
- the method of the present invention involves differentiating pluripotent stem cells into hypothalamic cells, pituitary progenitor cells and cell aggregates containing pituitary hormone-producing cells, and using EpCAM as a marker to identify functional pituitary hormone-producing cells and/or their By efficiently separating progenitor cells and further differentiating the cells, it is possible to efficiently obtain cell aggregates containing pituitary hormone-producing cells.
- the isolated and purified pituitary hormone-producing cells and the like exhibit excellent pituitary hormone secretion ability by physiological stimulation of pituitary hormone secretion, the cells can be used for the treatment of diseases related to the pituitary gland. is.
- This application is based on Japanese Patent Application 2021-162253 (filing date: September 30, 2021) and Japanese Patent Application 2022-116715 (filing date: July 21, 2022). , the entire contents of which are hereby incorporated by reference.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[1]下垂体ホルモン産生細胞を含む細胞凝集体であって、
(1)該細胞凝集体におけるEpCAM及びE-cadherinの少なくとも1つが陽性の細胞の存在割合が80%以上であり、
(2)該細胞凝集体における神経細胞の存在割合が20%以下であり、
(3)該細胞凝集体におけるACTH陽性細胞の存在割合が5%以上であり、
(4)該細胞凝集体の細胞密度が3,000~20,000 cells/mm2であり、
(5)該細胞凝集体の長径が200~3,000 μmであり、
(6)該細胞凝集体の表面において、EpCAM及びE-cadherinの少なくとも1つが陽性の細胞が互いに面接着し、上皮構造を形成しており、かつ、
(7)該細胞凝集体が、スポンジ状構造を形成している、
ことを特徴とする、細胞凝集体。
[2]該細胞凝集体における下垂体幹細胞の存在割合が3%以上である、[1]に記載の細胞凝集体。
[3]該細胞凝集体のACTH分泌能が200~1,000,000 pg/mLである、[1]に記載の細胞凝集体。
[4]該細胞凝集体のGH分泌能が0.05~100 ng/mLである、[1]に記載の細胞凝集体。
[5][1]~[4]のいずれか1つに記載の細胞凝集体を全細胞凝集体数の40%以上含む、細胞集団。
[6][1]~[4]のいずれか1つに記載の細胞凝集体を含む、下垂体の障害に基づく疾患の治療薬。
[7]以下の工程を含む、下垂体ホルモン産生細胞を含む細胞凝集体の製造方法:
(1)多能性幹細胞由来の、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む、分散された細胞集団から、EpCAMを発現する細胞を分離する工程、及び
(2)分離されたEpCAM発現細胞を、下垂体前駆細胞を下垂体ホルモン産生細胞へ成熟し得る条件下で14日以上浮遊培養する工程。
[8]工程(1)の細胞集団が、下記工程(A)及び(B)により得られる、[7]に記載の製造方法:
(A)視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体に分化誘導可能な条件下において、多能性幹細胞またはその細胞凝集体を培養する工程、及び、
(B)(A)で得られる視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を細胞集団に分散させる工程。
[9]工程(A)が、以下の工程を含む、[8]に記載の製造方法。
(1’)多能性幹細胞をWntシグナル伝達経路阻害物質の存在下で培養し、細胞凝集体を形成させる第一工程。
(2)第一工程で得られた細胞凝集体を、BMPシグナル伝達経路作用物質及びShhシグナル伝達経路作用物質の存在下に培養し、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を得る第二工程。
[10]工程(A)が、以下の工程を含む、[8]に記載の製造方法。
(a)多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はShhシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程、
(1’)a工程で得られた多能性幹細胞をWntシグナル伝達経路阻害物質の存在下で浮遊培養し、細胞凝集体を形成させる第一工程、
(2)第一工程で得られた細胞凝集体を、BMPシグナル伝達経路作用物質およびShhシグナル伝達経路作用物質の存在下で浮遊培養し、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を得る第二工程。
[11]工程(A)が、以下の工程を含む、[8]に記載の製造方法。
(a)多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はShhシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程。
(1)a工程で得られた多能性幹細胞をJNKシグナル伝達経路阻害物質およびWntシグナル伝達経路阻害物質の存在下で浮遊培養し、細胞凝集体を形成させる第一工程。
(2)第一工程で得られた細胞凝集体を、BMPシグナル伝達経路作用物質およびShhシグナル伝達経路作用物質の存在下で浮遊培養し、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を得る第二工程。
[12]第一工程における浮遊培養がさらにShhシグナル伝達経路作用物質の存在下であって、第一工程および第二工程におけるShhシグナル伝達経路作用物質の存在下における培養期間が、30日である、[11]に記載の製造方法。
[13]第二工程で得られた細胞凝集体を、Shhシグナル伝達経路作用物質の非存在下でさらに浮遊培養する、[9]~[12]のいずれか1つに記載の製造方法。
[14]工程(A)の培養期間が、ACTHを分泌する下垂体ホルモン産生細胞を含み、かつ、GH又はTSHを分泌する下垂体ホルモン産生細胞を含まない細胞凝集体が得られる期間である、[8]~[13]のいずれか1つに記載の製造方法。
[15]工程(A)の培養期間が、30日以上かつ100日以下である、[8]~[14]のいずれか1つに記載の製造方法。
[16]下垂体ホルモン産生細胞を含む細胞凝集体が以下の特徴を含む、[7]~[15]のいずれか1つに記載の製造方法:
(1)該細胞凝集体におけるEpCAM及びE-cadherinの少なくとも1つが陽性の細胞の存在割合が80%以上であり、
(2)該細胞凝集体における神経細胞の存在割合が20%以下であり、
(3)該細胞凝集体におけるACTH陽性細胞の存在割合が5%以上であり、
(4)該細胞凝集体の細胞密度が3,000~20,000 cells/mm2であり、
(5)該細胞凝集体の長径が200~3,000 μmであり、
(6)該細胞凝集体の表面において、EpCAM及びE-cadherinの少なくとも1つが陽性の細胞が互いに面接着し、上皮構造を形成しており、かつ、
(7)該細胞凝集体が、スポンジ状構造を形成している。
[17]該細胞凝集体における下垂体幹細胞の存在割合が3%以上である、[16]に記載の製造方法。
[18]該細胞凝集体のACTH分泌能が200~1,000,000 pg/mLである、[16]に記載の製造方法。
[19]該細胞凝集体のGH分泌能が0.05~100 ng/mLである、[16]に記載の製造方法。
本明細書において、用語の定義は下記のとおりである。「幹細胞」とは、分化能及び増殖能(特に自己複製能)を有する未分化な細胞を意味する。幹細胞には、分化能力に応じて、多能性幹細胞(pluripotent stem cell)、複能性幹細胞(multipotent stem cell)、単能性幹細胞(unipotent stem cell)等が含まれる。「多能性幹細胞」とは、インビトロにおいて培養することが可能で、かつ、生体を構成する全ての細胞に分化し得る能力(分化多能性:pluripotency)を有する幹細胞をいう。全ての細胞とは、外胚葉、中胚葉及び内胚葉の三胚葉由来の細胞である。「複能性幹細胞」とは、全ての種類ではないが、複数種の組織や細胞へ分化し得る能力を有する幹細胞を意味する。「単能性幹細胞」とは、特定の組織や細胞へ分化し得る能力を有する幹細胞を意味する。
(1)多能性幹細胞由来の、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む、分散された細胞集団から、EpCAMを発現する細胞を分離する工程、及び
(2)分離されたEpCAM発現細胞を、下垂体前駆細胞を下垂体ホルモン分泌細胞へ成熟し得る条件下で14日以上浮遊培養する工程。
(A)視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体に分化誘導可能な条件下において、多能性幹細胞またはその細胞凝集体を培養する工程。
(B)(A)で得られる視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を細胞集団に分散させる工程。
工程(A)において得られる、多能性幹細胞由来の、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体の一態様として、視床下部組織(Nkx2.1発現細胞を含んでいてもよい)及び前記下垂体組織を含む細胞凝集体(分化開始30日~60日頃の細胞凝集体)が挙げられる。
工程(A)において得られる、多能性幹細胞由来の、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体の一態様として、視床下部組織(Nkx2.1発現細胞を含んでいてもよい)及び中期下垂体組織を含む細胞凝集体(分化開始60日~100日頃の細胞凝集体)が挙げられる。
(1’)多能性幹細胞をWntシグナル伝達経路阻害物質の存在下で培養し、細胞集団を形成させる第一工程、
(2)第一工程で得られた細胞集団を、BMPシグナル伝達経路作用物質及びソニック・ヘッジホッグ(Shh)シグナル伝達経路作用物質の存在下に培養し、下垂体組織を含む細胞集団を得る第二工程。
好ましくは、第一工程は細胞の凝集体を形成させる工程であり、第二工程に付す第一工程で得られた細胞集団は細胞の凝集体であり得る。
工程(1’)において、好ましくは、Wntシグナル伝達経路阻害物質にJNKシグナル伝達経路阻害物質を併用する。
工程(2)で得られる下垂体組織を含む細胞集団は、培養時間の長さによって、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体になりうる。
(a)多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はShhシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程、
(1’)a工程で得られた多能性幹細胞をWntシグナル伝達経路阻害物質の存在下で培養(好ましくは浮遊培養)し、細胞集団を形成させる第一工程、
(2)第一工程で得られた細胞集団を、BMPシグナル伝達経路作用物質とShhシグナル伝達経路作用物質の存在下で培養(好ましくは浮遊培養)し、下垂体組織を含有する細胞集団を得る第二工程。
好ましくは、第一工程は細胞の凝集体を形成させる工程であり、第二工程に付す第一工程で得られた細胞集団は細胞の凝集体であり得る。
工程(1’)において、好ましくは、Wntシグナル伝達経路阻害物質にJNKシグナル伝達経路阻害物質を併用する。
工程(2)で得られる下垂体組織を含む細胞集団は、培養時間の長さによって、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体であり得る。
(a)多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はShhシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程、
(1)a工程で得られた多能性幹細胞をJNKシグナル伝達経路阻害物質およびWntシグナル伝達経路阻害物質の存在下で培養(好ましくは浮遊培養)し、細胞集団を形成させる第一工程、
(2)第一工程で得られた細胞集団を、BMPシグナル伝達経路作用物質とShhシグナル伝達経路作用物質の存在下で培養(好ましくは浮遊培養)し、下垂体組織を含有する細胞集団を得る第二工程。
好ましくは、第一工程は細胞の凝集体を形成させる工程であり、第二工程に付す第一工程で得られた細胞集団は細胞の凝集体であり得る。
工程(2)で得られる下垂体組織を含む細胞集団は、培養時間の長さによって、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体であり得る。
(3)第二工程で得られた細胞集団を、Shhシグナル伝達経路作用物質の非存在下で培養(好ましくは浮遊培養)し、下垂体組織を含む細胞集団を得る第三工程。
多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はShhシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程について説明する。
工程(a)において、多能性幹細胞をTGFβファミリーシグナル伝達経路阻害物質及び/又はShhシグナル伝達経路作用物質で処理してから、第一工程において培養(好ましくは浮遊培養)に付すことにより、多能性幹細胞の状態が変わり、非神経上皮組織の形成効率が改善し、得られる細胞集団(凝集体)の質が向上し、分化しやすく、細胞死が生じにくく、下垂体細胞の製造効率が向上する。
本発明におけるフィーダー細胞非存在下(フィーダーフリー)とは、フィーダー細胞を実質的に含まない(例えば、全細胞数に対するフィーダー細胞数の割合が3%以下)条件を意味する。
工程(a)において用いられる培地は、血清培地であっても無血清培地であってもよい。化学的に未決定な成分の混入を回避する観点から、工程(a)において用いられる培地は、好ましくは無血清培地である。培地は、血清代替物を含んでいてもよい。
工程(1’)では、Wntシグナル伝達経路阻害物質の存在下で多能性幹細胞を培養し、細胞集団を得る。
JNKはMAPKファミリーに属するキナーゼであり、各種の環境ストレス、炎症性サイトカイン、成長因子、GPCRアゴニストによる刺激の細胞内シグナル伝達に関与する。
培地中のShhシグナル伝達経路作用物質の濃度は、上述の効果を達成可能な範囲で用いる物質に応じて適宜設定することが可能である。第一工程においてShhシグナル伝達経路作用物質としてSAGを用いる場合は、通常、約1nM~約3μM、好ましくは約10nM~約2μM、より好ましくは約30nM~約1μM、更に好ましくは約50nM~約500nMの濃度で使用される。
工程(2)は、BMPシグナル伝達経路作用物質及びShhシグナル伝達経路作用物質の存在下で、第一工程で得られた細胞集団を培養する。第一工程で細胞を浮遊培養している場合は、工程(2)でも引き続き形成された細胞凝集体を浮遊培養すればよい。第一工程で細胞を接着培養している場合は、工程(2)でも引き続き細胞を接着培養すればよい。第一工程で細胞を浮遊培養した後、工程(2)で接着培養してもよい。
培地中のShhシグナル伝達経路作用物質の濃度は、上述の効果を達成可能な範囲で用いる物質に応じて適宜設定することが可能である。工程(2)においてShhシグナル伝達経路作用物質としてSAGを用いる場合は、通常、約1nM~約5μM、好ましくは約10nM~約4.5μM、より好ましくは約50nM~約4μM、更に好ましくは約100nM~約3μMの濃度で使用される。
工程(2)の後にさらに以下の工程(b)が含まれてもよい。工程(b)は、BMPシグナル伝達経路阻害物質の添加条件下で、工程(2)で得られた細胞集団を培養する。工程(2)で細胞を浮遊培養している場合は、工程(b)でも引き続き形成された細胞凝集体を浮遊培養すればよい。工程(2)で細胞を接着培養している場合は、工程(b)でも引き続き細胞を接着培養すればよい。
第三工程は、Shhシグナル伝達経路作用物質の非添加条件下で、工程(2)又は工程(b)で培養した細胞集団を培養する。第二工程で得られた細胞集団をShh伝達経路作用物質の非存在下で培養し、下垂体組織を含む細胞集団を得る第三工程を工程(3)、工程(b)で得られた細胞集団をShhシグナル伝達経路作用物質の非存在下で培養し、下垂体組織を含む細胞集団を得る第三工程を工程(3’)とする。工程(2)又は工程(b)で細胞を浮遊培養している場合は、第三工程でも引き続き形成された細胞凝集体を浮遊培養すればよい。工程(2)又は工程(b)で細胞を接着培養している場合は、第三工程でも引き続き細胞を接着培養すればよい。工程(2)又は工程(b)で細胞を浮遊培養した後、第三工程で接着培養してもよい。
当該前処理を行うための培地は、工程(A)の培養工程において用いる培地を用いることができる。なお、上記培地中に既に所望する濃度でROCK阻害剤が添加されている場合は、当該前処理工程を行う必要はない。
下垂体前駆細胞を下垂体ホルモン産生細胞へ成熟し得る条件下で浮遊培養する期間としては、通常、14日以上、好ましくは30日以上が挙げられる。
以下の工程:
(1)多能性幹細胞由来の、下垂体ホルモン産生細胞を1種類以上4種類以下含む分散された細胞集団(例:ACTHを分泌する下垂体ホルモン産生細胞を含み、かつ、GH又はTSHを分泌する下垂体ホルモン産生細胞を含まない細胞集団)から、EpCAMを発現する細胞を分離する工程、及び
(2)分離されたEpCAM発現細胞を、下垂体前駆細胞を下垂体ホルモン産生細胞へ成熟し得る条件下で14日以上浮遊培養する工程、
を含む、下垂体ホルモン産生細胞を含む細胞凝集体の製造方法。
以下の工程:
(1)多能性幹細胞由来の、下垂体前期組織又は下垂体中期組織を含む細胞凝集体を分散して得られる細胞集団から、EpCAMを発現する細胞を分離する工程、及び
(2)分離されたEpCAM発現細胞を、下垂体前駆細胞を下垂体ホルモン産生細胞へ成熟し得る条件下で14日以上浮遊培養する工程、
を含む、下垂体ホルモン産生細胞を含む細胞凝集体の製造方法。
以下の工程:
(1)多能性幹細胞由来の、下垂体ホルモン産生細胞を1種類以上4種類以下含む細胞凝集体を分散して得られる細胞集団から、EpCAMを発現する細胞を分離する工程、及び
(2)分離されたEpCAM発現細胞を、下垂体前駆細胞を下垂体ホルモン産生細胞へ成熟し得る条件下で14日以上浮遊培養する工程、
を含む、下垂体ホルモン産生細胞を含む細胞凝集体の製造方法。
以下の工程:
(1)多能性幹細胞由来の、下垂体ホルモン産生細胞を1種類以上4種類以下含み、かつ、視床下部組織においてNkx2.1発現細胞を含む細胞凝集体を分散して得られる細胞集団から、EpCAMを発現する細胞を分離する工程、及び
(2)分離されたEpCAM発現細胞を、下垂体前駆細胞を下垂体ホルモン産生細胞へ成熟し得る条件下で14日以上浮遊培養する工程、
を含む、下垂体ホルモン産生細胞を含む細胞凝集体の製造方法。
本発明の方法によって得られる下垂体ホルモン産生細胞を含む細胞凝集体(本発明の細胞凝集体)は、以下の特徴を有する。
(1)該細胞凝集体におけるEpCAM陽性細胞及びE-cadherinの少なくとも1つが陽性の細胞の存在割合が80%以上である。
(2)該細胞凝集体における神経細胞の存在割合が20%以下である。
(3)該細胞凝集体におけるACTH陽性細胞の存在割合が5%以上である。
(4)該細胞凝集体の細胞密度が3,000~20,000 cells/mm2である。
(5)該細胞凝集体の長径が200~3,000 μmである。
(6)該細胞凝集体の表面において、EpCAM陽性細胞及びE-cadherinの少なくとも1つが陽性の細胞が互いに面接着し、上皮構造を形成している。
(7)該細胞凝集体が、スポンジ状構造を形成している。
(1)EpCAM陽性細胞及びE-cadherin陽性細胞の存在割合が80%以上であり、
(2)神経細胞の存在割合が20%以下であり、かつ
(3)該細胞凝集体のACTH分泌能が200~1,000,000 pg/mLである。
本発明の一態様として、本発明の細胞凝集体又はその一部を含む医薬組成物(移植用組成物、移植用組織またはTransplant)が挙げられる。医薬組成物は好ましくは、本発明の細胞凝集体又はその一部の他に、さらに医薬として許容される担体を含む。細胞凝集体の一部とは、医薬組成物に利用できる細胞凝集体の一部であり、細胞凝集体から、移植に必要な大きさの下垂体組織を切り出すことによって得ることができる。
下垂体の障害に基づく疾患の治療薬としては、例えば本発明の細胞集団を含む懸濁液を含む移植片が挙げられる。
懸濁液としては、例えば本発明の細胞集団を人工涙液または生理食塩水に懸濁した液が挙げられる。懸濁液は、本発明の細胞集団から単離された下垂体ホルモン産生細胞を含んでいてもよく、細胞の接着を促進する因子、例えば細胞外基質やヒアルロン酸等を含んでいてもよい。
前記下垂体の障害に基づく疾患は、下垂体の障害に基づく動物の疾患であってよく、下垂体の障害に基づく非ヒト動物の疾患であってよい。下垂体の障害に基づく疾患としては、具体的には、汎下垂体機能低下症、下垂体性小人症、副腎皮質機能低下症、部分的下垂体機能低下症、下垂体前葉ホルモン単独欠損症、下垂体腺腫等の手術後の下垂体機能・ホルモン分泌不全、頭蓋咽頭腫などが挙げられる。
図1に、ヒトES/iPS細胞から下垂体ホルモン産生細胞を含む細胞凝集体を製造するまでの、全体の工程図(工程1 分化、工程2 中間精製、工程3 成熟培養)を示す。
以下では、ヒトES細胞から視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体に分化誘導し、分化誘導後の各日数における細胞凝集体の組成及び構造に関して検討した。
ヒトES細胞(KhES-1株、京都大学より入手)を、Scientific Reports, 4, 3594 (2014)に記載の方法に準じてフィーダーフリー条件で培養した。フィーダーフリー培地としてはStemFit培地(AK03、味の素社製)、フィーダーフリー足場にはLaminin511-E8(ニッピ社製)を用いた。
具体的な維持培養操作としては、まずサブコンフレントになったヒトES細胞(KhES-1株)を、PBSにて洗浄後、TrypLE Select(Life Technologies社製)を用いて単一細胞へ分散した。その後、前記単一細胞へ分散されたヒトES細胞を、Laminin511-E8にてコートしたプラスチック培養ディッシュに播種し、Y27632(ROCK阻害物質、10μM)存在下、StemFit培地にてフィーダーフリー培養した。前記プラスチック培養ディッシュとして、6ウェルプレート(イワキ社製、細胞培養用、培養面積9.4cm2)を用いた場合、前記単一細胞へ分散されたヒトES細胞の播種細胞数は2.4×104とした。播種した1日後に、Y27632を含まないStemFit培地に全量培地交換した。以降、1日~2日に一回Y27632を含まないStemFit培地にて全量培地交換した。その後、播種した7日後にサブコンフレント(培養面積の6割が細胞に覆われる程度)になるまで培養した。
ヒトES細胞から視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体へ分化誘導するためのプロトコルを図2に示す。分化誘導操作としては、ヒトES細胞(KhES-1株)を、StemFit培地を用いて、播種した6日後にStemFit培地の培地交換と同時にSB431542(5μM)とSAG(300nM)を添加して24時間培養した。調整したサブコンフレントのヒトES細胞を、TrypLE Select(Life Technologies社製)を用いて細胞分散液処理し、さらにピペッティング操作により単一細胞に分散した。その後、上記単一細胞に分散されたヒトES細胞を細胞非接着性の96穴培養プレート(PrimeSurface 96V底プレート、MS-9096V、住友ベークライト社製)の1ウェルあたり1.0×104細胞になるように100μLの無血清培地に浮遊させ、37℃、5%CO2の条件下で浮遊培養した。その際の無血清培地(gfCDM+KSR)には、F-12培地とIMDM培地の1:1混合液に5%KSR、450μM 1-モノチオグリセロール、1xChemically defined lipid concentrateを添加した無血清培地を用いた。浮遊培養開始時(分化誘導開始後0日目)に、前記無血清培地にY27632(終濃度20μM)、IWP-2(0.5μM)、SB431542(1μM)、SAG(100nM)を添加した。
分化誘導開始後2日目にY27632を含まず、IWP-2、SB431542、BMP4(0.5nM)、SAG(700nM)を含む無血清培地を1ウェルあたり100μL加えた。その後、分化誘導開始後6、9、12、15、19、22、26日目にY27632とBMP4を含まず、IWP-2、SB431542とSAGを含む無血清培地を用いて半量培地交換を行った。19日目以降は、培養時の酸素分圧を40%とした。
分化誘導開始後29日目に細胞凝集体を10cm浮遊培養用ディッシュへとディッシュ1枚あたり60個の細胞凝集体を移し、無血清培地を用いて40%O2、5%CO2の条件下で浮遊培養を継続した。分化誘導開始後29日目から50日目は10%KSRを添加した無血清培地を、分化誘導開始後50日目以降は20%KSRを添加した無血清培地用いて、培養した。
前記、分化誘導開始後29、61、103日目の細胞凝集体を、それぞれ4%パラホルムアルデヒドで固定し、凍結切片を作製した。これらの凍結切片に関し、下垂体の前駆マーカーであるPitx1(抗Pitx1抗体、自家製(非特許文献1および2)、ギニアピッグ)およびLhx3(抗Lhx3抗体、自家製(非特許文献1および2)、ウサギ)、上皮細胞マーカーであるE-cadherin(抗E-cadherin抗体、TAKARA社製、ラット)およびEpCAM(抗EpCAM抗体、R&D社製、ヤギ)、腹側視床下部マーカーであるNkx2.1(抗Nkx2.1抗体、progen社製、マウス)、下垂体ホルモン産生細胞マーカーである副腎皮質刺激ホルモン(ACTH)(抗ACTH抗体、Fitzgerald社製、マウス)、神経系細胞マーカーであるNestin(抗Nestin抗体、R&D社製、マウス)を用いて免疫染色を行った。DAPIで細胞核を染色した。これらの染色された切片を、共焦点レーザー走査型顕微鏡(オリンパス社製)を用いて観察し、免疫染色像を取得した。その結果、上記分化誘導法で誘導された分化誘導開始後29日目の細胞凝集体の内側にNkx2.1陽性の腹側視床下部組織が存在し(図3F)、外側にEpCAM、E-cadherin陽性の肥厚した上皮組織が形成されていた(図3B、D)。さらに、上皮組織の一部はPitx1、Lhx3陽性であり、下垂体前駆組織が形成されていることが分かった(図3C、E)。
さらに、分化誘導開始後61日目、103日目の細胞凝集体には、E-cadherin、EpCAM陽性の上皮組織(図3J、K、P、Q)の一部にACTH陽性の下垂体ホルモン産生細胞が存在していた(図3I、O)。また細胞凝集体の内側にはNestin陽性の神経組織が形成されていることが分かった(図3L)。
実施例1の分化誘導法で作製した細胞凝集体は、下垂体前駆組織および下垂体組織だけでなく、視床下部組織および神経組織を含むことが分かった。この細胞凝集体から、下垂体組織だけを含む高純度な細胞凝集体を作製するため、EpCAMを用いた精製及び長期培養を実施し、精製後に得られた細胞凝集体の組成及び構造に関して検討した。
実施例1と同様の分化誘導法で得られた、分化誘導開始後62日目、100日目の細胞凝集体で、抗EpCAM抗体を用いたセルソーティングを実施した。セルソーティングとしては、(1)前処理、(2) 細胞凝集体の分散、(3)EpCAM陽性細胞の分離の3つの工程にわけて実施した。
(1)Y27632による前処理
分散処理による細胞死を抑制するために、作業日の前日にY27632(20μM)を培地に添加し、細胞凝集体を前処理した。セルソーティング前までの以降の操作では、細胞が曝されるすべての溶液に20μM Y27632を添加した。
(2)細胞凝集体の分散
酵素処理による分散を促進するために、細胞凝集体にメスで細断または切込みを入れた。次に細胞凝集体を、PBSにて洗浄後、神経細胞分散キットの分散液(Wako社製)を加えて、37℃で30分酵素処理を行い、さらにピペッティング操作により細胞凝集体をほぐした。反応終了後、DMEM/F12(Wako社製)にて洗浄し、コラゲナーゼ溶液を加えて、37℃で30分旋回振盪(140~150 rpm)した。コラゲナーゼ溶液の組成は、上記のDMEM/F12に0.2%コラゲナーゼtype I(Wako社製)および0.1% BSA(Themofisher社製)を添加したものである。コラゲナーゼ処理終了後、PBSにて洗浄し、10×TrypLE Select溶液(Themofisher社製)+0.2mg/mL DNaseI(Roche社製)を加えて、37℃で10分酵素処理後、さらにピペッティング操作により単一細胞に分散した。20%KSRを添加した無血清培地にて懸濁・中和し、遠心後に10 μg/mL DnaseI、20%KSRを添加した無血清培地で再懸濁した単一細胞を、70μmセルストレイナーに通して凝集塊を取り除いた。
(3)FACSによるEpCAM陽性細胞の分離
上記で得られた単一細胞を、遠心後に1mM EDTA、1% FBSを添加したDMEM/F-12溶液に懸濁させた。PE標識抗EpCAM抗体(Miltenyi社製)を添加し、4℃で10分インキュベートし、蛍光活性化セルソーティング(FACS)を行い、EpCAM陽性細胞を分離・回収した。FACSのためのセルソーターとして、Stream-In-Air方式の機種であるBD社のFACS Aria Fusionを用いた。
精製したEpCAM陽性細胞を、細胞非接着性96ウェル培養プレートの1ウェルあたり10×104細胞になるように200μLの20%KSR、20μM Y27632を添加した無血清培地で再凝集させ、37℃、40%O2、5%CO2の条件下で浮遊培養した。浮遊培養開始後3日目以降は、Y27632を含まず、20%KSRを添加した無血清培地を用いて、3日~4日に一度の半量交換を行い、長期培養した(図4)。
分化誘導開始後62日目の細胞凝集体を用いて精製し、再凝集後41日間長期培養させた細胞凝集体(day62 sort + day41)および分化誘導開始後100日目の細胞凝集体を用いて精製し、再凝集後31日間長期培養させた細胞凝集体(day100 sort + day31)を、それぞれ4%パラホルムアルデヒドで固定し、凍結切片を作製した。これらの凍結切片に関し、下垂体の前駆マーカーであるLhx3、上皮細胞マーカーであるEpCAMおよびE-cadherin、下垂体ホルモン産生細胞マーカーである副腎皮質刺激ホルモン(ACTH)、プロラクチン(PRL)(抗PRL抗体、Dako社製、ウサギ)、卵胞刺激ホルモン(FSH)(抗FSH抗体、Dako社製、マウス)、黄体化ホルモン(LH)(抗LH抗体、Dako社製、マウス)、甲状腺刺激ホルモン(TSH)(抗TSH抗体、Dako社製、マウス)を用いて免疫染色を行った。DAPIで細胞核を染色した。これらの染色された切片を、共焦点レーザー走査型顕微鏡(オリンパス社製)を用いて観察し、免疫染色像を取得した。その結果、day62 sort + day41の細胞凝集体では、EpCAM、E-cadherin陽性細胞が互いに面接着し、凝集体の全面に上皮構造が形成されていることが分かった(図5A、C、D、F、H、I)。さらに、細胞凝集体内にACTH陽性および/またはLhx3陽性の下垂体ホルモン産生細胞又は下垂体前駆細胞が多数存在していた(図5B、E、G、J)。加えて、PRL、FSH陽性細胞が存在していることが分かった(図5L、N)。
また、day100 sort + day31の細胞凝集体においても、上記同様EpCAM、E-cadherin陽性細胞が互いに面接着し、凝集体の全面に上皮構造が形成されていることが分かった(図6A、C、D、E、G、H)。さらに、細胞凝集体内にACTH陽性の下垂体ホルモン産生細胞が多数存在していた(図6B、F)。加えて、PRL、FSH、LH、TSH陽性細胞が存在していることが分かった(図6J、L、N、P)。すなわち、EpCAM精製後の長期培養によって得られた細胞凝集体は、上皮構造を形成し、少なくとも1種類以上の下垂体ホルモン産生細胞を含む細胞凝集体であることが分かった。
さらに、day62 sort + day41の細胞凝集体およびday100 sort + day31の細胞凝集体におけるACTH陽性細胞率、細胞密度および長径を定量した。ACTH陽性細胞率の定量には、各凝集体につきACTH陽性細胞が観察される箇所を共焦点レーザー走査型顕微鏡(オリンパス社製)10倍レンズで撮像した画像から、凝集体あたりのACTH陽性細胞数およびDAPI陽性細胞数を解析し、割合を算出した。細胞密度の定量には、上記で撮像した画像を用いて、凝集体あたりのDAPI陽性細胞数および凝集体の表面積を解析し、算出した。長径の定量には、倒立顕微鏡(Keyence社製)10倍レンズで撮像した画像を用いて、計測した(図7C、D)。
その結果、day62 sort + day41の細胞凝集体およびday100 sort + day31の細胞凝集体において、ACTH陽性細胞率はそれぞれ11%、18%(図7A)、密度はそれぞれ7880 cells/mm2、7720 cells/mm2(図7B)、長径はそれぞれ633 μm、639 μm(図7E)であった。
実施例2の結果から、精製後の細胞凝集体は主にACTH産生細胞を含んでいることが分かった。そこで、精製後の培養時に、ステロイドとしてDexamethasoneを用いることで、細胞凝集体におけるGH産生細胞を増やすことが可能か、検討した。
実施例1と同様の条件で得られた、分化誘導開始後62日目、100日目の細胞凝集体を用いて、実施例2と同様の条件で精製し、得られたEpCAM陽性細胞を、細胞非接着性96ウェル培養プレートの1ウェルあたり10×104細胞になるように200μLの20%KSR、20μM Y27632を添加した無血清培地で再凝集させ、37℃、40%O2、5%CO2の条件下で浮遊培養した。浮遊培養開始後3日目に、Y27632を含まず、Dexamethasone(DX、アスペンジャパン社製、400 ng/mL)、20%KSRを添加した無血清培地を用いて、半量培地交換した。浮遊培養開始後3日目から24日目はDX(400 ng/mL)、20%KSRを添加した無血清培地を、浮遊培養開始後24日目以降は20%KSRを添加した無血清培地用いて、長期培養した(図8)。
分化誘導開始後62日目の細胞凝集体を用いて精製し、再凝集後41日間長期培養させた細胞凝集体(day62 sort + day41)および分化誘導開始後100日目の細胞凝集体を用いて精製し、再凝集後31日間長期培養させた細胞凝集体(day100 sort + day31)を、それぞれ4%パラホルムアルデヒドで固定し、凍結切片を作製した。これらの凍結切片に関し、上皮細胞マーカーであるEpCAM、下垂体ホルモン産生細胞マーカーである成長ホルモン(GH)(抗GH抗体、Santacruz社製、マウス)を用いて免疫染色を行った。DAPIで細胞核を染色した。これらの染色された切片を、共焦点レーザー走査型顕微鏡(オリンパス社製)を用いて観察し、免疫染色像を取得した。その結果、day62 sort + day41の細胞凝集体およびday100 sort + day31の細胞凝集体では、DXを添加しない培養条件においても、GH陽性の下垂体ホルモン産生細胞が存在していたが(図9B、D)、DXを添加する培養条件で、さらにGH陽性細胞数が増加することが分かった(図9F、H)。すなわち、精製・再凝集後にDX添加することで、GH産生細胞へ分化誘導されることが示された。
実施例2及び実施例3で、精製後の細胞凝集体はACTHやGH等の下垂体ホルモン産生細胞を含むことが分かった。そこで、精製後の長期培養によるACTH及びGH分泌能への影響について検討した。
実施例1と同様の条件で得られた、分化誘導開始後62日目、100日目の細胞凝集体を用いて、実施例2又は実施例3と同様の条件で精製し、長期浮遊培養を実施した。
分化誘導開始後62日目及び100日目の細胞凝集体を用いて精製・再凝集させた、EpCAM陽性及びEpCAM陰性それぞれの細胞凝集体の培養上清を経時的に回収し、ACTH及びGHの分泌量を測定した。また、精製後の細胞凝集体の培養日数と同時期に相当する、精製前の細胞凝集体(day62 sort + day41=分化誘導開始後103日目)の培養上清も回収・測定し、比較した。回収した培養上清中のACTH及びGH濃度は、臨床検査で使われているELISA法によって測定した(株式会社SRLへ検査委託)。取得したACTH及びGHの濃度(pg/mL、ng/mL)のデータをもとに、サンプリング時の細胞凝集体の総数及び培養培地の総量から1細胞凝集体あたりの分泌量(pg/aggregate、ng/aggregate)を計算し、グラフにした。精製前の細胞凝集体は、20~60個/20mL/dishで、精製後の細胞凝集体は、1個/200μL/wellで培養していた。
その結果、分化誘導開始後62日目の細胞凝集体から精製・再凝集させ、69日間浮遊培養した細胞凝集体では、ACTHの分泌量が経時的に増加していた(図10A)。さらに、精製後にDXを添加して培養することで、GHの分泌量が増加し、ACTHだけでなくGHも同時に分泌されていることが分かった(図10B)。
また、分化誘導開始後100日目の細胞凝集体から精製・再凝集させ、31日間浮遊培養した細胞凝集体では、ACTHの分泌量は浮遊培養開始後13日目までは増加するが、その後減少していた(図11A)。さらに、精製後にDXを添加して培養することで、GHの分泌量が経時的に増加し、ACTHだけでなくGHも同時に分泌されていることが分かった(図11B)。
これらの結果から、精製・再凝集後に少なくとも13日間長期培養することで、ACTH及びGHの分泌能が向上することが分かった。
分化誘導開始後62日目の細胞凝集体から精製・再凝集させ、41日間浮遊培養した細胞凝集体を用いて、CRH(ニプロESファーマ社製)によるACTH刺激試験を実施した。細胞凝集体20個を、20%KSRを添加した無血清培地 10mLが入った10cm浮遊培養用ディッシュに移し、37℃、40%O2条件下で24時間培養後、培養上清を回収した。細胞凝集体を、20%KSRを添加した無血清培地で洗浄後、20%KSRを添加した新しい無血清培地 10mLが入った10cm浮遊培養用ディッシュに移し、CRH 5μg/mLを添加した。37℃、40%O2条件下で24時間培養後、培養上清を回収した。回収した培養上清中のACTH濃度は、臨床検査で使われているELISA法によって測定した(株式会社SRLへ検査委託)。
その結果、CRHの添加によってACTH分泌量が2倍弱に増加していた(図10C)。以上の結果から、精製・再凝集後の長期培養で得られた細胞凝集体は、分泌能だけでなく応答性も有した、機能的な下垂体ホルモン産生細胞を含む細胞凝集体であることが分かった。
実施例1と同様の分化誘導法(抗EpCAM抗体を用いたセルソーティングを実施しない方法)を用いて、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を製造した。分化誘導開始後の各培養日数における分化の程度を確認するために、下垂体マーカー(PITX1, LHX3, POMC (ACTH前駆細胞))及び視床下部マーカー(RAX, NKX2.1 (TTF1))の発現変化を、定量PCRにより検討した。具体的には、以下の通り実施した。RNeasy Micro Kit (Qiagen社)を用いて、1サンプル当たり6つの細胞凝集体からRNAを抽出した。定量PCRは、StepOne Plus real-time PCR system (Applied Biosystems)又はBiomark HD (Fluidigm)を用いて実施した。なお、各遺伝子のプローブは、GAPDH (Hs02758991_g1), PITX1 (Hs00267528-m1), LHX3 (Hs01033412_m1), POMC (Hs01596743_m1), RAX (Hs00429459-m1), TTF1 (Hs00968940-m1) (TaqMan Probes; Thermo Fisher Scientific)を用いた。得られたデータは内在性のコントロールとしてGAPDH を用いて規格化(normalize)した上で、比較Ct法(ΔΔCt法)を用いて定量結果を得た。
その結果、LHX3の発現は分化誘導開始6日目から60日目にかけて増加し、LHX3の発現は分化誘導開始19日目から30日目にかけて増加し、POMCの発現は分化誘導開始30日目以降に増加した(図12A)。これらの結果から、段階的に下垂体への分化が誘導されていることが示された。
一方、RAXの発現は分化誘導開始3日目から6日目頃にはプラトーに達し、その後減少した(図12B)。また、TTF1の発現は分化誘導開始6日目から19日目にかけて増加し、その後減少した(図12B)。これらの結果から、分化の初期段階において、下垂体前駆組織への分化と共に、視床下部(腹側視床下部)への分化が進行していることが示唆された。
実施例1と同様の分化誘導法を用いて、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を製造した。セルソーティングを行わない細胞凝集体については、分化誘導開始後131日目まで培養した。一部の細胞凝集体においては、分化誘導開始後30日目、60日目及び100日目に、抗EpCAM抗体を用いたセルソーティングを実施した。セルソーティングは、実施例2と同様に実施した。精製したEpCAM陽性細胞又はEpCAM陰性細胞を、細胞非接着性96ウェル培養プレートの1ウェルあたり10×104細胞になるように200μLの20%KSR、20μM Y27632を添加した無血清培地で再凝集させ、37℃、40%O2、5%CO2の条件下で浮遊培養した。浮遊培養開始後3日目以降は、Y27632を含まず、20%KSRを添加した無血清培地を用いて、3日~4日に一度の半量交換を行い、分化誘導開始後131日まで培養した(図4)。その後、得られた細胞凝集体におけるPOMC、NESTIN及びSOX11の遺伝子発現を、定量PCRを用いて定量した。定量PCR及びその解析は、実施例5と同様に実施した。なお、各遺伝子のプローブは、GAPDH (Hs02758991_g1), POMC (Hs01596743_m1), NESTIN (Hs04187831-g1), SOX11 (Hs00846583_s1) (TaqMan Probes; Thermo Fisher Scientific)を用いた。
その結果、EpCAM陽性細胞を再凝集させた細胞凝集体ではPOMCの発現量が高く、EpCAM陰性細胞を再凝集させた細胞凝集体ではほとんどPOMCの発現が認められなかった(図13A、C、E)。この結果は、抗EpCAM抗体を用いたセルソーティングの実施タイミングに関わらず同様であった(図13A、C、E)。
一方、分化誘導開始後60日目、100日目にソーティングした場合には、EpCAM陽性細胞を再凝集させた細胞凝集体において目的外細胞のマーカーであるNESTIN及びSOX11の発現は低く、EpCAM陰性細胞を再凝集させた細胞凝集体において同マーカーの発現量は高かった(図13D、F)。これに対し、分化誘導開始後30日目にソーティングした場合には、EpCAM陰性細胞を再凝集させた細胞凝集体だけでなく、EpCAM陽性細胞を再凝集させた細胞凝集体においても、NESTIN及びSOX11の発現量は高かった(図13B)。
これらの結果から、EpCAM抗体を用いたセルソーティングを行うことにより、下垂体細胞を精製できることが判明した。また、目的外細胞の混入を減少させるためには、本願の分化誘導方法において、分化誘導開始60日以降にソーティングする方が好ましいことが判明した。
実施例1と同様の分化誘導法を用いて、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を製造した。分化誘導開始後60日目に、抗EpCAM抗体を用いたセルソーティングを実施し、その後EpCAM陰性細胞及びEpCAM陽性細胞をそれぞれ再凝集させた。セルソーティング及び再凝集は、実施例6と同様に実施した。その後、分化誘導開始103日目又は107日目まで培養し、実施例2と同様に、それぞれ凍結切片を作製した。これらの凍結切片に対し、実施例2に記載している抗体を用いて免疫染色を行い、DAPIで細胞核を染色した。これらの染色された切片を、共焦点レーザー走査型顕微鏡(オリンパス社製)を用いて観察し、免疫染色像を取得した。
その結果、EpCAM陽性細胞の再凝集体について、実施例2と同様の染色像が得られた。すなわち、EpCAM、E-cadherin陽性細胞が互いに面接着し、凝集体の全面に上皮構造が形成され、細胞凝集体内にACTH陽性の下垂体ホルモン産生細胞が多数存在し(10.8 ± 1.3% of total cells)、PRL、FSH、LH、TSH陽性細胞が存在していることが分かった(data not shown)。さらに、抗ACTH抗体 (mouse, 1:200; Fitzgerald)及び下垂体幹細胞マーカーCXADRに対する抗CXADR抗体(rabbit; 1:100; Atlas antibodies)を用いて免疫染色をおこなった結果、CXADR陽性及びACTH陰性細胞が存在していることが分かった (図14A、B、C)。従って、EpCAM陽性細胞の再凝集体では、下垂体ホルモン産生細胞のみならず、CXADR陽性の下垂体幹細胞も存在すること、及び、CXADR陽性はACTH分泌細胞とは別に存在していることが判明した。
一方、EpCAM陰性細胞の再凝集体において、視床下部細胞(RAX陽性細胞:図14E、F、H)、目的外細胞(NESTIN陽性細胞、SOX11細胞:図14E、F、G、I、J)が存在し、非下垂体細胞(ACTH陰性、EpCAM陰性かつE-cadherin陰性:図14D)であることが確認された。
さらに、EpCAM陽性細胞の再凝集後、分化誘導開始201日目まで培養した細胞凝集体を、4%パラホルムアルデヒド、1%グルタルアルデヒド及び2%スクロースを用い、4℃で3日間固定した。常法に従い、アルコール溶液による脱水及びLR-WHlTE樹脂 (Nissin EM)により重合及び包埋の後、超薄切片を作成し、電子顕微鏡により観察した(Hitachi H-7500)。その結果、細胞凝集体において、複数の島状構造が互いにクラスターを形成していることが分かった(図15A、破線)。島状構造の表面には、線毛細胞(ciliated cells)が多く点在しており、島状構造の間に空隙(voids:図中*)が存在する事が示唆された。すなわち細胞凝集体全体がスポンジ状構造を有していることが分かった。細胞凝集体の中心部の細胞においてもネクローシスは観察されず、この理由として、空隙の存在によって培養液の栄養や酸素が内部にまで到達可能であるからと考察できる。また、ソーティングを行っていない細胞凝集体と比べて、分泌顆粒を含む細胞は内側、外側に対する極性が弱いことが分かり、結果としてヒト生体の下垂体内分泌細胞が作る、前葉の小柱構造(Trabecular structure)により近似していることが示唆された(図15A、B)。なお、下垂体・視床下部オルガノイドと同様、濾胞星状細胞(folliculo-stellate cells:FSCs)の存在も認められた(図15B、C、破線)。
また、EpCAM陽性細胞の再凝集体のホルモンに対する反応を検討した。分化誘導開始後60日目に、抗EpCAM抗体を用いたセルソーティングを実施し、その後EpCAM陽性細胞を再凝集させ、分化誘導開始103日目まで培養した。その後、CRH(ニプロESファーマ社製)又はDexamethasone(DX、アスペンジャパン社製)によるACTH刺激試験を実施した。具体的には、細胞凝集体20個を、20%KSRを添加した無血清培地10mLが入った10cm浮遊培養用ディッシュに移し、37℃、40%O2条件下で24時間培養後、培養上清を回収した。細胞凝集体を、20%KSRを添加した無血清培地で洗浄後、20%KSRを添加した新しい無血清培地10mLが入った10cm浮遊培養用ディッシュに移し、CRH 5μg/mL又はDexamethasone 500ng/mLを添加した。それぞれ、無添加群をコントロールとして設定した。37℃、40%O2条件下で24時間培養後、培養上清を回収した。回収した培養上清中のACTH濃度は、臨床検査で使われているELISA法によって測定した(株式会社SRLへ検査委託)。その結果、CRH刺激によりACTH分泌量は約2.2倍に増加し、Dexamethasone刺激によりACTH分泌量は約50%低下した(図16)。これらの結果より、EpCAM陽性細胞の再凝集体において、ホルモンによるホメオスタシスが維持されていることが示された。
実施例1と同様の分化誘導法を用いて、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を製造した。分化誘導開始後60日目に、抗EpCAM抗体を用いたセルソーティングを実施し、その後EpCAM陽性細胞を再凝集させた。セルソーティング及び再凝集は、実施例6と同様に実施した。その後、分化誘導開始107日目まで培養し、外科的に下垂体を切除した下垂体機能不全マウス(10-17週齢)の左腎被膜下に移植した(移植群)。移植手技のみ実施し、EpCAM陽性細胞を移植しない対象群(シャム群)も設定した。なお、外科的に下垂体を切除した下垂体機能不全マウスは、SCIDマウス(7-9週齢、雄)に対し公知の継耳的手術を行うことで作製した。移植24週後、腎臓を摘出し、各種抗体(human nuclei (mouse, 1:1000; Millipore)、ACTH (mouse, 1:200; Fitzgerald)、EpCAM (goat; 1:500; R&D Systems)、CXADR (rabbit; 1:100; Atlas antibodies))を用い、常法により免疫染色を実施した。その結果、ヒト核陽性かつEpCAM陽性移植片は、ACTH陽性細胞を含んでいることが分かった(図17A、B、B’、C)。また、移植片、特に細胞間隙においてCXADRの発現が認められ、移植片において、FSCsの下垂体幹細胞ニッチ様構造の存在が示唆された(図17D、E)。なお、観察期間中において、がんの形成は認められなかった。図17A、図17B、図17B’、図17D、図17Eの右下のスケールバーは50μm、図17Cの右下のスケールバーは10μmを示す。
移植群及びシャム群に対しCRH刺激を加え、ACTH分泌能に与える影響を検討した。具体的には、移植4週、12週又は24週後のマウスにCRH投与(2 μg/kg、腹腔内投与)を行い、CRH投与前及びCHR投与1時間後の血液を採取した。ACTH ELISA kit (MD Bioproducts)を用い、それぞれの血中ACTH濃度を測定した。
その結果、移植4週後には、シャム群に比べ移植群における血中ACTH濃度が顕著に上昇していた(図18A)。CRH刺激による血中ACTH濃度の更なる上昇も認められた(図18A)。血中ACTH濃度上昇及びCRH刺激による更なるACTH濃度上昇は、移植24週後まで認められた(図18A)。
移植群に対しDexamethasone刺激を加え、ACTH分泌能に与える影響を検討した。具体的には、移植6週後にdexamethasone投与(0.2 mg、筋肉内投与) を行い、dexamethasone投与前及びdexamethasone投与2時間後の血液を採取した。dexamethasone投与2時間後の採血ののち、さらにCRH投与(2 μg/kg、腹腔内投与)を行い、CRH投与1時間後の血液を採取した。上記同様血中ACTH濃度を測定した。
その結果、移植6週後のマウスにdexamethasone投与した群では、血中ACTH濃度が顕著に減少することが分かった(図18B)。また、dexamethasone投与した上でCRH投与を行っても、血中ACTH濃度はほぼ完全に抑えられたままであった(図18B)。dexamethasoneによるネガティブフィードバックシグナルに反応を示したことは、生体内でACTH分泌が不要となった時に下流のグルココルチコイドからの刺激で分泌が止まることを示唆し、グルココルチコイド過剰を防ぐ観点で重要である。
感染や手術のような強いストレスがかかった場合、健常人では下垂体から大量のACTHが分泌され、コルチコステロイドの分泌を刺激することで、ストレスに対する耐性を示すことが知られている。そこで、移植群及びシャム群に対し、疑似感染ストレスを誘発するために、LPS(InvivoGen, E. coli origin, serotype O111:B4)刺激を加え、ACTH分泌能に与える影響を検討した。具体的には、移植4週後のマウスにLPS投与(2.2 μg/kg、腹腔内投与)を行い、LPS投与前及びLPS投与2時間後の血液を採取した。上記同様血中ACTH濃度を測定した。
その結果、シャム群においてLPS刺激によるACTH分泌促進は認められなかったが、移植群においてLPS刺激による顕著なACTH分泌促進が認められた(図18C)。当該効果は、移植するEpCAM陽性細胞の凝集体の個数を増やすことにより上昇し、用量依存性が認められた(図18C)。従って、移植したEpCAM陽性細胞は、感染ストレスに対する反応を示すことが示唆された。
実施例1と同様の分化誘導法(抗EpCAM抗体を用いたセルソーティングを実施しない方法)を用いて、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を製造した。ただし、SAGの処理期間について、分化誘導開始直後から30日目までSAGを添加する群(図2参照)と、分化誘導開始直後から30日目以降(61日目、103日目及び131日目まで)もSAGを添加する群の2群を設定し、ACTH分泌能を比較した。
その結果、分化誘導開始30日後にSAG処理を止めることにより、ACTH分泌能が向上することが分かった(図19)。
実施例3および実施例4の結果から、精製後の細胞凝集体の培養時にDXを用いることで、GH産生細胞に分化誘導できることが分かった。そこで、培養時のDX添加期間を変えることによる、細胞凝集体におけるACTH産生細胞およびGH産生細胞への分化の影響について、検討した。
実施例1と同様の条件で得られた、分化誘導開始後63日目の細胞凝集体を用いて、実施例2と同様の条件で精製し、得られたEpCAM陽性細胞を、細胞非接着性96ウェル培養プレートの1ウェルあたり10×104細胞になるように200 μLの20%KSR、20 μM Y27632を添加した無血清培地で再凝集させ、37℃、40%O2、5%CO2の条件下で浮遊培養した。浮遊培養開始後3日目に、Y27632を含まず、DX(400 ng/mL)、20%KSRを添加した無血清培地を用いて、半量培地交換した。DX添加期間の条件検討として、DXを3、7、14日間添加した条件と無添加条件を比較した。浮遊培養開始後3日目からDX添加している際はDX(400 ng/mL)、20%KSRを添加した無血清培地を、DX添加していない際は20%KSRを添加した無血清培地用いて、長期培養した(図20)。
分化誘導開始後63日目の細胞凝集体を用いて精製し、再凝集後40日間長期培養させた細胞凝集体(day63 sort + day40)を、それぞれ4%パラホルムアルデヒドで固定し、凍結切片を作製した。これらの凍結切片に関し、上皮細胞マーカーであるEpCAM、下垂体ホルモン産生細胞マーカーである副腎皮質刺激ホルモン(ACTH)、成長ホルモン(GH)を用いて免疫染色を行った。その結果、day63 sort + day40の細胞凝集体では、DXの添加期間が長くなるに従って、ACTH陽性細胞数が減少し、GH陽性細胞数が増加することが分かった(図21)。
また、分化誘導開始後63日目の細胞凝集体を用いて精製・再凝集させた、DX添加したEpCAM陽性及びEpCAM陰性それぞれの細胞凝集体の培養上清を経時的に回収し、ACTH及びGHの分泌量を実施例4と同様の条件で測定した。その結果、分化誘導開始後63日目の細胞凝集体から精製し、再凝集後40日間長期培養させた細胞凝集体(day63 sort + day40)では、DX添加期間依存的にACTHの分泌量が減少し(図22A)、GHの分泌量が増加していた(図22B)。すなわち、精製・再凝集後のDX添加期間を変えることで、ACTH産生細胞及びGH産生細胞への分化誘導の比率を調節できることが示された。
分化誘導開始後63日目の細胞凝集体から精製・再凝集させ、40日間浮遊培養し、そのうち14日間DXを処置した細胞凝集体を用いて、GRFによるGH刺激試験およびsomatostatinによるGH抑制試験を実施した。細胞凝集体15個を、20%KSRを添加した無血清培地2 mLが入った6穴培養プレート(住友ベークライト社製、浮遊細胞培養用、培養面積9.2cm2)に移し、37℃、40%O2条件下で24時間培養後、培養上清を回収した。細胞凝集体を、20%KSRを添加した無血清培地で洗浄後、20%KSRを添加した新しい無血清培地 2mLが入った6穴培養プレートに移し、GRF 2 μg/mLまたはsomatostatin 100 ng/mLを添加した。37℃、40%O2条件下で24時間培養後、培養上清を回収した。回収した培養上清中のACTH濃度は、臨床検査で使われているELISA法によって測定した(株式会社SRLへ検査委託)。その結果、GRFの添加によってGH分泌量が2倍弱に増加し(図22C)、somatostatinの添加によってGH分泌量が2割減少していた(図22D)。以上の結果から、精製・再凝集後の長期培養時にDX処置して得られた細胞凝集体は、GHの分泌能だけでなく応答性も有した、機能的な下垂体ホルモン産生細胞を含む細胞凝集体であることが分かった。
本出願は、日本で出願された特願2021-162253(出願日:令和3年9月30日)および特願2022-116715(出願日:令和4年7月21日)を基礎としており、その内容はすべて本明細書に包含されるものとする。
Claims (19)
- 下垂体ホルモン産生細胞を含む細胞凝集体であって、
(1)該細胞凝集体におけるEpCAM及びE-cadherinの少なくとも1つが陽性の細胞の存在割合が80%以上であり、
(2)該細胞凝集体における神経細胞の存在割合が20%以下であり、
(3)該細胞凝集体におけるACTH陽性細胞の存在割合が5%以上であり、
(4)該細胞凝集体の細胞密度が3,000~20,000 cells/mm2であり、
(5)該細胞凝集体の長径が200~3,000 μmであり、
(6)該細胞凝集体の表面において、EpCAM及びE-cadherinの少なくとも1つが陽性の細胞が互いに面接着し、上皮構造を形成しており、かつ、
(7)該細胞凝集体の内部が、スポンジ状構造を形成している、
ことを特徴とする、細胞凝集体。 - 該細胞凝集体における下垂体幹細胞の存在割合が3%以上である、請求項1に記載の細胞凝集体。
- 該細胞凝集体のACTH分泌能が200~1,000,000 pg/mLである、請求項1に記載の細胞凝集体。
- 該細胞凝集体のGH分泌能が0.05~100 ng/mLである、請求項1に記載の細胞凝集体。
- 請求項1に記載の細胞凝集体を全細胞凝集体数の40%以上含む、細胞集団。
- 請求項1に記載の細胞凝集体を含む、下垂体の障害に基づく疾患の治療薬。
- 以下の工程を含む、下垂体ホルモン産生細胞を含む細胞凝集体の製造方法:
(1)多能性幹細胞由来の、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む、分散された細胞集団から、EpCAMを発現する細胞を分離する工程、及び
(2)分離されたEpCAM発現細胞を、下垂体前駆細胞を下垂体ホルモン産生細胞へ成熟し得る条件下で14日以上浮遊培養する工程。 - 工程(1)の細胞集団が、下記工程(A)及び(B)により得られる、請求項7に記載の製造方法:
(A)視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体に分化誘導可能な条件下において、多能性幹細胞またはその細胞凝集体を培養する工程、及び、
(B)(A)で得られる視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を細胞集団に分散させる工程。 - 工程(A)が、以下の工程を含む、請求項8に記載の製造方法。
(1’)多能性幹細胞をWntシグナル伝達経路阻害物質の存在下で培養し、細胞凝集体を形成させる第一工程。
(2)第一工程で得られた細胞凝集体を、BMPシグナル伝達経路作用物質及びShhシグナル伝達経路作用物質の存在下に培養し、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を得る第二工程。 - 工程(A)が、以下の工程を含む、請求項8に記載の製造方法。
(a)多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はShhシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程、
(1’)a工程で得られた多能性幹細胞をWntシグナル伝達経路阻害物質の存在下で浮遊培養し、細胞凝集体を形成させる第一工程、
(2)第一工程で得られた細胞凝集体を、BMPシグナル伝達経路作用物質およびShhシグナル伝達経路作用物質の存在下で浮遊培養し、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を得る第二工程。 - 工程(A)が、以下の工程を含む、請求項8に記載の製造方法。
(a)多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はShhシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程。
(1)a工程で得られた多能性幹細胞をJNKシグナル伝達経路阻害物質およびWntシグナル伝達経路阻害物質の存在下で浮遊培養し、細胞凝集体を形成させる第一工程。
(2)第一工程で得られた細胞凝集体を、BMPシグナル伝達経路作用物質およびShhシグナル伝達経路作用物質の存在下で浮遊培養し、視床下部細胞、下垂体前駆細胞および下垂体ホルモン産生細胞を含む細胞凝集体を得る第二工程。 - 第一工程における浮遊培養がさらにShhシグナル伝達経路作用物質の存在下であって、第一工程および第二工程におけるShhシグナル伝達経路作用物質の存在下における培養期間が、30日である、請求項11に記載の製造方法。
- 第二工程で得られた細胞凝集体を、Shhシグナル伝達経路作用物質の非存在下でさらに浮遊培養する、請求項9~12のいずれか1項に記載の製造方法。
- 工程(A)の培養期間が、ACTHを分泌する下垂体ホルモン産生細胞を含み、かつ、GH又はTSHを分泌する下垂体ホルモン産生細胞を含まない細胞凝集体が得られる期間である、請求項8~12のいずれか1項に記載の製造方法。
- 工程(A)の培養期間が、30日以上かつ100日以下である、請求項8~12のいずれか1項に記載の製造方法。
- 下垂体ホルモン産生細胞を含む細胞凝集体が以下の特徴を含む、請求項7~12のいずれか1項に記載の製造方法:
(1)該細胞凝集体におけるEpCAM及びE-cadherinの少なくとも1つが陽性の細胞の存在割合が80%以上であり、
(2)該細胞凝集体における神経細胞の存在割合が20%以下であり、
(3)該細胞凝集体におけるACTH陽性細胞の存在割合が5%以上であり、
(4)該細胞凝集体の細胞密度が3,000~20,000 cells/mm2であり、
(5)該細胞凝集体の長径が200~3,000 μmであり、
(6)該細胞凝集体の表面において、EpCAM及びE-cadherinの少なくとも1つが陽性の細胞が互いに面接着し、上皮構造を形成しており、かつ、
(7)該細胞凝集体が、スポンジ状構造を形成している。 - 該細胞凝集体における下垂体幹細胞の存在割合が3%以上である、請求項16に記載の製造方法。
- 該細胞凝集体のACTH分泌能が200~1,000,000 pg/mLである、請求項16に記載の製造方法。
- 該細胞凝集体のGH分泌能が0.05~100 ng/mLである、請求項16に記載の製造方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022355700A AU2022355700A1 (en) | 2021-09-30 | 2022-09-27 | Cell aggregate including pituitary hormone-producing cells and method for producing same |
CA3234334A CA3234334A1 (en) | 2021-09-30 | 2022-09-27 | Cell aggregate including pituitary hormone-producing cells and method for producing same |
IL311818A IL311818A (en) | 2021-09-30 | 2022-09-27 | A cell aggregate comprising cells that form adrenal gland hormone and a method for its preparation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-162253 | 2021-09-30 | ||
JP2021162253 | 2021-09-30 | ||
JP2022116715 | 2022-07-21 | ||
JP2022-116715 | 2022-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023054395A1 true WO2023054395A1 (ja) | 2023-04-06 |
Family
ID=85782782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/036018 WO2023054395A1 (ja) | 2021-09-30 | 2022-09-27 | 下垂体ホルモン産生細胞を含む細胞凝集体及びその製造方法 |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU2022355700A1 (ja) |
CA (1) | CA3234334A1 (ja) |
IL (1) | IL311818A (ja) |
TW (1) | TW202330905A (ja) |
WO (1) | WO2023054395A1 (ja) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996022362A1 (en) | 1995-01-20 | 1996-07-25 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
WO1998030679A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
US6280718B1 (en) | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
WO2002101057A1 (fr) | 2001-06-08 | 2002-12-19 | Dnavec Research Inc. | Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur |
WO2013065763A1 (ja) * | 2011-10-31 | 2013-05-10 | 独立行政法人理化学研究所 | 幹細胞の培養方法 |
US8772460B2 (en) | 2011-12-16 | 2014-07-08 | Wisconsin Alumni Research Foundation | Thermostable FGF-2 mutant having enhanced stability |
WO2016013669A1 (ja) | 2014-07-25 | 2016-01-28 | 国立研究開発法人理化学研究所 | 腺性下垂体又はその前駆組織の製造方法 |
US20160326491A1 (en) | 2013-11-21 | 2016-11-10 | Memorial Sloan-Kettering Cancer Center | Specification of functional cranial placode derivatives from human pluripotent stem cells |
WO2017126551A1 (ja) * | 2016-01-22 | 2017-07-27 | 国立大学法人名古屋大学 | ヒト多能性幹細胞から視床下部ニューロンへの分化誘導 |
WO2019103129A1 (ja) | 2017-11-24 | 2019-05-31 | 住友化学株式会社 | 下垂体組織を含む細胞塊の製造方法及びその細胞塊 |
WO2021201175A1 (ja) * | 2020-03-31 | 2021-10-07 | 学校法人藤田学園 | 下垂体ホルモン産生細胞及びその前駆細胞の分離法 |
JP2021162253A (ja) | 2020-03-31 | 2021-10-11 | 株式会社富士通ゼネラル | 空気調和システム |
JP2022116715A (ja) | 2021-01-29 | 2022-08-10 | 株式会社サンセイアールアンドディ | 遊技機 |
-
2022
- 2022-09-27 CA CA3234334A patent/CA3234334A1/en active Pending
- 2022-09-27 WO PCT/JP2022/036018 patent/WO2023054395A1/ja active Application Filing
- 2022-09-27 TW TW111136534A patent/TW202330905A/zh unknown
- 2022-09-27 AU AU2022355700A patent/AU2022355700A1/en active Pending
- 2022-09-27 IL IL311818A patent/IL311818A/en unknown
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996022362A1 (en) | 1995-01-20 | 1996-07-25 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US6200806B1 (en) | 1995-01-20 | 2001-03-13 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
WO1998030679A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
JP2001508302A (ja) | 1997-01-10 | 2001-06-26 | ライフ テクノロジーズ,インコーポレイテッド | 胚性幹細胞血清置換 |
US6280718B1 (en) | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
WO2002101057A1 (fr) | 2001-06-08 | 2002-12-19 | Dnavec Research Inc. | Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur |
WO2013065763A1 (ja) * | 2011-10-31 | 2013-05-10 | 独立行政法人理化学研究所 | 幹細胞の培養方法 |
US8772460B2 (en) | 2011-12-16 | 2014-07-08 | Wisconsin Alumni Research Foundation | Thermostable FGF-2 mutant having enhanced stability |
US20160326491A1 (en) | 2013-11-21 | 2016-11-10 | Memorial Sloan-Kettering Cancer Center | Specification of functional cranial placode derivatives from human pluripotent stem cells |
WO2016013669A1 (ja) | 2014-07-25 | 2016-01-28 | 国立研究開発法人理化学研究所 | 腺性下垂体又はその前駆組織の製造方法 |
WO2017126551A1 (ja) * | 2016-01-22 | 2017-07-27 | 国立大学法人名古屋大学 | ヒト多能性幹細胞から視床下部ニューロンへの分化誘導 |
WO2019103129A1 (ja) | 2017-11-24 | 2019-05-31 | 住友化学株式会社 | 下垂体組織を含む細胞塊の製造方法及びその細胞塊 |
WO2021201175A1 (ja) * | 2020-03-31 | 2021-10-07 | 学校法人藤田学園 | 下垂体ホルモン産生細胞及びその前駆細胞の分離法 |
JP2021162253A (ja) | 2020-03-31 | 2021-10-11 | 株式会社富士通ゼネラル | 空気調和システム |
JP2022116715A (ja) | 2021-01-29 | 2022-08-10 | 株式会社サンセイアールアンドディ | 遊技機 |
Non-Patent Citations (27)
Title |
---|
"A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS, article "Manipulating the Mouse Embryo" |
"A Practical Approach", 1993, IRL PRESS AT OXFORD UNIVERSITY PRESS, article "Gene Targeting" |
"Biomanual Series 8", 1995, YODOSHA CO., LTD., article "Gene Targeting, Making of Mutant Mouse using ES cell" |
"Gene Targeting, A Practical Approach", 1993, IRL PRESS AT OXFORD UNIVERSITY PRESS |
AM J CANCER RES, vol. 5, no. 8, 2015, pages 2344 - 2360 |
CELL REPORTS, vol. 30, 7 January 2020 (2020-01-07), pages 18 - 24 |
CELL, vol. 126, no. 4, 2006, pages 663 - 676 |
CELL, vol. 131, no. 5, 2007, pages 861 - 872 |
CELL, vol. 70, 1992, pages 841 - 847 |
EMBO J., vol. 3, 1984, pages 1463 - 1468 |
GENES, vol. 11, 2020, pages 603 |
J. CELL BIOL., vol. 105, 1987, pages 589 - 598 |
M. KATOH: "WNT Signaling Pathway and Stem Cell Signaling Network", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, vol. 13, no. 14, 15 July 2007 (2007-07-15), pages 4042 - 4045, XP055080256, ISSN: 10780432, DOI: 10.1158/1078-0432.CCR-06-2316 * |
NAT BIOTECHNOL, vol. 19, 2001, pages 971 - 974 |
NAT BIOTECHNOL, vol. 28, 2010, pages 611 - 615 |
NAT COMMUN, vol. 3, 2012, pages 1236 |
NAT PROTOC, vol. 14, 2019, pages 518 - 540 |
NAT. BIOTECHNOL., vol. 26, no. 1, 2008, pages 101 - 106 |
NATURE COMMUNICATIONS, vol. 7, 2016, pages 10351 |
NATURE METHODS, vol. 8, 2011, pages 424 - 429 |
NATURE PROTOCOLS, vol. 11, no. 11, pages 2223 - 2232 |
NATURE, vol. 499, 2013, pages 481 - 484 |
ONCO TARGETS THER, vol. 6, 2013, pages 943 - 955 |
ONCOGENE, vol. 26, 2007, pages 5163 - 5168 |
SCIENCE, vol. 318, no. 5858, 2007, pages 1917 - 1920 |
SCIENCE, vol. 341, 2013, pages 651 - 654 |
SCIENTIFIC REPORTS, vol. 4, 2014, pages 3549 |
Also Published As
Publication number | Publication date |
---|---|
IL311818A (en) | 2024-05-01 |
CA3234334A1 (en) | 2023-04-06 |
AU2022355700A1 (en) | 2024-05-02 |
TW202330905A (zh) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016305705B2 (en) | Induced extended pluripotent stem cells, methods of making and using | |
JP6995314B2 (ja) | 網膜組織の製造法 | |
US10220117B2 (en) | Methods of mammalian retinal stem cell production and applications | |
JP7029144B2 (ja) | 腺性下垂体又はその前駆組織の製造方法 | |
WO2015087231A1 (en) | Method for producing retinal pigment epithelial cells | |
WO2019054514A1 (ja) | 網膜組織の製造方法 | |
US20150159134A1 (en) | Method for producing retinal pigment epithelial cells | |
JP7352553B2 (ja) | 嗅神経細胞又はその前駆細胞を含む細胞塊、及びその製造方法 | |
AU2017211858A1 (en) | Differentiation of cortical neurons from human pluripotent stem cells | |
JP2022088676A (ja) | 幹細胞由来外胚葉系統前駆体を分化する方法 | |
WO2023277135A1 (ja) | 鼻腔上皮を構成する細胞の製造方法、及び鼻腔上皮を構成する細胞又はその前駆細胞を含む細胞集団 | |
US20220313733A1 (en) | Method for producing renal interstitial cell | |
JP2023055915A (ja) | 幹細胞からの成長ホルモン産生細胞の誘導およびその使用 | |
WO2023054395A1 (ja) | 下垂体ホルモン産生細胞を含む細胞凝集体及びその製造方法 | |
WO2022210968A1 (ja) | 嚢胞構造を有する人工集合管オルガノイド | |
WO2023054396A1 (ja) | 下垂体組織を含む細胞集団の製造方法及びその細胞集団 | |
CN118043447A (zh) | 包含垂体组织的细胞群的制备方法及该细胞群 | |
US20220259558A1 (en) | Methods for obtaining eye field progenitor cells from human pluripotent stem cells | |
WO2022172960A1 (ja) | 成熟化剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22876261 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023551554 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 3234334 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 311818 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2401002100 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022355700 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022355700 Country of ref document: AU Date of ref document: 20220927 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022876261 Country of ref document: EP Effective date: 20240430 |